



US006340583B1

(12) **United States Patent**
Yan et al.

(10) **Patent No.:** **US 6,340,583 B1**
(45) Date of Patent: **Jan. 22, 2002**

(54) **ISOLATED HUMAN KINASE PROTEINS,
 NUCLEIC ACID MOLECULES ENCODING
 HUMAN KINASE PROTEINS, AND USES
 THEREOF**

(75) **Inventors:** **Chunhua Yan, Boyds; Karen A.
 Ketchum, Germantown; Valentina Di
 Francesco, Rockville; Ellen M.
 Beasley, Darnestown, all of MD (US)**

(73) **Assignee:** **PE Corporation (NY), Norwalk, CT
 (US)**

(*) **Notice:** Subject to any disclaimer, the term of this
 patent is extended or adjusted under 35
 U.S.C. 154(b) by 0 days.

(21) **Appl. No.:** **09/813,817**

(22) **Filed:** **Mar. 22, 2001**

(51) **Int. Cl.⁷** **C12N 9/12; C12N 1/20;
 C12N 15/00; C12N 5/00; C07H 21/04**

(52) **U.S. Cl.** **435/194; 435/320.1; 435/252.3;
 435/325; 536/23.2**

(58) **Field of Search** **435/194, 252.3,
 435/325, 320.1; 536/23.2**

(56) **References Cited**

PUBLICATIONS

GenEmbl Database, Accession No. D45906, Feb. 1999.*

Sambrook et al., Molecular Cloning Manual, 2nd edition,
 Cold Spring Harbor Laboratory Press, 1989.*

* cited by examiner

Primary Examiner—Rebecca E. Prouty

Assistant Examiner—M. Monshipouri

(74) *Attorney, Agent, or Firm*—Celera Genomics; Robert
 A. Millman; Justin D. Karjala

(57) **ABSTRACT**

The present invention provides amino acid sequences of
 peptides that are encoded by genes within the human
 genome, the kinase peptides of the present invention. The
 present invention specifically provides isolated peptide and
 nucleic acid molecules, methods of identifying orthologs
 and paralogs of the kinase peptides, and methods of iden-
 tifying modulators of the kinase peptides.

9 Claims, 41 Drawing Sheets

1 CCCAGGGCGC CGTAGGCGGT GCATCCCCTT CGCGCCTGGG GCTGTGGTCT
51 TCCCGCGCCT GAGGCGGCGG CGGCAGGAGC TGAGGGGAGT TGTAGGGAAC
101 TGAGGGGAGC TGCTGTGTCC CCCGCCTCCT CCTCCCCATT TCCGCGCTCC
151 CGGGACCATG TCCGCGCTGG CGGGTGAAGA TGTCTGGAGG TGTCCAGGCT
201 GTGGGGACCA CATTGCTCCA AGCCAGATAT GGTACAGGAC TGTCAACGAA
251 ACCTGGCAGC GCTCTTGCTT CCGGTGAAAG TGATGCGCAG CCTGGACCAC
301 CCCAATGTGC TCAAGTTCAT TGGTGTGCTG TACAAGGATA AGAAGCTGAA
351 CCTGCTGACA GAGTACATTG AGGGGGGCAC ACTGAAGGAC TTTCTGCGCA
401 GTATGGATCC GTTCCCCTGG CAGCAGAAGG TCAGGTTTGC CAAAGGAATC
451 GCCTCCGGAA TGGACAAGAC TGTGGTGGTG GCAGACTTTG GGCTGTCACG
501 GCTCATAGTG GAAGAGAGGA AAAGGGCCCC CATGGAGAAG GCCACCACCA
551 AGAAACGCAC CTTGCGCAAG AACGACCGCA AGAAGCGCTA CACGGTGGTG
601 GGAAACCCCT ACTGGATGGC CCCTGAGATG CTGAACGGAA AGAGCTATGA
651 TGAGACGGTG GATATCTTCT CTTTGGGAT CGTTCTCTGT GAGATCATTG
701 GGCAGGTGTA TGCAGATCCT GACTGCCTTC CCCGAACACT GGACTTTGGC
751 CTC AACGTGA AGCTTTTCTG GGAGAAGTT GTTCCACAG ATTGTCCCCC
801 GGCCTTCTTC CCGCTGGCCG CCATCTGCTG CAGACTGGAG CCTGAGAGCA
851 GACCAGCATT CTCGAAATTG GAGGACTCCT TTGAGGCCCT CTCCCTGTAC
901 CTGGGGGAGC TGGGCATCCC GCTGCCTGCA GAGCTGGAGG AGTTGGACCA
951 CACTGTGAGC ATGCAGTACG GCCTGACCCG GGACTCACCT CCCTAGCCCT
1001 GGCCAGCCC CCTGCAGGGG GGTGTTCTAC AGCCAGCATT GCCCCTCTGT
1051 GCCCCATTCC TGCTGTGAGC AGGGCCGTCC GGGCTTCTG TGGATTGGCG
1101 GAATGTTTAG AAGCAGAACA AACCATTCCT ATTACCTCCC CAGGAGGCAA
1151 GTGGGCGCAG CACCAGGGAA ATGTATCTCC ACAGGTTCTG GGGCCTAGTT
1201 ACTGTCTGTA AATCCAATAC TTGCCTGAAA GCTGTGAAGA AGAAAAAAC
1251 CCCTGGCCTT TGGGCCAGGA GGAATCTGTT ACTCGAATCC ACCCAGGAAC
1301 TCCCTGGCAG TGGATTGTGG GAGGCTCTTG CTTACACTAA TCAGCGTGAC
1351 CTGGACCTGC TGGGCAGGAT CCCAGGGTGA ACCTGCCTGT GAACTCTGAA
1401 GTC ACTAGTC CAGCTGGGTG CAGGAGGACT TCAAGTGTGT GGACGAAAGA
1451 AAGACTGATG GCTCAAAGGG TGTGAAAAAG TCAGTGATGC TCCCCCTTC
1501 TACTCCAGAT CCTGTCCTTC CTGGAGCAAG GTTGAGGGAG TAGGTTTTGA
1551 AGAGTCCCTT AATATGTGGT GGAACAGGCC AGGAGTTAGA GAAAGGGCTG
1601 GCTTCTGTTT ACCTGCTCAC TGGCTCTAGC CAGCCCAGGG ACCACATCAA
1651 TGTGAGAGGA AGCCTCCACC TCATGTTTTT AACTTAATA CTGGAGACTG
1701 GCTGAGAACT TACGGACAAC ATCCTTTCTG TCTGAAACAA ACAGTCACAA
1751 GCACAGGAAG AGGCTGGGGG ACTAGAAAGA GGCCCTGCCC TCTAGAAAGC
1801 TCAGATCTTG GCTTCTGTGA CTCATACTCG GGTGGGCTCC TTAGTCAGAT
1851 GCCTAAAACA TTTTGCCTAA AGCTCGATGG GTTCTGGAGG ACAGTGTGGC
1901 TTGTCACAGG CCTAGAGTCT GAGGGAGGGG AGTGGGAGTC TCAGCAATCT
1951 CTTGGTCTTG GCTTCATGGC AACCACTGCT CACCCTTCAA CATGCCTGGT
2001 TTAGGCAGCA GCTTGGGCTG GGAAGAGGTG GTGGCAGAGT CTC AAAGCTG
2051 AGATGCTGAG AGAGATAGCT CCCTGAGCTG GGCCATCTGA CTTCTACCTC
2101 CCATGTTTGC TCTCCCAACT CATTAGCTCC TGGGCAGCAT CCTCTGAGC
2151 CACATGTGCA GGTACTGGAA AACCTCCATC TTGGCTCCCA GAGCTCTAGG
2201 AACTCTTCAT CACAAC TAGA TTTGCCTCTT CTAAGTGTCT ATGAGCTTGC
2251 ACCATATTTA ATAAATTGGG AATGGGTTTG GGGTATTAAA AAAAAAAAAA
2301 AAAAAAAAAA AAAAAAAAAA (SEQ ID NO:1)

FIG. 1A

FEATURES:

5'UTR: 1-228
Start Codon: 229
Stop Codon: 994
3'UTR: 997

Homologous proteins:

Top 10 BLAST Hits

	Score	E
CRA 1000682328847 /altid=gi 8051618 /def=ref NP_057952.1 LIM d...	485	e-136
CRA 18000005015874 /altid=gi 5031869 /def=ref NP_005560.1 LIM ...	485	e-136
CRA 88000001156379 /altid=gi 7434382 /def=pir JC5814 LIM motif...	469	e-131
CRA 88000001156378 /altid=gi 7434381 /def=pir JC5813 LIM motif...	469	e-131
CRA 18000005154371 /altid=gi 7428032 /def=pir JE0240 LIM kinas...	469	e-131
CRA 18000005126937 /altid=gi 6754550 /def=ref NP_034848.1 LIM ...	469	e-131
CRA 18000005127186 /altid=gi 2804562 /def=dbj BAA24491.1 (AB00...	469	e-131
CRA 18000005127185 /altid=gi 2804553 /def=dbj BAA24489.1 (AB00...	469	e-131
CRA 18000005004416 /altid=gi 2143830 /def=pir I78847 LIM motif...	468	e-131
CRA 18000005004415 /altid=gi 1708825 /def=sp P53670 LIK2_RAT LI...	468	e-131

BLAST dbEST hits:

	Score	E
gi 10950740 /dataset=dbest /taxon=96...	1049	0.0
gi 10156485 /dataset=dbest /taxon=96...	975	0.0
gi 5421647 /dataset=dbest /taxon=9606 ...	952	0.0
gi 10895718 /dataset=dbest /taxon=96...	757	0.0
gi 13043102 /dataset=dbest /taxon=960...	714	0.0
gi 519615 /dataset=dbest /taxon=9606 /...	531	e-149
gi 11002869 /dataset=dbest /taxon=96...	511	e-143

EXPRESSION INFORMATION FOR MODULATORY USE:

library source:From BLAST dbEST hits:

gi|10950740 teratocarcinoma
gi|10156485 ovary
gi|5421647 testis
gi|10895718 nervous_normal
gi|13043102 bladder
gi|519615 infant brain
gi|11002869 thyroid gland

From tissue screening panels:

Fetal whole brain

FIG.1B

1 MVQDCQRNLA RLLLPVKVMR SLDHPNVLFK IGVLYKDKKL NLLTEYIEGG
51 TLKDFLRSM D PFPWQKQVRF AKGIASGMDK TVVVA DFGLS RLIVEERKRA
101 PMEKATTKKR TLRKNDRKKR YTVVGNPYWM APEMLNGKSY DETVDIFSFG
151 IVLCEIIGQV YADPDCLPRT LDFGLNVKLF WEK FVPTDCP PAFFPLAAIC
201 CRLEPESRPA FSKLEDSFEA LSLYL GELGI PLPAELEELD HTVSMQYGLT
251 RDSPP (SEQ ID NO:2)

FEATURES:

Functional domains and key regions:

[1] PDOC00004 PS00004 CAMP_PHOSPHO SITE

cAMP- and cGMP-dependent protein kinase phosphorylation site

Number of matches: 2

1 108-111 KKRT

2 119-122 KRYT

[2] PDOC00005 PS00005 PKC_PHOSPHO SITE
Protein kinase C phosphorylation site

Number of matches: 4

1 51-53 TLK

2 106-108 TTK

3 107-109 TKK

4 111-113 TLR

[3] PDOC00006 PS00006 CK2_PHOSPHO SITE
Casein kinase II phosphorylation site

Number of matches: 4

1 51-54 TLKD

2 76-79 SGMD

3 139-142 SYDE

4 212-215 SKLE

[4] PDOC00008 PS00008 MYRISTYL
N-myristoylation site

Number of matches: 4

1 73-78 GIASGM

FIG.2A

2 77-82 GMDKTV

3 150-155 GIVLCE

4 158-163 GQVYAD

Membrane spanning structure and domains:

Helix	Begin	End	Score	Certainty
1	142	162	0.872	Putative
2	184	204	0.652	Putative

BLAST Alignment to Top Hit:

>CRA|1000682328847 /altid=gi|8051618 /def=ref|NP_057952.1| LIM
domain kinase 2 isoform 2b [Homo sapiens] /org=Homo
sapiens /taxon=9606 /dataset=nraa /length=617
Length = 617

Score = 485 bits (1235), Expect = e-136
Identities = 241/265 (90%), Positives = 241/265 (90%), Gaps = 22/265 (8%)

Query: 13 LLPVKVMRSLDHPNVLKFIGVLYKDKKLNLLTEYIEGGTLKDFLRSMDFPFPWQQKVRFAK 72
L VKVMRSLDHPNVLKFIGVLYKDKKLNLLTEYIEGGTLKDFLRSMDFPFPWQQKVRFAK
Sbjct: 353 LTEVKVMRSLDHPNVLKFIGVLYKDKKLNLLTEYIEGGTLKDFLRSMDFPFPWQQKVRFAK 412

Query: 73 GIASGM-----DKTVVVDGFLSRLIVEERKRAPMEKATTKKR 110
GIASGM DKTVVVDGFLSRLIVEERKRAPMEKATTKKR
Sbjct: 413 GIASGMAYLHSMCIHRDLNSHNCLIKDKTVVVDGFLSRLIVEERKRAPMEKATTKKR 472

Query: 111 TLRKNDRKKRYTVVGNPYWMAPEMLNGKSYDETVDIFSFGIVLCEIIGQVYADPDCLPRT 170
TLRKNDRKKRYTVVGNPYWMAPEMLNGKSYDETVDIFSFGIVLCEIIGQVYADPDCLPRT
Sbjct: 473 TLRKNDRKKRYTVVGNPYWMAPEMLNGKSYDETVDIFSFGIVLCEIIGQVYADPDCLPRT 532

Query: 171 LDFGLNVKLFWEKFVPTDCPPAFFPLAAICCRLEPESRPAFSKLEDSFEALSPLYLGELGI 230
LDFGLNVKLFWEKFVPTDCPPAFFPLAAICCRLEPESRPAFSKLEDSFEALSPLYLGELGI
Sbjct: 533 LDFGLNVKLFWEKFVPTDCPPAFFPLAAICCRLEPESRPAFSKLEDSFEALSPLYLGELGI 592

Query: 231 PLPAELEELDHTVSMQYGLTRDSPP 255
PLPAELEELDHTVSMQYGLTRDSPP
Sbjct: 593 PLPAELEELDHTVSMQYGLTRDSPP 617 (SEQ ID NO:4)

Hmmer search results (Pfam):

Model	Description	Score	E-value	N
PF00069	Eukaryotic protein kinase domain	100.1	1.1e-26	2
CE00031	CE00031 VEGFR	4.9	0.14	1
CE00204	CE00204 FIBROBLAST_GROWTH_RECEPTOR	4.7	1	1
CE00359	E00359 bone morphogenetic protein_receptor	1.8	7.9	1
CE00022	CE00022 MAGUK_subfamily_d	1.5	2.5	1
CE00287	CE00287 PTK_Eph_orphan_receptor	-48.4	3.8e-05	1
CE00292	CE00292 PTK_membrane_span	-61.8	2.1e-05	1

FIG.2B

CE00291	CE00291	PTK_fgf_receptor	-113.0	0.027	1
CE00286	E00286	PTK_EGF_receptor	-125.1	0.0021	1
CE00290	CE00290	PTK_Trk_family	-151.3	6.5e-05	1
CE00288	CE00288	PTK_Insulin_receptor	-210.4	0.014	1

Parsed for domains:

Model	Domain	seq-f	seq-t	hmm-f	hmm-t	score	E-value
PF00069	1/2	16	79 ..	41	105 ..	52.1	2.3e-13
CE00022	1/1	124	153 ..	187	216 ..	1.5	2.5
PF00069	2/2	81	156 ..	129	182 ..	48.0	3.1e-12
CE00031	1/1	129	156 ..	1114	1141 ..	4.9	0.14
CE00204	1/1	129	156 ..	705	732 ..	4.7	1
CE00359	1/1	79	157 ..	287	356 ..	1.8	7.9
CE00290	1/1	9	218 ..	1	282 []	-151.3	6.5e-05
CE00287	1/1	1	218 [.	1	260 []	-48.4	3.8e-05
CE00291	1/1	1	218 [.	1	285 []	-113.0	0.027
CE00292	1/1	1	218 [.	1	288 []	-61.8	2.1e-05
CE00288	1/1	1	218 [.	1	269 []	-210.4	0.014
CE00286	1/1	6	218 ..	1	263 []	-125.1	0.0021

FIG.2C

1 TCATCCTTGC GCAGGGGCCA TGCTAACCTT CTGTGTCTCA GTCCAATTTT
51 AATGTATGTG CTGCTGAAGC GAGAGTACCA GAGGTTTTTT TGATGGCAGT
101 GACTTGAAC TATTTAAAAG ATAAGGAGGA GCCAGTGAGG GAGAGGGGTG
151 CTGTAAAGAT AACTAAAAGT GCACTTCTTC TAAGAAGTAA GATGGAATGG
201 GATCCAGAAC AGGGGTGTCA TACCGAGTAG CCCAGCCTTT GTTCCGTGGA
251 CACTGGGGAG TCTAACCAG AGCTGAGATA GCTTGCAGTG TGGATGAGCC
301 AGCTGAGTAC AGCAGATAGG GAAAAGAAGC CAAAAATCTG AAGTAGGGCT
351 GGGGTGAAGG ACAGGGAAGG GCTAGAGAGA CATTTGGAAA GTGAAACCAG
401 GTGGATATGA GAGGAGAGAG TAGAGGGTCT TGATTTGCGG TCTTTCATGC
451 TTAACCCAAA GCAGGTAATA AAGTATGTGT TGATTGAATG TCTTTGGGTT
501 TCTCAAGACT GGAGAAAGCA GGGCAAGCTC TGGAGGGTAT GGCAATAACA
551 AGTTATCTTG AATATCCTCA TGGTGGAAG TCCTGATCCT GTTTGAATTT
601 TGGAAATAGA AATCATTGAG AGCCAAGAGA TTGAATTGTT GAGTAAGTGG
651 GTGGTCAGGT TACAGACTTA ATTTTGGGTT AAAAAGTAAA AACAGAAGAC
701 AAGGTGTGGC TCTAAAATAA TGAGATGTGC TGGGGGTGGG GCATGGCAGC
751 TCATAAACTG ACCCTGAAAG CTCTTACATG TAAGAGTTCC AAAAAATTTT
801 CCAAACTTG GAAGATTCAT TTGGATGTT GTGTTCATTA AAATCTCTCA
851 CTAATTCATT GTCTGTCCA CTGTCCGTAA CCCAACCTGG GATTGGTTTG
901 AGTGAGTCTC TCAGACTTTC TGCCTTGGAG TTTGTGAGAG AGATGGCATA
951 CTCTGTGACC ACTGTCACCC TAAACCAAAA AAGGCCCTC TTGACAAGGA
1001 GTCTGAGGAT TTTAGACCCA GGAAGAATGA GTGATGGGCA TATATATATC
1051 CTATTACTGA GGCATGAGAA GAGTGAATG GGTGGGTTGA GGTGGTGTTC
1101 TAAGGCCTCT TGCCAGCTTG TTTAACTCTT CTCTGGGGAA CGAGGGGGAC
1151 AACTGTGTAC ATTGGCTGCT CCAGAATGAT GTTGAGCAAT CTTGAAGTGC
1201 CAGGAGCTGT GCTTTGTCTA TTCATGGCCC CTGTGCCTGT GAAACAGGGT
1251 TCGGTGACTG TCACTGTGCC TGTGGCAGTC TGTAGTTACC CAGAGAGAAC
1301 AAAGCTGCAT ACACAGAGCG CACAAGGGAG TCTTGTAACA ACCTTGTCTT
1351 GCTTTCTAGG GCTGAGTCAG GTACCACAGC TTGATCTCAG CTGTCCTCTT
1401 TATTTCAAGA AGTTGACATC TGAGCCATAC CAGGAGTATT GTATTTTGTTC
1451 TGAGGCCTCT CTTTTTGGAG GAACATGGAC CGACTCTGTG CTTTTGTCTA
1501 TGCTGGTCTC TGAGCTCACA CAACCCTTCA CCTCCTTTC TCAGCCAGTG
1551 ATAGGTAAGT CTTCCCTATC TTGCAAGGCT CAGCTCAAGT GTCAGCTTCC
1601 TCTACAAAGA CTTTCCTGGT TCCCCTCATT GGAGTGAACA AGAGTTGACA
1651 TGGTAGAATG GAAAGAGCAG AAGCTTTAGA ATGAGCCAGA CCTGAGTATG
1701 AATGCTAGAT CCACCACTTA GCTAGTCAAC CCTGCCCCCT GCCTCAAGTT
1751 TTAATTTTCC TATCCATTAA GTGAATATAA TAATACCTGT GTCACAGGAT
1801 TATTTTGAGA ATTAATGAG ATTAGGTCTA TGAAAGCACC TAGCAGAGTT
1851 CTTGGCATAT AGGAGGCATT CATTAAATAT TTGTTCTTCC CCTTTTATAC
1901 CCATTACTTT TCTTTTCTG AACTAAAATA ATACTTGGTT CTATCTCTGA
1951 AATAACATCC AAGTGAAAAA TCAACAACAT GAAAGAGCAG TTCTTTTCCA
2001 GTGGATTTGC TTCTTAAGGA GCAGAGATTA TGTAATCTAA CAGCCTCCAA
2051 CATACAAAGA GCTTTGTATC TAGAACAGGG GTCCCCAGCC CCTGGACCGC
2101 CAACTGGTAC GGGTCTGTAG CCTGTTAGGA ACCAGGCTGC ACAGCAGGAG
2151 GTGAGCGGCG GGCCAGTGAG CATTGCTGCC TGAGCTCTGC CTCCTGTCAG
2201 ATCAGTGGTG GCATTAGATT CTCATAGGAG TGTGAACCTT ATTGTGAACT
2251 GCACATGCAA GGGATCTGGG TTGCATGCTC CTTATGAGAA TCTCACTAAT
2301 GGCTGATGAT CTGAGTTGGA ACAGTTTGAT ACCAAAACCA TCCCCCGCC
2351 CCCCACCCC CAGCCTAGGG TCCGTGGAAA AATTGGCCCC TGGTGCCAAA
2401 AAGGTTGAGG ACTGCTGATC TAGAGGACCA ATTTATTCAA TGTTGGTTGA
2451 GTAAATGAGC TCTTGGATTA GGTGATGGAA AAATCTGAAA AACAGGGCT

FIG. 3-1

2501 TTTGAGGAAT AGGAAAAGGC AGTAACATGT TTAACCCAGA GAGAAGTTTC
2551 TGGCTGTTGG CTGGGAATAG TCATAGGAAG GGCTGACACT GAAAAGAAGG
2601 AGATTGTGTT CGTTTCTTCT TCTCAGAGCT ATAAGCAAAG GCTGAAAGTT
2651 CTAGAAAAAG GCAAGTTTTG TTTCAGTAGA AAAAAGGATA ATCAGAACCA
2701 TTTTATAGAA ATGGAATGAG ACTACTTTTG AGGCCATGAG TTCCTTGTCC
2751 CTGGAGAGAT GAGCAGAGGT TGGACAAGTG CTTACCAGAG ATCTTGTGGA
2801 GGCAGAAACT GTGCATCTAG CAGAGCATTG GCCTAACCTT TTCAAATGAG
2851 ATGCTGTTAA CTCAGTCTTA TTCTACATGG TAGGAATCCT GTCCCTTTGC
2901 CTCCTGCTAC TTTGGGCCTC TCAACCTCTT GGTTTTGTGT GCAGGTGAAG
2951 ATGTCTGGAG GTGTCCAGGC TGTGGGGACC ACATTGCTCC AAGCCAGATA
3001 TGGTACAGGA CTGTCAACGA AACCTGGCAC GGCTCTTGCT TCCGGTAGGT
3051 GGGCCTATCC TCCCATCTTT ACCAGTGTAC TATGGGCCAA GCACTATTTT
3101 ATGTTCTGAT GGAAAACACA GAAACAAGCT TCTGAGTTGA GAATTTCAAT
3151 CTTAGGGTGG GGAAAGGAAT GTACCAAGGA AGAGCTCATG ACCAAACCTC
3201 AAGTGTGGCC CCCCTGAACC CAGGTAAAT TGGAAGAGCC ATAAATGGGC
3251 CAGCTGGAGG CAGGGTGGGG GGATGAGAGG AGCCCTTTCC AGGGTTGTCC
3301 CATATCCCTC ACTTTATGGG TGAGGAACT GAGGCCAGG AAGAGTGAAT
3351 TTCCTGTGGC TGCCTACAG ATTATGCAGG TACTTCAAGA GTTGTGTTGA
3401 TTCTTATTTT ATTTTATTTT ATTTTATTTT ATTTTATTTT ATTTTATGAG
3451 AGGGATTCTT GCTGTTGCC AGGCTGGAGT GCAGTGGTGC AATCTCGGCT
3501 CACTGCAATC TCTGCCTGCT GGGTTCAAGT GATTTTTCTG CCTTAGCTTC
3551 CTGAGTAGCT GAGATGACAG GCACCTGCCA CCATGCGCAG CTAATTTTTG
3601 TATTTTAGTG GAGACGGGGG TTTCAACATG TTGGTCAGGC TGGTCTTGAA
3651 CTCCTGACCT CAAATGATGC ACCCACCTCG ACCTCCCAA GTGCTGGAAT
3701 TACAGGCGTG AACCACTGTG CCCAGCCAAG AGTTGTTTTT AGTGTGGTTG
3751 GCAGAGCCAG CTCTTCCTTC ACCACAGGAT GCCTCCCTAG GTTCCTACTT
3801 TTTGTTACTA GCTTTTATTA TAGCTATATT ATTATTATTA TTATTATTAT
3851 TATTATTATT ATTATTGAGA CAGAGTCTCG CTCTGTCGCC CAGGCTGGTG
3901 TACAGTGGTG CGATCCCGGG CTCCTGCAA CCTCTGCCTC CCGAGTTCAA
3951 GCAGTTCTCC TGCCTCAGCC CCCCAGTAG GTGGGACTAC AGGCGCCTGC
4001 CACCACACCC GGCTAATTTT TGTATTTTTA GTAGAGACGG GGTTCACCT
4051 TGTTGACCAG GCTGGTCTGG AGCTCCTGAC CTCAGGTAAG TGCTAGAATC
4101 ACAGGCGTGA ACCACTGCGC CCAGCCAAGA GTTGTTTTTA GTGTGGTTGG
4151 CAGAGCCAGC TCTTCCTCAC CACAGGTTGC CTCCCTAGGT TCCTACTTTT
4201 TGTTACTAGC TTTATTATAG CTACATTATT ATTATTATTG TTATTATTAT
4251 TGAGACAGAG TCTCGCTCTG TCGCCCAGGC TGGTGTACAG TGATGTGATC
4301 TTGGCTCACT GCAACCTCTG CCCCCGAGT TCAAGCAATT CTCCTGCTTC
4351 AGCCCCCTA GTAGGTGGGA CTCCAGGCAC CTGCCACCAC GCCAGCTAA
4401 TTTTGTATT TTTAGTAGAG GCGGGGTTTC ACCTTGTTGG CCAGGCTGGT
4451 CTCAAACCTC TGACCTCAGG TGATCCGCCT GCCTCGGCCT CCCAAAATGT
4501 TGGGATTACA GGCATGAGCC ACCGCGCCCT GCCTATAGCT ACATTATTTT
4551 TGTAGGCAGC TCAGTTTCTT AAAAATTATA CAGACTTCAA ATCAGATTTG
4601 TTCCTGCTGT CTGAGGCTCA GTTCTTTCAT CTGGAATATG GATGGTAATA
4651 ATCTTGTTGA GATTGAATGA AATAATATAT GCAGTGTATC CAGTACATGG
4701 TAGACACCCA GTGAATGGTT ATTCCTTCCT CCCATCGGAT TGGAAATCTC
4751 AAGGGTGGGA ACTTGCTTTT ATATTCTTCA CAACGTAAAA TAGTTGAAAT
4801 TTGTTGGTGG AAAGAAGAGC AGTCCACTCC AGAGGCTGGA TGGGCATGCC
4851 TGGCCCCCAA GGTCTGAAGT GGTAGGGCTG TGCCTATATC CTGAGAATGA
4901 GATAGACTAG GCAGGCACCT TGTGCTGTAG ATTCCAGCTC CTGCACATAG
4951 CTCTTGTTGT AAAACATCCC TGTGCTTATA CCAAGTAATT GAGTTGACCT

FIG.3-2

5001 TTAAACACTT GCCTCTTCCC TGGGAACCAT ATAGGGGATT GGCCTGGAGA
5051 CGTCTGGCCT CTGGAAGAGT TGGAAAGCAG CCATCATTAT TATCCTTTCC
5101 TTTCAGCTAT AACTCAGAGC TCTCAAGTCT TTTCTGTGGA TCTTATTGCC
5151 TTGGTTCTTG CCCCTTTTAC TCCCAGGGAA GTTGATTCTG TCTTTTCTGT
5201 TCCATTTAGT ATGACAGGAG CAGAGAATGT CAGAGCTGTA AGGGACCTTA
5251 TAGTTAAAGC CTTTGGCTGG TCCTTTCATT TTATAGCTGG GACTAATAAG
5301 TAACGTCAA ACCCAATGAG TTCACAGATT GGGTCTCGCC TTGGCATGTA
5351 ACCCATATGT TCATATTCTT GCTGTTTTCC TATGTGTATG AATATTTTCT
5401 ATCCAAAATA AGCAGGACAG GGTAGAGCAA GTTAATCTTT GGAATTTCTG
5451 GATTCTCTTA GAGCTAAAA ACTTCAGAAC TAGAAGAAAC CACCCACTAT
5501 ATGGTATAAC CCATTTCAT CACAGATGAG GCCTGAAACC AAAAGACTT
5551 GCTCAGGCCA TGGATGACAA GAGCTGGCCC TAGCACTGAA CTCTTGGGTC
5601 ATTTGTAGGT CTAGTCAGAT GCTAGCTTGT TAGCTCTGTG CGTGCCTGTG
5651 TGTGTGTGTG TGTGTGTGTG TGTGTGAGAT AGAGACAGAA AGATAACATA
5701 TGTACACAAA TACATAAAGA GGAAGTAGAC ACGTTAGCAT GGTAGATAAG
5751 AGTACAGGCA GGCCAGGCGT GGTGGCTCAC GCCTGTAATC CCAGCACTTT
5801 GGGAGGCCAA GGCAGGTGGA TCACCTGAGG TCAGGAATTC GAGACCAGCC
5851 TGACCAACAT GGTGAAACCC CATCTCTACT AAATACAGAA AAAAATTAGC
5901 TTGGCATGGT GGCACATGCC TGTAATCCCA GCTACTTGGG AAGCTGAAGC
5951 AGGAGAATCG CTTGAATCCG GGAAGCAGAA GTTGCAGTGA GCCGAGATTG
6001 TGCCATTACA GTCTAGCCTG GGCAACAAGA GGGAAACTCC ATCGCAAAAA
6051 AACAACCACC ACCAAGAGTA CAGGCTATGG AATGAGACTA TGGTTTTAAA
6101 TCCTGGCTTT GCAATTTATT AACTAGCCTT AAGTGACTTC CCTGAGCTTC
6151 AGGCACCAAT CTGTAAATG AGGATAAGAA TATTACTCAT GCCACATGGT
6201 TGTTAGGGAG GATTAAATGT GATAACCTAT ATAAAGTGGC TAGCATAGCA
6251 TCTGACATAT AGAAAACTCT TAATAGGGCC GGACGTGGTG GCTTATGCCT
6301 GTAATCCTAG CACTCTGGGA GGCCGAGGCA GAAGGATCGC TTGAGCCCAT
6351 GAGCCCAGGA GTTTGAGACC AGCCTGGCCA ACATGGCAA ACTCCACCTC
6401 TACAAAAAAT AAAAAAATAT TAGCCAGGCG TGATGGCACA CACCTGTAGT
6451 CCCAGCTACT TGGGAAGCTG AGGAGCGATG ATTACCTGAG CCCAGGGATA
6501 TCAAGGCTGT AGTGAGCTGT GATCATGCCA CTGTACTCCA TCCAGCTGGG
6551 GGACAGAGTG AAACCCCTGT CTCAAAACAA AACAAATGAA AAAAAAACCC
6601 CTTAATAATC AGTAACTGTC ACTTTATATT ATGTTGTGAG TGTGTGCTA
6651 TATACACCTA TATGTATACA TTTCTTTAT TACACATTCA TTGGTGATCT
6701 GATGTGGAGC CCCAGGGATT AAGGGCAACT TTGAACTACC CTGACACAAT
6751 CAAGCCAAAT ATCATTCCCG TGGAGGAAGT AGAGTATCTA GGTTCGTCT
6801 CCTAGTTGCA GCTTTACCTT GAGGACAGAG ACTCTAATCC AGCTGTGCTG
6851 AAGGAGCACA TCTCCTGACT TCTGAGCTTT CCCCTGGTAA ATTCAAACCTG
6901 GATGTCACGG CGCCCTCAGA TAGAGCCTGG TAATTTGCCC TGGGGAGAGT
6951 GACTGTCTTT TGGATCTAAT TTGACTTTTG CCCCAGTTGG AGGAAAATCT
7001 TCAGGGCTAG GAAGGATTGT ATTTGTCTGA CCCCAGAGAT AACCTGGGTT
7051 TTGAGGAACA TGGGGCATCA ACCTGAATGG TCTTGTAAGA TCTCTCCAC
7101 GCCAGCTTGC CAGTGTCTT CTGATGAATT TAGAGTACCT GAGTAGTGCA
7151 GGCTGCTGG GAGGAGGACT CTCCCTCTGT GCTACTCAGA GAAATTCATT
7201 CTTCAAGGCC CCCTTCCAGC CTTGCTCTTA CCCAGCTGGG CTACAGTTAC
7251 AATAAAGGAA ATGACTTTTC TTCTCCCTT CCCCAGTAC CTTTGTTC
7301 CTAGTCACAG GGTGGGGCTG GATATTGAAT GGAGAAATTG CTGGGGTCCA
7351 TCCTAAACTC CTCCCTCAT CTCTCCCTTA CATTACCCCA TTCTTCTGTC
7401 TGCAGCCACA TCCATAATCC TGCTCTGTT AGCCTTCCGA CAGACCCTCA
7451 GGTGCCCAGG ACAACAGGAA GCTACTTAAA GCTGGAACCT CAGACTGTGC

FIG. 3-3

7501	AATGGAGGCC	AGTGACAAAA	CTGAAAGTAG	CTCTGTCAGT	AATTGTGCTG
7551	GTGCGATTAG	GCAGCTGGCC	AGAATCTTTT	GGATCTCCTG	GACATATGGC
7601	TGACTAGTCC	TCCCAAGCCT	TCCCAACAGG	CCTCTTTTTT	TTCCTTTTTT
7651	TCTTTTCTTT	TTTTTCTTTC	TTTCTTTCTT	TCTTTTTTTT	TTTTTTTTTAG
7701	GCTAGTGAAG	TGAAATTGTG	GGAGTGGAAG	AGGAACAAAG	AAATCGGTAA
7751	CTGGTAGTGA	TCAATTACTT	GTAAACACTA	TTGTACTTGG	ACCAGCCCAG
7801	TAGGCCTTTT	TTAAAACTCT	GAGTTACCTC	TCTTTCCTTT	CCTTGAGCAG
7851	TGCCATTAAT	TCTGTATCTG	GGCAATCCT	TTCTGATGTT	CTCTGGACCT
7901	GGCTCTCTCT	CCTTAGGAGA	GGCCAGGAGA	GTAGCCAGAG	AGCATGTCAT
7951	TTGTAGCTGA	GGTTAAAGTG	TGGAGCTATC	AATGGTGACC	TGGCCTCTTG
8001	GCATGTTAGC	AAGCCAGAGG	ACCTTGACAA	CTTTTTTGAT	GATTGTCCGT
8051	TCACCCTGAT	CAAAGGTGTT	TGGCTTAGGA	GGAGGGAAGA	AAAGCTACCC
8101	CTATTAGTCT	TGATGGCCCC	AGCGTGGGTC	TCTATTGCTT	GACCTGGTTC
8151	CTAGCAGCAT	TATCAGAAGG	AAAATCCACC	GCTCTTAAGG	CTCCTGGGAA
8201	CTTTCAGGAC	TTCCTTCTC	AGGATTGCAA	ACATAAGACT	ATTTGAGCTT
8251	TCACTTTTGA	AAAGCGGTTA	CTAATACCTA	TACTCTGGGA	AAGGGCTAAT
8301	GCAGATAGAA	GACTGTGGTC	ACTGCATCAG	GCAACAGACC	ATTTCCGCTA
8351	AATTTAGTGA	CTCCAGGAAG	GCCAGTGAAG	AAATAACACA	CGTAGCAACC
8401	AGAGACTGTG	TTGTAATATG	TTGGCTGACA	GCAGGGTACT	TTCTGTGATG
8451	CTGAAAGCCA	CATTCATTTT	CTCTCCCCTC	ATCCCCATCT	AAGCAAGCCT
8501	GGTAGAATCA	TAATTACAGT	AATAGGTACC	ACTTATTGAG	TACTCTGTGC
8551	CAGACACCCT	CCTGAGCATA	CGACATGCAT	AGCACATTTA	ATCCTTACAA
8601	TGACTTAATA	AAATGTAGTA	CTAGTCTTAC	CTACTTCGAG	AATAGGGAAA
8651	TGGAGGTTAC	TTGTTTAAAG	TCACAGAGCT	AATAGGTAGC	ATAGCTGAGA
8701	TTTGAACTCA	GGCATTCTTA	CTCCTTGCCCT	GCAAGAGTCT	CTTGGCATTG
8751	TTGAATGCAA	GCATATTTCT	TAACCTCACT	GAGGCTCAGT	TTCTCTTAT
8801	ATAATATGGG	GTAAAGAGCC	CTCACCCCTGC	CTGCCACACA	CTGGTAGTGT
8851	CAGATAACAT	TGAAGGGTGT	TAGTTTAAAG	GCTTCATGGA	CTCTATAATG
8901	TCAACAAAAG	TGCTGTTAAC	TTTCTTCTGG	GTCTCAGGCT	CCTGATGTAG
8951	AGTCAGTGGA	GCAACCCTGC	CATCTGCTGT	TATGCTGTTG	ATGTTGCTGC
9001	CACACTTACT	AACCTAAACC	TTTGATTCTG	GCTGTGGCCT	TCTCCAGAAG
9051	GTGTTTACTC	ATTTGTCCAG	TTTATCTTTT	AGGAAACAGC	CAGCCCGTAG
9101	ATCATTAAAG	CTGGCTATTG	GACAGGGGGC	TGGGGCCTGC	CTGACAGAGG
9151	AAGGAAGGGC	AGACATCTGG	TTCTTCCTCT	GCCCCACAA	GAGACTCCAG
9201	CCTGACCACA	GAGTGGTACT	CCTAGGATGT	AGCAGCAGCA	TATGAGCTTG
9251	AATGTGCCTT	AATCCTGCTC	TTTACTTTGA	GAAGAGAGAA	CTAAGGACCC
9301	ACAGATGTTT	CACAGCTTCT	ATAGGAGGCA	GAGGTAGAAA	AATGGAGAGA
9351	GATGAGGCCA	GAGATAGATA	ACTGATATTA	ATTAAACGTT	GTATTAAGAA
9401	CCTCACTTAG	ATTATCTGAT	TCAATCTTCA	TAATAACCCT	GCAACCCCCA
9451	CCTTTTTTTG	AGAACAGGGT	CTTGCTCTGT	TGTCCAGGCT	ACAGTGCAT
9501	GGTACAATCA	TAGTTCCTG	CAGTGTCAAC	CTCCTGAGCT	CAAGCAATCC
9551	TCCCACCTCA	GCCTTGCAAG	CAGCTTGGAC	TACAGGCGTG	CCACCACACC
9601	TTGCCATTTT	TTTTTATTTT	AAGTAGAAAC	AAGGTCTTAT	TAATACTATG
9651	TTGCCCAGGC	TGGTCTTGAA	CTCCAGCGAT	CCTCCTGCCC	CAGCCTCCCA
9701	AAGTGCTTGG	GATTACGGAA	GTAAGCCACT	GTGCCTGGCC	AGTGCAACCC
9751	CCATTTTATA	CTAAAAACAGG	AAGGCCCAGA	AAGGTTTGGG	GTAACCTGTC
9801	CAGGGTCACA	CAGATGATAT	TTGAACTCAG	GTCTCCCTGG	CTCCCAAGAG
9851	AGTCTGCTTT	CCACTAGGAC	TCCCAGGAGA	AAAAAAAAAA	AAAAAACAGT
9901	AGACTTGGAG	ACAGAAAATC	TGATTTGAGT	CTTAGTTGAG	CTAGGCTAAC
9951	TGTGTAAC TG	TGGGCAAGTT	CCTTAGCCCC	TGTGAGCCTC	AGTTTCTTAT

FIG.3-4

10001 CTGTAAAATG TCATAAAAGA AATCCATCTC ATGGAGTAGT TGTGATGATC
10051 AAGGACTCTG AAAACATTAG AATGGTTTAA TGTGAAGGAT TAGCAGCAGC
10101 ACATGGCAAC ATTGTGCATC TTATATTAAC TATCCAAATA TATCAAGCGT
10151 CATTTGCTAT ATATAAAAGT CATCAAATTA GGCAGTGTGG GGGATACGGA
10201 GTTGGCATACTAGCCTGGCC TCTTAATTAA TTCATTAATT AGCTTATTTA
10251 TTTTGTGAGAT AGGTCTTGCT CTATTGCCCA GGCTGGAGTG CAGTGGCATG
10301 ATGATAGCTT ACTATAGCCT CAATCTCCCA GGCTTAAACA ATCCTCCTGA
10351 GTAGCTGGGA CTACAGGCAC AACTACCAT GCCCAGCTAA TTTTTTTTTA
10401 ATTTTTGTGTA GAGACAGGGT CTTGCTCTGT TGCCAGGCT GGTCTCAAC
10451 TCCTGGGCTC GAGATCCTCC CACCTGGGCC TCACAAAGTG TTGGGATTAC
10501 AGGTATGAGC CACGGCACCT GGCCTGGTCT CTTAACTGGT TCCCTAAGAC
10551 AGCTGGAAT AGAGAATGTC ATGGAGCATT CCTAACCATG GGCTCCAGCC
10601 TGGCTTTCAT TCTGTTTCTC CCCTGAAACA ACATTCCTTT AGTAATATTC
10651 CGAATAACAG CTTTCATCAGT CTGTCTACCG ACCACTCTTC AGGCTTCATC
10701 TTATATGACC TCCCAAACCTG CACTAAGGGT TGTATTAGAG AAAAGTGGAT
10751 AAAGTTCGGA GTCAGGCTGC TTGAGCTTAA ATGCCAGCTT CACTTACCAG
10801 CCACCTGACC ATGAGTCAGC TGCTTAACCA TTCTTTGCCA CAGTTTCCTT
10851 GTCTATGAAA AGGGAAATGG CTCCCACCTC AAAAAGTTGT TAACATTAAA
10901 TTCAATCATG TATTCAAAGT CCTGAGCAGA ATGTCTGGCC ATGACATGGA
10951 CTTAACAGAT GTTAGCATT ATTATTAGTA TCTGTCAGTC TTGAAATGTT
11001 CTCTTCCCTT GGCTTTCATG ACATTCCACA CTCTCCTGGT TTTCTCTTAC
11051 CTCTCTGGTA ATACCTGTTT GCTTATCCTT CTTTGTCCAG CTCTGGGATG
11101 TTACCATTCC TTCAGGCGTG CTGTTTTCTC CTTAGGCAGT CTTACACACA
11151 CTCATGACTT CCTTCCATTG TCCTCCACAC ACTGATGACC CTAATATCAG
11201 TATCTCCAGC CTAAACCTTT CCACTGAGTT CTAGACCCAT ATGTTGTACT
11251 ATCAACCTGG CTTGTCCATT TGAATGTCTT CCAGGCACTT CAGACTCTCT
11301 TCTCTAGACT TTGCTGGACT TTCACTCTTC CCCCTAAAC TGGCTCCTCT
11351 TCCACTGAAA CATGTATGTC ATTGAGAGGC ACCACCATCC ACCCAGTGCC
11401 TAAGCCAGAA ACCTAGGAAT CCTTGATACC TGTCTCTCT CATCCTGCAT
11451 ATCCAAGCCT ATCAGTTTTA TCTCTAAATT ATATTTTGGT AGGTTTACTT
11501 CTTTCTTTT CTCCCACCAC CACCCTGCTC CAAGCTACCA TCATCTCACC
11551 TGGATGTCTG CAATAGCCTC ATCTCCACA GCCACTCTGC ACCCCCTAAT
11601 CTGTTCTCTA TAGAGCAGTT GGAAGGAGTG ATTTTGTGTG TTTGTTTGT
11651 TTTGTTTTAG ACAGAGTCTC ACTCTGTTCC CCAAGGCTGG AGTGCAGTGG
11701 CACAATTCG GCTCACTGCA ACTTCTGCCT CCCGGGTTTA AGCAATTCTC
11751 CTGCCTCAGC CTCCAAGTA GCTGGGATTA AGGCACCGGC CCCCATACCC
11801 AGCTAATTTT TATATTTTTA GTAGAGATGG GGTTTTGCCA TGTTGGCCAA
11851 GCTAGTCTCG AACTCCTGAC CTCAAGTGAT CCACCTGCCT CGGCCTCCCA
11901 AAGTGCTGGG ATTACAGGTG TGAGCCACTG CACCTGGCTG GAAGGAGTGA
11951 TCTTAAAAAA AAAAAAACA AAAAAAACT TGAAGTGTG ACTCTGTGTT
12001 GTCTCTCCTA CTTGTATAC TTCCACAAC TCCCAGTGTT CTTGGATAAA
12051 GACCAAATC CTTAACTTGG CCAGGCGCGG TGGCTCACAC CTATCATCTC
12101 AGCACTTTGG GAGGCCGAGG CAGGCAGATC ATGAAGTCAA GAGATTGAGA
12151 CCATCCTGGC CAACATGGTG AAACCCCATC TCTACTAAAA ATACAAAAAT
12201 TAGCTGGTCG TGGTGGCGTG TGCCTGTAGT CCCAGCTACT TGGGAGGCTG
12251 AGGCAGGAGA ATCACTTGAA CCTGGGAGGC AGAGGTTGCA GTGAGCCAG
12301 ATCAGCCAC TGCACTCCAG CCTGGTGACA GAGTAAGACT CCATCTCAA
12351 AAAAAAAAAA AAAAAAAAAA TTCCTTAATT TGGCCTACAG TAGAGCCCTC
12401 CGTAATGTGG CCTCTCTCCA CATCTCCACA ACCTCCTGCT CCCTGCATT
12451 CAGCCTCACC TCTCTTCTGG ACAGGCCCTC CTTCTGACAA GGGCTTTGTT

FIG.3-5

12501 CATTCTGCTC CCTCTGCCTA GAATGCCCCC TTA CTCTGTT CACTTAACTC
12551 CTGCTTATCG TTTAGATCTT TACCTGGATG GCTCAGAGAA ATATAGAAGT
12601 AATTCCTCAC CCTGAAAAAT AGGTTAGGTC CCTGTTTTAT GTTTTCATAG
12651 ACCTTTCCTT TGAGGCTTTT TTTAAAAAAG TAGTTTTAAT CTCACATTTA
12701 TTCATGTGAT CATCTCCTTA ATGATATCTT AAGACCTCTA ATAGAACAAT
12751 TTGGTCATGG ACTGTGGGGT TTTTGCCCTT CATTGTGTCA GCACTGAGCA
12801 TATTGTTGGC ATAGGAGGGA TATTTGTTGA ATGAATTGCT AGAGGTGGCC
12851 AAGAGATATG ATGTAAGTCA GGCTTTTCCC TGCCCTTCCC CTTCCCTTC
12901 CCCACATCCT TCCTATAGCA GCCACCGTGG CTGCAGTTAC TGTAAATGGC
12951 AAGACGGAAT CAGTTCGGA CATTGGGTTG TTTTAGAAAA TTGCCTGCAA
13001 GTGTCAGGGT GATAAGTTAA AGCTTTGTCT TTTGCCCTCA GAGGAGCTAT
13051 CCCATAGTGA GTAGAAGCCA GAGAAGCTGA CCCAGGAGT CCTTCTTTCC
13101 AGCAGCAGGT CTTGAGCTGC ACTTCTCTGT AGCTACAATC CAGGCAGGAA
13151 CAAGCCCTAG GTACCTCCGG AGAGGAGGGC AAGAGAGGAA GAATGAGTTC
13201 AGCTACTCTA GCCACCAAAC TGATTATGAA TTGCCCTGAA ATCTGAAAAA
13251 TTTCAATTCC AATCGTAAGT TTGTTTTGTT TCATTTTGT TTCTTAAATT
13301 GTATATTTGA AAGATGGCAT TAACTAAAGA TATATATTCA ATATAGAGTG
13351 GAAAAAATGG AATACTTGCA TAGTATCTTT TACTTATAGG TGATTATGA
13401 TGGGGAGTGG GGTGGATAGG TTGGCAGTTC CCCAAGAAG TTGGAATGA
13451 AGTTTGTCTT CTGTGAGTTG AACTAATTAG ATCCACAAGT AATGAAAGCA
13501 GTATTGTGTT GTAGTTAAGA GCACACTCTA GAACCAGATT GCTTAGTTTC
13551 AAATCCTGGT TCTGCCTTTT ATTATCTGTG TACTTTGGGC AAGTTACTTG
13601 CCCTTTGTGT GCTTCATTTT TCTCATCTAG AAAATGGAGA GGCCAGCGCT
13651 AGTGGCTCAT GCCTATAATC CCAGCACTTT GGGAGGCCGA GGCGGCGAGA
13701 TCACCTGAGG TGAGAAGTTC AAGACCAGCC TGGCCAACAT GGTGAAACCC
13751 TGTCTCTACA AAAATACAAA AATTAGCCAG GCATGATGGC GGGTGCTGT
13801 AATCCCAGCT ACCCAGGAGC CTGAGGCGGG AGAAACACTT GAACCTGGAA
13851 GGCAGAGGTT GTAGTGAGCC AGGATTGCAC CACTGCACTC CAGCCTGGGT
13901 GACAAGAGCT AGACTCAGTC TAAAAA AAAA AAAA AA AACTGGAGA
13951 TACAGGCTGG GTGCAGGGCT TACACTTATA ATATCAGCAC TTTGGGAGGC
14001 CTAGGCGGGA GGATTGCTTG AACTCAGGAG TTTCAAGATC AGTCTGGGTA
14051 ACAGAGCAAG ACCTCATCCC CACAAAAAAT CAAAAATTTA GCCAGGCATG
14101 GTGGCTCATG CCTGTGGTCC CAGCTACTCA GGAGGCTGAG GCGAGAGGAT
14151 TGCTTGAGCC CAGGAGGTTG AGGCTGCAGT GAACCATGAC TGCACCACTA
14201 CATGCCAGCC TGGATGACAG AGCAAGACCC TATCTCAAAA AAAAAAAAAA
14251 AAAGAAACGA GCCAGGCGCG TTTGCTCACG CCAGTAATCC CAGCACTTTG
14301 GGAGGCCAAG GCAGGTGGAT CACTTGAGGT CAGGAGATCG AGACTAGCCT
14351 GGCCAACATG GTGAAACCCC ATCTCAACTG AAAATACAAA AATTAGCCAG
14401 GCATGGTGGC ATGCTCCTGT AGTCCCAGCT ACTCACTTGG AGGCTGAGGC
14451 ACGAGAATCG CTTGAACCCA GGAGGCGGAG GTTGCACTGG GCCAACATCA
14501 TGTCAC TGCA CTCCAGCCTG GGAGACAGAG CGAGACTCTG TCTCAATAAA
14551 TAAATAAACA TAAATAAAAA TAAATAAAAA TAAATAAAAA TAAAAAATA
14601 TGGAGGCCAG CAGGCACGGT GGCTCACGCA TGTAATCCCA GCACTTTGGG
14651 AGGCCGAGGG GGGCGGATCA CAAGGTCAGG AGATCGAGAC CATCCTGGCT
14701 AACACAGTGA AACC GCGTCT TACTAAAAA TACACAAAAT TAGCCAGGCA
14751 TGGTGGCAGG CACCTGTAGT CCCTGCTACT CAGGAGGCTG AGGCAGGAGA
14801 ATGGCGTGAA CCCGGGAGGC GGAGCTTGCA GTGAGCTGAG ATCGGCCAC
14851 TGCAGTCCAG CCTGGGCGAC AGAGCAAGAC TCTGTCTCAA AAAAAAAAAA
14901 AAAAATGGAG GTTGGGCGCG GTGGCTCGCG CCTGTAATCC CAGCACTTTG
14951 GGAGGTCGAG GCGGGCGGAT CACCTGAGGT CAGGAGTTCC AGACCAGCCT

FIG.3-6

15001 GGCCAACATG GTGAAACCTT GTCTCTACTA AAATTACAAA AATTAGCCAG
15051 GCACGATGGC AGGCACCTGT AATCCCAGCT ACTTAGGAGA CTAAGGCAGG
15101 AGAATAGCTT GAACCTGGGA GATGGAGGTT GCAGTGTGCT GAGATCGCGC
15151 CACTGCCCTC CAGTAGAGTG AGATTCCGTC TCAAAAAAAAA AAAAAAAGAA
15201 GAAATGGAGA TACAACTTA CTACCTACCT CCTTACAACC TACCCTCACA
15251 GTATTACTGT GAATAAAAGT GTGTGTAGCA CTGGGAACAC TATTCACAGA
15301 GCACTCATGA ATGTTTGTTC TTTGTTATTA GTTACTAGAG AGGCAAATGT
15351 CTGCCAGGGC TGAATAATAT GTGTGAATTG GTGATTGTCG CACATATCTA
15401 AAGAAGTAGT TATTTTTTTC AATTA AAACT TAGTTTAAAA ACCAATATAA
15451 GGCCGAGCGC AGTGGCTCAC ACCTGTAATC CCAGCACTTT GGGAGGCCGA
15501 GGTGGGCAGA TCATTTGAGG TCAGGAGTTC GAGACTAGCC TGGCCAACAT
15551 GGTGAAACCC TGTCTCTGCT AAAAAAAAAA AAAAAGTACA AAAATTAGCC
15601 AGGCATGATG GCAGGTCCCT GTAATCCCAG CTA CTGGGA GGCCGAGGCA
15651 GGAGAATTGC TTGAACCCAG GAGGTGGAGG TTGTAGTGAG CCGAGTTTGT
15701 GCCACTGCAC TTCAGCCTGG GTGACAGAGG GAGACACTGT CTCAAAAAAA
15751 AAAAAAAAAA ACCAAAACCA ATATAATAAA TAAGTGGCCA GCAATGAAAC
15801 AGAAAGTGAA AAGTTAGTGA AGCAAACTA GTACTGTATT CAGATAAAGA
15851 TGCTGAATCT AGATTTGGTC ACCAGAATAG GGTCTTTTGT GGCAACCTGG
15901 GCTAGTTTGG CTGACTCACC ACTGCCAGGA TGA AATTCT TTCAGTGGCT
15951 ACTCATTTCC CTTTATTTTA AGTCCATGCT CACAGAGCAA CCTTCTGATG
16001 CCTAATTCAG CTTCTGGGA TACTTAATAA CAGGAAGGGT CTGGAAGTAG
16051 TACCTGTATA GGGGATATGA GTGTTCTGAT TTTAATAGTC AATTCATAAG
16101 TGTACAGAGG GTTTGATAAA TGGTTAGGTC AGAACCATCA CAGAATGTCT
16151 ACACCTCTTT GGACATTAGG AAGGTCAAAA ACCTGAAAGG CCAAAAGCTA
16201 GGCCTAGATT AGGGTCATT ACCAAGAAAA CATCAGCCTT GAAGAGTTCT
16251 CTGGGTGGTC CACCAGTCAA CCTTCCTTTG ATCACACCTC CTTCTCGTT
16301 GCTTCTTTAA GCATTGACCT GTAATGGGTA TGG AATTTTT TGCTCACCTA
16351 ACTCCTTCCT TTTACAGAGG AAGAAGTTGA AGCCCAGAGA GATTTAATGG
16401 CTTGCCTAAG ATCACACGCA GATTTTCTGT TAACCAGGGT GATTTTTAG
16451 GTGTTCCCTG CCAGACGAGG GCTTTTTTCC TTGAATTGCC TAGAGATTTC
16501 TTGAGATATC CGAAGCATTT TTCCAGTGC AGCCTGGAGA AGGATGTCCC
16551 TGTC AACACA GCATTTGTTA CTCAATGTTA GACATTCAAT TTTCTAATTA
16601 GTATCATGGA GCAACAGTGG ATGATTATCT ATAAGGGGTT GCAATTCCAT
16651 GCTTATGTGC TTACAGCCCA TATAGACAAA TATCAGCTGT TAAAATGACA
16701 AGGCAGTAGA GATGTGGCCC CAGGACAAAG GCATACTCTG CTGTTAGTGA
16751 AACTAGTTG GCCAGCAAAT TTCACATGGG CATATACAG GCCAACTGTA
16801 GACTTTAGGC ATTTATACCC ATTCAGAGAG CCAAAGTGGC AACTAAAGAT
16851 CAGCATTCTC TTTGGCATT CAGCTTTGCG TTCTGTAAA AATCACTGCT
16901 TGCTTAAATA CCTCTGATAG CTCTTCACTG CCTGTAGGCA ACTCTTAGC
16951 CTAGCAGACT TGGTCTTTAG TGCTCTGCCC CTA CTCTCTT CCACCATCT
17001 GGCTCCTGT CTAATTGCTG CCCATATGTG CCATGCACTA GAGCTTACAG
17051 ACCTGCTCAG CGTTATATGA GCATACCATA CTCTTTATGC CTCAGTGCAT
17101 TTGCACATGT TGTTCTTCA GGCCAGAATG CCTGTACTG CCTGGCAATC
17151 AGCCTATTAG AGTCTGCCAA TACCATCCCA TCTTCTGTGG AGGAGCCCCC
17201 CGCCAAATCC ACCCATACCT CTCCCCACCA ATCAGAGACT TCTTCTCTCT
17251 TTGTTATTCT CTTCGTTATT CTCTTCATAC CTCAGTTATA TCCATTTAG
17301 TATTTGTTTA CACATCTAGC ATCACTCTTA GAGTGTGAAA TTCTCCAAGT
17351 GTGGAGCCGT ATCTAGTTTG TCTTTGTATC CCAGAGCTTA GCAAAGTGCC
17401 TAGAATGTAG TGGGTGCTCA GAGTGTGTTG TGGGTGAATG ATGTATTTGT
17451 TGAACGACTC TTTGGACACT TGAATAAAGT CCATCCAGTA TGCACCATTA

FIG.3-7

17501 CCATCTCTTC GCTCTACAAT ATTCTTTTAG GCAAGAGCTT ATCTTTTGAG
17551 GTGATAAGAT AAGCTCAAAC TTATGTAGAC TAAGACCTCA GTCTGTAAAT
17601 GTCATCCCTA AGTCTTAAAC CATCAAAACC AGGGCCTCAA GGAATGGCAT
17651 GCCTTCTGCA ACTGTAGCAA CCTGCTGTGC TTATTTTGCC GTGTTTTTCA
17701 TTTTCCCCC AAAAGCTAGA GTCCCTTCTC CCATGGGCAG TGCTGGAAGT
17751 GTGCTAACAA ATTCTTCTC CATACTGCTT ACGATTACAA AAAAAACCCT
17801 CAGCATCTCA TGCCAGACTT GAGTTAAGGT TGTTCCTTT TGTGTGTCAG
17851 CTGTATTCTG GTCATGACTT CCTGATGATG CCCTATAGAG ATTTTGCTGA
17901 GATCAGAGGG TGCTCCACTG CCATCAGTAG CACTGACTCT TGCAGAAGCA
17951 CCGTTTCTGA AGTTGGCTAA TGTATCCCT CACGTTTGTT TGTTTGAAT
18001 TTGTTTTAGT TCCAGAGATA GCACTTTCAT GGAATGACGC TATCTTCTAG
18051 AATCACTTTT TTTTTTTTTT TGAGTTGGAG TCTCGCTGTG TCGCCAGGCT
18101 GGAGTGCAGT GGCACAATCT CAGCTCACTG CAATCTCCAC CTTCGGGT
18151 CAAGTGATTC CCCTGCCTCA GCCTCCCGAG GAGCTGTTAC TACAGGCGCA
18201 CACCCCACT CCTGGCTAAT TTTATGTGTT TTAGTAGAGA CGGGGTTTCA
18251 CCGTGTGGC CAGGATGGTC TCGATCTCCT GACTTTGTGA TCTGCCTGCT
18301 TCAGCCTCCC AAAGTGCTGG GATTACAGGT GTGAGTCACC GCGCCTGGCC
18351 TAGAATCACC TTTTATACC ATAACGTGAG CACCACTGCC GCGTCACCAA
18401 GGAAAGAGAG AGGCAGCTAC TGTGGGGTTA CAAATGGGTA AGAGTGGCAC
18451 CAGGAAGGTG AAAGTCTCTA CTTAGCCAAG GCTTAACAAA ATGTCAATCA
18501 CCAAACATTT ATTTATTAAG CTACGTTTCA GATAAGAAGA TGAACAAGCT
18551 ATCTGTACAT TCATTTTCTC GTTTGTAACA AGGTAATGAT AGTGATCTAT
18601 CCTGCCTGCC TCTGAGGGTT ATTGTGAGAA TAAAATGAAA TCAAGTGGAA
18651 AAGCACTTAG GAAAAAGAAA AGCATTGGTT TTCAATTGTT AGTGTGGATC
18701 AGAAACACTG GGGCTTGTTT AAAATGCAGA TTCTTAGCCC CAGTCTCAGC
18751 GATTCTGATT CTGTATATCT GAAGTGGGAC TCAGGAATCT TGATTTTCAA
18801 CAAGCTGACC AGAGGGTCCA ATGCTGCTAT TCCTTTAGTT ACACTTTTCA
18851 AAATATTACT GTAAATCAAA TGGCAAGAAT AAAATAGTTA TTTGAGGCAG
18901 TTTTAGTATG TTGGACCTGG AGTCCAAAGA CTTGGGTCAA ACTCCAGCTT
18951 TGTCAGTTCC TAGACCTGTG ACCTTAAACA GCAACCTTCT CTGTGAACCT
19001 TAGTCCCTC AGGAACGGCT CTGGTCACCT CCTGCTGTAC TCCATTGATG
19051 ACTCACCACA TAAGGCTCCC TGGGAGTCCC CCAAACCTTT GCTCTCTTAA
19101 CTCCTTTTAC AGCCTCCTAC ATCTCCTGCA GGTGCTGTCT TCTCCTCCTT
19151 TTTCCAGGCC CTGCTCTGAC ACAGCATTCA TTCTCCTCTG GGAAGGGTTC
19201 CTTCAATGTG TCTCCAAGCA CATCACACCC AGGAAGGACC CTGTGGCCAT
19251 ATCTGTCTAT CACCAGATCA AACTACGTGA AGGCAGGCAC TAGGTACTGT
19301 CAGTGCCCAG CATAGGCCTG GCCCATACCA GGTGTCCACA GATGCCTAGT
19351 AAAGAAACCT ATGATTCAGG ACCCCCATGA TGAGCAACTA TAGCACTAGA
19401 ACAGTGATAA TAACTAATGT TTATAATGCA TCTTCAGTTT ACAGAGGGCT
19451 TTTGTAATCA TCATCTAGTT TAGTTCCTGC AACAACTCTT TGAGGAATAT
19501 AGCACAAGCA GGACAAGGGA AGCCCAGAGA TGTTAAATAA TTTATCCAAG
19551 TTTATGCTGC TGGGAAGGGC AGCACTGAAA TTAAGAGAAA AGTTTTCTGA
19601 GCTCAAATCC CATGCCCTTT CCTCAATGTG AGCTCTAGCA AGGTATTCAG
19651 GAATCCTGCC TCTACAGTTC AGAGCCTCAA ATTGCTGGGT ATGTTGAGTT
19701 CTTGTATCTG ATTTTCTAG ATTTCTGCC CACATTCTTA CTGTCTGGAT
19751 ATCAGGAAAG AGTTTATCAA ATGCCTGTGG AAATCCAAGA TAAGGTCTCA
19801 TGATGAGTAA CCCAGTGAAA ACATGAAGTC AAGTCTAACT AGTCACTACT
19851 ATTTCACTAC TGCTGACTCC TGATGATCAG CTCCTTTTCT AAGTGCTTAC
19901 TGTCCACTTA TTCCATCATC TGCCTAGAAT TTATGTGAAG GAATCAAAGC
19951 AAAAGGATCA TAAGGCTTCC TTTTCCAGT ATGTTTTTCC TCCTTTTGA

FIG.3-8

20001 AAACTGGGCC AGTTAGCTAT CTCCATTTTT ATTTTCATGAA TACATCCCCA
20051 GCGCCTGGTA TATAGTAGAT ATGGAACATT ACACTTTGGA GATATTGCAC
20101 CCATTCTCCA GTTCTCCAA AGTTACTAAC AATGGTTCCA TCACTGTGCC
20151 AACATATTTT CTTTTTCAA TATATTGGGA AATAATTCTC CCAGTCTGAA
20201 AATCTGAACA CATTTTCATGT GACTTGGTAT CCTCATATGT CTTGGGCTTC
20251 CAATTCTCCA TTCCTAGTTT CAAGTTCATG AACTGTAAAA CAAAGGATTA
20301 GACTAAATCT CTAAAGTTCT ATCCAGATGC CAAATTCTTT TCTCTTTCCA
20351 TGATACCTAA GATAGATGCC AAATATTGTC TTTTACCTGG TGTGTGTGAA
20401 CATGACATCA CATTACAGGA GTAGCAGATA CTAAACTCTC ACTCTGTAAA
20451 ACACTGACTG AGTTCATGA GCCAGATACT GAAGTGAGCT TGTTACATA
20501 TGTTCTCATT TAATGCTCAT AACCCTGTGA AGCTGGGAAT TGCTGGGACA
20551 TTTTATTTAT TTATTTATTG AGACGGAGTC TGGCTCTGTC ACCTAGGCTG
20601 GTGTGCAATG GCATGATCTT GGCTCACC GC AACCTCCGCC TCCCGGGTTC
20651 AAGCGATTCT CTTGCCTCAG CCTCCGCAGT AGCTGGGATT ACGGGGCACA
20701 CACCACCACA TCCAGCTAAT TTTGTATTTT TAGCAGAGAT GGAGTTTCTC
20751 CATGTTGGCC AGGTTGGTCA CGAACACTTG ACCTCAAGTG ATCTGCCTGC
20801 CTCAGCCTCC CAAAGTGCTG GGATTACAGG CATGAGCCAC CATGCCTGCC
20851 CGGGACCCTT GTTTTAGAAG GATGACTGCT GCTATAATGT AGAAAGTGAT
20901 TTGGAAGAGG GGAGGAGTGG GGCACGAAAG ATGGTTAGTA GATGGGGGTG
20951 GTAATGCTTA CCTTTCAGTA TTTGGAGGCT TCGGAGTCTT CAAAAATTCT
21001 CTTCTTGAT TGGAGTCTC CCAGCCAATA GAGGGCTTCA CACAAACAGT
21051 TTCTTGGGT TTGAATTGTT TGACCAGAGC TTTCTCCGA CAAAAGTTG
21101 GGGTGATTCA TTCATTACC ACACCTTGCC TGAACATTCA CTTGGGGCTG
21151 CCGGTTATGA AGGCTATTGT TCTCCAGCCT GTCACAGACG CTTTGAAGAC
21201 CTGTGCCTCA GCTGGTTCTA AGGAGTCAGT TTGTTAGCT CCGTGCCAGG
21251 TTTCCAACTT ATGAAATGTG CTGGAGATTA ACACCTCTCC TGCCATTTTA
21301 TCCCTACTAT AATTGCCAGT CAAAGGATTC CTGCAGTTGC CTCTGGCAGC
21351 CATAACTGAT GAATGTTCTG CCAGCTGCTC TGAGGACCTA GAAGAGCAGT
21401 TTTCTATCCA GGACCAGTTT CCAAGGGTGG GAGGGTGAAA TATATCTTCC
21451 AGTGTGACAT TTCATCTCCC AGTGATGGGT GGCTTGGGCC CTTTGAAGTT
21501 GGCTCTGAGG AACCACACAC TTGGGTCTGA GCAGCCAGCA GCTTATCACA
21551 TCTGGTGATC AATCCTTCAA AGGTTCTTCC TGAAGTCTGA ATTTTGGAG
21601 GTCAAATGGA TTCCACCTGG GAGGGGCTTC TGCTTCACT CAGGACATGG
21651 GGAGAAGGCT GTTCTCTTC CAGGGGGAGG CAGTTTTCAT GGCATTGAGA
21701 TGTCTCTCA CTTATTCCCC ACCACCCAC CAAGTCTTTT GTAAGAGGAG
21751 TAGGGGAGGA GGAGAGCGCC TGCAGCCTCC TGCTCACATT CCTAGACACC
21801 GACTCACTGA GCGCGTCGCC GCTGGAACAG CAGAGCTGTG TGAAATGTCA
21851 AGAGGAGTTA TGCTCATAGG CTCCCTGGCC TCAGTCTCTT TGTGGCTTGC
21901 ATATTCTTCC ATTAGTACTG TGTTCATCAC ATGGAAATCA GAGGGTACAA
21951 TTAAGAGATA ATTTGCTAGT CCCAGACTTA ATTTGGGGCC CCCTTCTTGC
22001 CTGATTGAAT TACAGGGGAA CATAATAGAT TTTTGGTGAG AAATAGTTGT
22051 CTGTGTGGCT GGGAGAAAGA TTGCTCCAG CTCTCCAGCT GGGCAGCCCT
22101 TTCAGTATCC CGTATGTTAT TTCCCACTT CCAGCCACC TCACCTCTC
22151 TGTGGCCCTT GTGTGTCCC TCGGCTAGGA TCCTGACCTC CTGCTCAAGA
22201 GTTTAAACTC AACTTGAGAC CCAAGGAAAA TAGAGAGCCC TCTGCAACCT
22251 CATAGGGGTG AAAAATGTTG ATGCTGGGAG CTATTTAGAG ACCTAACCAA
22301 GGCCAGACA GAGAGAGTGA CTTGCTAAAG GCCACATAGC TAGCCACAG
22351 TAGTTGTAA CATAAGTCTTA ATGATATTAA TGGCTAACAT TTATCAACCT
22401 TTAATGTGTC CCAGACTTTG TGCCAAGGGC TTACATGCAG TGCATTGTG
22451 CATTCAAACC CAGACAGTCT GGCTCTGGGC CCAGGCTGAG CTTTGGTATA

FIG.3-9

22501	GCATGGTAGA	ACGTTGTCTA	TAATGTCTAG	TCTGGGTTCA	AATCCTGGCT
22551	TCACCTTCTCA	CATTTACAGC	TGAGTGACCT	CAGGCAAGTG	ATTTAACCTC
22601	CCTGTACCTC	AGTTGCTTTA	TCTGTAAAGA	GAAAAATCAC	AGCACTGTGG
22651	AATAGTGGGG	GTAAAAATTC	ATTCATACAA	GTAGTGCTGC	AAGCAATGTT
22701	TAATACAGGG	TGAGCACCTG	TTCAGTGCTT	CCTTCTTCTG	GCTGCCTCTG
22751	GGGCTAGAGT	GTGGTGTCTT	CGTGGTATAG	ATAGATAGAT	ATGGCTGAGC
22801	TCTGCACAAA	CACCAAGAGC	TGTTCTTCAC	TATTAGAGGT	AGTAAACAGA
22851	GTGGTTGAGC	TCTGTGGTTC	TAGAACAGAG	GCCGGCAAGC	TATGGCCCAT
22901	TGCCTATTTT	AATACGGCCT	GTGATTGATT	GATTTTTTTT	TTCTTTTGA
22951	GACAGAGTTT	CACTCTTGTT	GCCCAGGCTG	GAATGCAATG	GCACGAACTC
23001	AGCTCACCGC	AACCTCTGCC	TCCTGGGTTT	AAGCGATTCT	CCTGTCTCAG
23051	CCTCTCGAGT	AGCTGGGATT	ACAGGCATGT	GCCACCACGC	CTGGCTAATT
23101	TTTGTATTTT	TAGTAGAGAC	AGGGTTTCTC	CATGTTGGTC	AGGCTAGTCT
23151	CGAACTTCCA	ACCTCAGGTG	ATCTGCCCGC	CTCAGCCTTC	CAAAGTGCTG
23201	GGATTACAGG	CGTGAGCCAC	CATGACTGGC	CTGATTGACT	GATTTTTTTA
23251	GTAGAGATAG	GGTCTTGGTT	TGTTACCCAG	GCTGGTCTCA	AACTTCTGGC
23301	TTCAAGCAGT	CCTCCCTCCT	TGGCCTCTCG	AATGCTGGGA	TTATAGGCAT
23351	GAGCCACTAT	GCCTGGCCTA	TATGACCTGT	GATTTTTAAT	GGTTAGGGGA
23401	AAAAAAGCAA	AAGAATGCTT	TGTGACATGT	GGAAATTACA	TGAAACTCAA
23451	ATATCAGTGT	CCCAGCCTGG	GCAACAAAGT	GAGACCCTGT	CTCTACAAAA
23501	AATAAAAAAA	AATAAGCCAG	GGCCGGGCGC	AGTGGCTCAC	ACCTATAATC
23551	TCAGCACTTT	GGGAGGCCGA	GGCAAGTGGA	TCACCTGAGG	TCAGGAGTTC
23601	AAGACCAGCC	TGACCAATAT	GGTGAAACCC	TGTCTGTACT	AAAAACACAA
23651	AAATTAGCCG	AGCATGGTGG	CATGCGCCTG	TAGTCCCAGC	TACTTGGGAG
23701	GCTGAGACAA	GAGAATTGCT	TGAACCTGGG	AGGCGGAGGT	TGCAGTGAGC
23751	CAAGATCGCG	ACACTACACT	GCAGCCTGGG	CAACAGAGCG	AGACTCCGAC
23801	ACACGCACGC	ACGCACACAC	ACACACACAC	ACACACACAC	ACGCTGGGTA
23851	TGGTGGCCAG	CACGTGTGGT	CCCAGGATGC	ACTGGAGGCT	TAGGTAGGAG
23901	GATCACTTGA	GCTTAGGTGG	TTGAGACTAC	AATGAACCAT	GTTTATACCA
23951	CTGCACTTTA	GCCAGGGCAA	CAGTGTGAGA	CTGAATCTCA	AAAGAAAAAA
24001	AAAAAAAAGA	AAAAAATCTT	TCCATAAGTA	AATATCTGTT	GGAACATAGC
24051	CATGTCCCTT	AGTTTATGTT	TTATATATGG	CTGCTTTTGC	CCTATAATGA
24101	CACAATTGAG	TGGCCACGAC	AGTCTGTATG	GCCTGCAGAG	CCTAAGATAT
24151	TTGCTCTCTG	GCCCTTTACA	GAAAAAGTGC	CTTGACCTGT	GCTCTAGAGC
24201	CATATGTACC	AGGTTTGAAA	CTCAGCCTCA	CAGCTGGGTG	TGATGGCAGG
24251	CATCTGTAGT	CCCAGCTACT	CTGGAGGCTG	AGGTGAGAGG	ATCACTTGAG
24301	TCCAGAAGGT	CGAGGTCAAG	ATTGTAGTGA	GCCATGATGG	CATCACCAGC
24351	CTCCAGCCTG	AGTGACAGAG	AGAGACCCTG	AETCAAAAAA	AAAAAAACAA
24401	AAAAAAAATA	CACCCTCACC	ACTTATCAGC	TATTTGTCTT	GAGAATAGTG
24451	ACATAACCCC	TCAGAACCTA	TTTCCTAATC	TGTTAAATGA	GGCTGATGAC
24501	GTTTCCTCCT	TTTACTGGCA	ATTTAAACAT	GATGGATAAT	AAATGCTAAG
24551	CACTTAACAC	AGGGCCTAGA	AGATATTAAC	TGCTCAATAA	ATGGTAGCTT
24601	CTTAACAGTA	TTCAAACCCA	TGTGCTCTTA	TCACATGCAT	TGTTGTCCCT
24651	GTGTCCAGTT	GGTGAATGG	GAAAAGGCTC	CCTTGTAACC	CCATCTACCA
24701	TCTTTATCAG	ACTTTCCTGC	CATGGTTCAC	AGTAAGAGAT	AGAAGCTGCA
24751	CGGTGACTTC	TGGCTCTTTA	CAATGGTGAG	CGGTGTGTGC	CTGGTAAGGG
24801	AGAGCTGATG	TACTGCCCCC	AAATCCAGTA	GTGAGATCTG	AGTGTCTCTG
24851	TTTCCTCCAG	CAGCCTTGCT	TTTTCTTTA	CAATCCTGCA	GGCAGGGAGA
24901	CAAGGGCTTT	CTACATGGTA	GGCTCTGGTT	TGGTCATCGT	CACAACCTGG
24951	GGCTGTTCAG	GTGGGCTCCC	ATTCCAGATA	CCTAGGCTTA	TCAATCCCTT

FIG.3-10

25001 TTGGCACCCC AGGCCTTTTT CTCCTCATG CCCCATTTTT CAGTTTGAAA
25051 AGCATGGTTA TCACAGGACA AGTAGAAGAA GCTCCACTGT CCACTGAGGC
25101 CAATGGATGG TGTTCGTCAT GTGAACACTC AGTGAATAGT GAGTGAATGA
25151 GAGTAACCTG GGCTCCATCC TATTTGCAGA GAGCTTTGGA AAAGATTTTT
25201 CTCCTTAAAG AGCCAGAATG AAGCCTGGTA GTGGGAGAGC TCCAGCTCTA
25251 GAGTCACATG AGCCTACATT TAAATTCCAG CCCTGCCACT GACTCCCTTT
25301 TTGACCTTGA GTGAGTTACC TAATCTCTCT GTACCTCACT TTTCTTGCT
25351 GTAGAGTGGG AATAATTCCT GTCTCAGAGA AATAAAAGAG TGCATATAGT
25401 GTTTGCCACA TGGAGACACA TCAGGTGTAG GTTAATACTC TGGGCCTTGT
25451 TTCCTTATTT GCAACACAGC CCTGCCCTGG AGTGGAAGTG GCACCTCCCA
25501 TTGGTCAGCT CTTGAGGCTG TCCCAGGAC AGGCAGAGGG AGGGAATGAA
25551 TGGGAGCCCT AGTGCCAGGA CAGAACAGAT GGCAGCTCAG AGCTAGGATG
25601 GCTCTCTGGA CCTGTCTCTC CTACCAGAGG TCCCCCGTC TGGTGTGGCT
25651 CTTCTGGAC CTGGCATCCT CTGCTTTTTT TTTTTTCCA CCTCCAAGCA
25701 GAATTACTGT CCTGTAGGCA GCTCCTCTGC TTGAGGACAT CTGGGGCCAG
25751 ATATGTTTAC ACTCTATCCT GCCTTGCCCT TCCCTGAGCT CAGGATGGAC
25801 GCTCAATTGG TCCCAGTTAT TGTCTGCAGC GCCTGCCTGC AGCCTCGATC
25851 CAGCCCAGCT CCACCCCTTG CCTGCAAGGT CTGTTTCCTA ACAGCTGCTC
25901 CAACCACACA CCTCGGTTCT GCGGGAGCCC CTCCTCTTCC TCCCTCCCTC
25951 CCTCATTGAG GGGTGGGACT GAAGAAGAAG GCTAACTTGA CAGCAGCGCT
26001 TCTTCTTAG CTAGTCACCG GCCCTGCTC AAGAATGCCA GTGTGTGTGT
26051 AGCCTCCACA GAGAGGTCGT TTTCTCGGAG TCCAGAGGGG CCGCTGAGC
26101 TTCTGAGAAC TAGGGAGGAG CCATCCCAGC CATGAGCCCC TGTGGGAATC
26151 TGCTGGGGGC CAAGTGGCCT GGAGTCCTCA GGCTCCCGCA GCTGCTCCGG
26201 AGGGAGAGGT GAGCTCAGGG CAGCCTGCCT GCAGCCAGAG GTGCCGGGAG
26251 CCCCAGGCT GTCATGGTGG CCATCTACAG CCGGCTGAG GCAGTCACAG
26301 ACGGATTTGC AGCTGAGCCT GTCTATCTGG TGTGGGAAGA AGATGGGGAG
26351 TTAATTGTCA GTCCCGGCTT ACTTCACCTC CAGAGACCTG TTTCGGTGAG
26401 TTGGTCTCCG AGTTCCCCTC TCCATCTCTC CTGGCCCCTG GTCCTGAGAG
26451 GAGGGTGGTC TCCCTAAATC TCCTTCTCAC TTAGTCCTTT ACCATCGGTT
26501 CTGCCGGGCA GAAGCCAGCG GAGGTTATAC CCAAGGAGAA TCGGCCTTGT
26551 GAGGTACCCC CATTATGTCC TGGAAGTGGT GAGGGGAGGG ATATACCCAG
26601 AAGGAACTTC TTAGGGAGCT CCAGCTCCCC TTCTATCCCA GACAAACCTG
26651 AAGGAGCCTC CAAAAGATGC CACTGACCTG CCCATTGTAG ATGTTACTGC
26701 TTCCGGGGGG AATAGCCCAA ATAGAGTGCT GTTTCAGCT CTCACATGTC
26751 TTACCTGCGG GCCATGCTGC CTGCCAGGA ATTTGTCCCA ACAAGCAGGA
26801 TGGGCAGGTT TTGCCAAACT GTGGAAACTG GCAAGTCCTG GGTGTGGGTA
26851 GCCTGGTACA CAGTAGGCAC CTTATAAACG TTTGTTCTCT TAATGGCAGG
26901 CACATTTGCC TCTGGCCTTG AAGGGCTTCT GAGCTCCCAG GTGAATGTAG
26951 TTGCTGGGGA AAGACCTGGG CGAGTGCTTC TAAGACTGGA GCAATGGGCT
27001 TTAGAGTGTT CCTGAGCTGC TGGGCCAGCC CCCACACCTC CTCAGTCCCT
27051 AGGCCTAAGT ACCTCCACGA GCCTCTCTCT GTGGGGCTTC TCAGAGGGAG
27101 ATGTGGAAAC TCTACCTCTA ACCTGGCTTT CTTTGCTCAT TGCCCCACTC
27151 CACCTCCCAT AGAAACTCCC CAGGGGGTTT CTGGCCCTCT GGTGCCCTTC
27201 TGAATGGAGC CATTCCAGGC TAGGGTGGGG TTTGTTTTCA TTCTTTGGGA
27251 GCAGCCTGTT GTTCCAAAAA GGCTGCCTCC CCCTCACCAG TGGTCTGGT
27301 CGACTTTTCC CTTCTGGCTT CTCTAAGCTA GGTCCAGTGC CCAGATCTTG
27351 CTGCCGGGAT ACTAGTCAGG TGGCCAGGCC CTGGGCAGAA AAGCAGTGTA
27401 CCATGTGGTT TTGTGGAATG ACCGGACCCT GGTAGATTGC TGGGAAGTGT
27451 CTGGACAGGG GGAAGGGGGA AGGGAAGTGG TCCTCAATGC TGA CTCTACC

FIG.3-11

27501 AAGCGCCCTG CTAGACACTT TATCCTTTAA TCTCTCAACA GCCTAAAGAG
27551 ATTATATATC CCCATTTTAC AGATGAGGCA ACCAGTTTCA ACAGAGTTAA
27601 CATATGGAGC CTCCTGGGC AGCTTTTCT GTCTTCTGA CTTTCTCTCA
27651 TCCTTCAGGG GGCTGCAGGT TTGTTTTCTT CTCCTAGTGG AGAGGAAATT
27701 CTCAGGTTTG TTTTCTCTC CTAGCAGAGA GTAAAAAAG GGATAGTTTG
27751 CCTGACTTGT TGAAGGTGTG GCTGAGATTG TTTTCTAAAG AGCCAATGGA
27801 AATTGATCTT GAGTTTAGGA GAAAGCTTTT ACATGTGGAA TTAAGATGCC
27851 AAGTGTTGAA GTAGCCACAT TTCAGGTCCT CATTAAATTC TCTTAATCCT
27901 GGAAGGCAG CTTAGGAGAA GGGTTGTTCC TTTAGGAGCC AGGAACTATA
27951 CCCCTTTTAC CTTGGAGAG GCAGGGAAGC CAGGGAGGAC ACAACTTCTC
28001 AGGAAGAGGA GAAGCTAGAG CAGATAGTGA ACTCTCAACC TGAACCTTTA
28051 AGGGCCAGAC CACTAATGCC ACCCAAGTCC ACCTGCCGTT TGTCTTGTTT
28101 TGTCCCAGGC TTTCTGGAGA ACCTGATCTT CTTGCCCTA CCCCCAAGCT
28151 CCGTTTGCCC AGCTAGAGTC TGGGGGTAC TGAAGTCTT TCGTAGACAT
28201 TCTTCCCTTC CCCAAATAAG AGGCCACATT CCTGAAGTCA CTTCTGAAGA
28251 GATAGCTGCC ACACAGGGCT CTTTCCCCC AGGGAGGGAC CACCCAGACC
28301 CTCTGCTCTC CCAGGTATCC GTTACCACAT CACTACCTGG TCAGAAAGCT
28351 GTTCTGCCA TTAGCCCTC CCTTTTTAT TATAGGATAT CCTCAAGGGC
28401 TCCTCTTGG GCCTCAGTTT CATCCTTGGC AGAAAGTAGA AGCTAGACTT
28451 CTTGGGCTCC TGAACAGGGT CTTGCTGGA TTCTGTGAAA CAAATTAAGT
28501 TCTTGACCCT AGGCCTCTGG GGGAGTACAA AGTCTATGGG AGTTCTGGGG
28551 CTGTGGTTGC AAGGAAAGTG ACGCAACCAG ATTCCATGGG GACATGATCA
28601 GGCGTGACAT GTGAGGGAGG AAGAGGGAGC AAGGGAATGA AGAATACAAC
28651 TTCTGTGTCC CATAACCCC TGCCTGACAG GCCATACATA CTCAGCAGAG
28701 AATGCACTGT CTTTCTACC AACTAGCGT GAGGAGTGAG CTGCAATTAC
28751 CACTGTGCTT CCAAGTAAGA AAATACCTCA AATTGGAATT TACAAAAGAG
28801 GTAAATTAGG GAGTGGCTTT TGTCGGACAT CTTTAAAGCA TTTTCTTTT
28851 TATAGAATTT CACTTAATGT CCAATACTGA TTTAATGAGC TTGGGTTTAC
28901 ACATTATCTC TTGAAGAAAA CAAATGAACC TTTGTGTTCC AAAGCAATCC
28951 ATGTTTAAAG GGAAAAAATT ATGCATAACT CTGCCAGCT TCACAGTAAC
29001 CTTTGGCAGG TGCCTTAGGT CCTCTGGGAC TCTTTTCTT ATCTGAAAAA
29051 TGAAGGACTT GGATCAGGTG AATGGTTCCC AGCTCTGCAA CTTATGTGGC
29101 TCCTCAGAGG CACACAAGCT CTTTCCATT ATTTGCCAAA TAATGGAGGC
29151 CCTGTCTTTA ACTGCAGTAC AACTACACAA AATACTTGAA ACTACAGTCT
29201 TCCTGGTTTT TGGTTGGAAC TGAATCAGTG CACTCTAGCA ACACTTATTT
29251 CTTGCTGTTT GTAGGCTTCA TTATGTGTTT GGTTAATTTT TTAACAAC
29301 AATAACATAT TCCATAATAA TTACAGCTTA ATTGGCAGAC TGTTTCAGTC
29351 TATAGGATCT GCAGGAAGGA GGAGTAATAA AGGGATTTT GACTGAGCTC
29401 TTATGGAACA GAGTCTCTCT AGGCCCTGT CATATCTGCC CTTCTGGGCC
29451 CTGGGGAAAA GTTGGCATCC CCAGTTGTGG TGCTCTCCAG GTGCCCTCAG
29501 GCTGTGGTGG AGGGAGCTTC CCATTCTCTC CTTAGCCCA CTCAATTCAG
29551 AGGCTAGGGG CTGAAAGAAG CTTCTCTACA ACTGGCTGTT CACTGGGAGG
29601 TTAAGGGATG ACCATCCAGC CAGGCCTTCC TCAGGACATG GGAGGGCTTA
29651 TGCTTTAACA TGTGTAAATC CACTGCAATA ATGACTGGTT CTTTTACCCC
29701 ATAAGTTGA GAATTTACCT GTAAACATTT TTGTCTGAAG AATTTGGATG
29751 TAAGTGAGGG CTGGGCTCT ATCTTATCTC ACTTGGCTTC TCTCAGCACA
29801 GCACCTTGCC TGCTTGTCT TACACATCCT AGATGCACAG TAACTATTTT
29851 CTAATTATTA GAAATCTATT AGAATCAATT GATTTAGCT GGGCTTGGTG
29901 GCTCCTTCCT GTAATCCAG CACTTTGGGA GGCTAAGGCT GGAGGATCAC
29951 CTGAGTCCAG GAGTTTAAGA CCAGCCTGGG CAACATAGGG AGACCCTGTC

FIG.3-12

30001 TCTACAAAA ATAAAAAATT AGCCAGGCAT GGTGGTGTGC ACCTGTAGTC
30051 CCAGCTACTC AGGAGGCTGA GGCAGGAGGA TCTCTTGAGC CTGGGAGGTC
30101 AGACTACAGT GAGCAATGAT TGTGCCACTG CACTCCAGCC TGGGTGACAG
30151 AGTAAGACTC TGTCTCTTAA AAAAAAAAAA AAAAAAGTTG ATTTCTATTT
30201 GGATAGATAA ATAATTCATT TTAGGACCTT TCTTTTTTAC TTACAGAAAT
30251 CTGTTTCATT CTGGGCTGAG AAGCAGGTCC ATATTGCTAG GCATAGGAGA
30301 AAAAGGGGTC TGTCTGCATT TGCCCTTGGT GGTCTCAAAT TGGGGAGGGA
30351 AAGAAATGAA CACTTACTGG CTACCTTCTG TGAGCCAGGC ATCATGCAAG
30401 ACATCTGTAC ATAATTTAAT TCTCATAACC CCATAAGATA TTATTAGCAA
30451 TGTACAAGTG AGGAAACTGA GGCTCAGAGT CATGAAGTAA CTGGCCTTGG
30501 GTGACACAGA TGGTAAATGG CAGAGAAGGA ATATGGATCC AGGTCTTGAA
30551 AGAGAAAATC TCAACTGATT ATCTTTTTTA AAAAACTCAT ATGTTCTCTG
30601 CTGACTCAAA AGGTCTCTGT GTGGATCTGG GTTGACCCAC TGAAGTACC
30651 ATCAGGGTTC CATGCACTTT GTATCTGCCC AAGCCCTCAG AACCCCTCAG
30701 TAATGTTTTG GAAGATGAGT TTTGGAGGTT GTCCTTAGGC ATAGCCTCAG
30751 CGTATGTAGG CCTCTAGGTG ATCTCCCCTA ACCTGAGGAT TTCAGCTCAA
30801 TTCCTCTGG CTCCTCAGGA CAGTGGGATG ACTGGTTCAG ACCTCAGCTT
30851 TACCACCTCC CAGCTGGGTA CTCTTCTACC TACAGCCAGG GCAGATTTTG
30901 ACTTTCACTT GAAACTTCCA AAAATTGAAA GGTAGAAAAA CAGCCTTGCC
30951 TTTGGGAAGA ACGTATGATG TCCATGGCCT CTAAGCATCT GAGGTGGGAC
31001 ATGTTTCGAGT AGCACCTTAC AGTTCCAAAG TGTGTTCTGG GTTCTTTGTT
31051 TAAAAGAACA GAGACTGCTG GGGAAATTGA CACTGTGAAG TATATGAAGG
31101 AGGAGAATTG TGCTATTTAA CATTCACTAC TTGGGCTAAA GGAGAAGCAT
31151 CACGAAGTGT TAACACTCAA AGGGTCTTGA GCTGTCAGGG CTCCAGCTTC
31201 CTTATTTTCA CAGGTGAGAA TCCTGAGGCT CAGCTGTTGA GATGTGCTGT
31251 CTCCTCCGG TGACATAGTA CAGTGGATGT GGCTTTGCAG CCAAGCACAC
31301 ATAGCTTCAC ATTCCAGCTC CATCAATTAT GTATTGGGCA GCTTTGCAGA
31351 ATGATTTGAC TTTAACTCTG CTTTTAGTC TTCTGTAAAA CAGGGATAAT
31401 CCTGCTACCG TAGGGTTGTC AGGATTAGAG ATAATATAAA TAAGGTACCT
31451 CATATAGGAC CTGGATTATG GCTGGCATT CATAAATAGT AGCTGTTAAT
31501 TGATAGCTAA GCTAGAACTC TGAAGTCTAC CATGGCAACT TCTTAAGTGG
31551 TCTGAGAACC CAGTTGTGTT CTGTGGCAAA ACACAGCTTA GGGATCCATA
31601 CCCAGCCCTC CTGTCAGCTG TTCACCTTCC AGTTCCTCAG AGACATGTGT
31651 GGCAGTGACT TTGGCCACAT AGCTGGCTGT GCCCTTTAAA GGCATTCTTT
31701 GACACAGATA TGTGGACTGG TGACGTTGCT CTCCAGCCAG GTGTTCTTCC
31751 CAGCAGGCTG GCCTGGCTGT CTCCTGCATG CCTGTACTTG TTTGTCTCCC
31801 TGCTCCCTCT CCTGGGCCTG GCCAGAGCTA CTTGCAGCAA ACAAAGCAG
31851 GATATTGGCA ATGGAAAGGA GGGTGTGTTT TGGTGTCCC ATGCCCTGCG
31901 GCGCACATAC CATTGCAAGG GCGTAACAGA GCCAGGCCT GCATTTGGGT
31951 GCAAATAAGT CTGCACACAG AAGAAAAGAA GGACCTGGTG ACCAGGAGCC
32001 ATGGAACCTT TGTGCTCCCC TACCTGGGCT ACTGGTTCTT GCCACTCCTA
32051 CCATTTTCAG TTTGGAAATA TTTGTTAAGG CTTTGTCTTT CCAGGTCTTT
32101 TGCTTGGTGC TGAGTCTACC AAGAGTAAGT GGGATGCTGT TTTTGTCTCT
32151 AGGGAGCTAA CAGTCTAGTG AAGAAGAAAG ATGGTTGCC AGGAAGTCTT
32201 AAGTCAGAAG GCAGGAGGCA AGAAGGAAGC CCCTGCTCCT ACTGCCAGCC
32251 CTCTGTTGGG CACCCCATAG TTCTTCAGAA CCACATTTAA TCCTCACTGC
32301 AGGCCAGGCA TAGTGGCTCA CACCTGTAAT CGCAGCACTT CGGGAGGCCA
32351 AGGCGGGCAG ATCACTTGAG GTCGGGAGTT CGAGACCAGC CTCACCAACA
32401 TGGGGAACCC CCGTCTCTAC TAAAAATAGA AAAATTAGCC GGGTGTGGTG
32451 GCATGCGCCA GTAATCCCAG CTAATCAGGA GGCTGAGGTG GGAAATCAC

FIG.3-13

32501 TTGAACTCGG GAAGCAGAGG TTGCAGTGAG CCGAGATTGT GCCACTGCAC
32551 TCCAGCCTGG GCGATAAGAG CAAAATTCCA TCTCAAAAAA AAAAAGAAAA
32601 AAGAAAAAAT CCTCACTGCT ACCTTGAAAG TAGGTGATGA CATTGCCATT
32651 TCACAAATGA GAAGTGAAGG GGCTAGCCCA AGATCACTTA GGTGGTAAAT
32701 GGTGGTGCTA AGATTAGAAC CTCAGATCAT CTAGGGAAAA ACACAGATAT
32751 GCACAGAGTT AAGGGGACCC AGGGTATTGT TTGTCCTCTT GTTTCACAGG
32801 TGGGGAAACA ACCCAGAGAG GGAAAGGGGC TTGTCCAAGG CAATTTAGCA
32851 CCCAAGAACT TGAACCCATA TCTCTCTCCT CCTCATTTAG AGCTCATCCC
32901 ACATGTATCT TATATTGAGA GGAGTGTGAG CCACATACCA AGAACAGTCT
32951 TCCCCTCTGC CTCCAACCTC ACTGTGCAGT TTTGAGACAC TTCACAGCCA
33001 TACTCTTCAT GCCATACCCA GCCCTTAAGA CCCTGAAGTT CCCCTTCCAT
33051 AAGACAAGTA GGAAAAGCTA TAGGGTAAAA ATAGCCATCA GTGTTTGTG
33101 AGCACCAGG AGGAATTGGG CACTCCAGAA AGATAAAGGG ATTCTCAGGG
33151 ACTTGCTTCT CTAGACTTCC CTAGCTCAGC TGCTTCAACT CATTCTGCC
33201 CCTCTTCTCT ACCTCCCGCA GTGCTCAGAA GTAGTAGAAC TCACTGTGGC
33251 CTCTCACCTT GCATTGTTGA GTTTTATTTA GACTTTCTCT TCCTCAACTC
33301 TTCATAAGCT CATGAAAGGT GAAGTAGGGT GCCCTGTGTA TTTATCTTTT
33351 ATATCTGCAG TGCTTAGCAA GTTATAATAA TGCACTTGCC TGGCAAAAGG
33401 CTTTCTCTCA TACATTAGCT TATTTCTCT TCACATTGGC TCTTTGTAGT
33451 AATAGGATGC TATTAGTTAT TTTCAATGAG AGAAAGCTAC TAAGAGAAGT
33501 TGTCCAGCTA GTGACAGTAA GTGGCTGATA AAGTGAGCTG CCATTACATT
33551 GTCATCATCT TTAATAGAAG TTAACACATA CTGAGTTTCT ACTATATTGG
33601 GTCTTTTTTT TTTTTTTTTT TTTTTTTTGA GAGACGGAAT CTTGCTCTGT
33651 TGTCCAGGCT GGAACGCAGT GGTGCAATTT TGGGTCACCA CAACCTCCGC
33701 TTCCAGGTT CAAGCGATTC TCCTGCCTCA GCCTCCTGAG TAGCTGGGAC
33751 TACCAGTGCA CGCCACCACG CCCGGCTAAT TTTTGTATTT TTAGTAGAGA
33801 CAGGGTTTCA CCATGTTGGC CAGGCTGGTC TTGAACCTCT GACCTTGTA
33851 TCTGCCC GCC TCAGCCTCCC AAAGTGCTGG GATTACAGGT GTGAGCCACC
33901 GCGCCCTGCC TATATTAGGA CTTTTATATA AGCTATCTCT AGCTAGTAG
33951 CTAGCTAGCT ATAATGTTTT TTGAGACAGA GTCTGACTCT GTCACCCAGG
34001 CTGGAGTGCA GTGGCGTGAT CTCGACTCAC TGCAACCTCC ACCTCCTGGG
34051 TTCCAGTGAT TCTCCTGCCT CAGCCTCCCG AGTAGCTGGG ATTATAGGTG
34101 CATGCCACCA CGCCCAGCTA ATTTTTTGTA TTTTATAGTAG ACCAGGTTTC
34151 ACCATGTTGG CCAGGCTGGT CTCGAACTCC TGACTTCAAG TGATCCACCC
34201 GCCTCGGCCT CCCAAAGTGC TGGGATTATA AGCATAAGCC ACTGTGCCCA
34251 GCTGCTCTCT ATATTTTTAA TACATATTAT TTCCATTAA TTTACAGCA
34301 GTTCATTTTA TAGATGAGGA AACTAGGCCA GAGAAGTAAA ATATCTTGCC
34351 CAAGATGATG TAACTAGTAA GTGGCAGGAT CAAGATTCAA ACCAAGCAAT
34401 GTTCAAACCT CTTGGAAGCA AGAATGTGGC CACTGTGGAA GGTGCAAGGC
34451 CTTGACAACA AGAATAGGGA AAAGAAGGAA CTAGAAGGAA AGAGATGGCA
34501 TGGGCTCAGC AGGCCAGGGA GCTCTTAGCT GTGTGTGTTG GGAAGCTCAG
34551 AAGGGAGGAA GAGGTTGTCT GTGCAGGTAA GTCCTGAGAA CACACCAGAC
34601 TTTTGAGAGG TGGAGCTTCA TAGCCAGGTC ATTAGGGGAG AAGGGAGCTA
34651 TAGATTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTAG AGACGGGGTC
34701 TTAATATGTT GCCCAGGCTG GTCTTGAAC CTGGGCTCA AGTGATCCTC
34751 CCACCTCAGC CTCCCAAAGT GCTGGGATTA GAGGCATCAG CCACCCGCC
34801 CAGCGAGCTA TGGATCTAAC ATGTACATCT TACACAGTGC TAATAGAATG
34851 TTGGGTTTCT TCCCAATAT TTTATTTTGA AAAAAAATTC AAATATATAG
34901 AAAAGTTGAA AAATGTAGTT CAAAGAACAC CTACATACCT TTCACATAGA
34951 TTCATGATTT GTTAATGTTA TGCCACTTGG TATATATCTC TCTCCCTCCT

FIG.3-14

35001 ATCTGTATAC TTTTATTTAT TTATTTTTGC TGAACATTT CAGAGTAACT
35051 TAAAGGCATC TTGATTTTAC CCTTGAACAG TTCAATATGT TTCTGCTAAG
35101 AATTCTCCTA TATAAGTCAG ATATCATTAC ATCTAAGAAA ATTCACGGCA
35151 ATTTTACAAT ATAATATTAT AGTCCAAATC CATATTTCCCT CAGTTGTTCC
35201 AAAAAATGTT CATGGCTGTT TCCTTTTTTA ATCTAAATTT GAATCCAAGT
35251 TTGAGGCATT GTATTTGGTT GCTGTGTCTC TAGGGTTTTT AAAATCTGTG
35301 CCTTTTCTTC TCCCCATGAC TTTTTAGAAG AGTCAAGACC GGTTATTCTT
35351 ATAGAATAAC CCACATTCTA GATTTGCCTG ATTAGTTTTT TTATACTTAA
35401 CGTATTTTTG GCAAGAACAT TACATTGGTA ACGCTGTTGG TGATGGGTCA
35451 GTTTTGAAGA GTGGAGATGA TTAACCTGCT TTTGTTCAAT GAAGTATCTG
35501 TCAAGACCAG AGATCCTTAA CTGGTGCCAT AAATAGGTTT CAGAGAATCC
35551 TTTATATATA CACCCTGTCC CCCACCTAAA TTATATACAC ATCTTCTTTA
35601 TATATTCATT TTTCTAGGGG AGGCTTCTTG GCTTTTATCA AATTCTCAGA
35651 GGGCCCCAAG ACCCAAAGAG GTTATGAAAC ACTAGTCTGT CCACTGAGGC
35701 AGGCAACACA GAGCTGGTTT CTGGGGCCTT GTTCAGTCTG AACCAGCTTC
35751 CCTTGGGGAG ATAGCACAAAG GCTGTAACCT TGCCCCATCT TGGCTTTGGA
35801 TCAAAGAGGA CTGTCCATTT TGTGTGCTA CCTAGGAACC AGGGACAGCT
35851 TATGTGGCCT GGTTCCAGGG ATCCAGGAGA ATTTCAGTTC TTGTCTTGCC
35901 TTTCAAGTGT TCAGAAATGCC AGGATTCCTT CACCAACTGG TACTATGAGA
35951 AGGATGGGAA GCTCTACTGC CCCAAGGACT ACTGGGGGAA GTTTGGGGAG
36001 TTCTGTCATG GGTGCTCCCT GCTGATGACA GGGCCTTTTA TGGTGAGTGA
36051 ATCCCTTCAT ATCTGCCCTT CTTGGTCTTC AGAGTCCATT GACAGTGCTT
36101 CCAGTTCCCT GTGGCCTGTT AATCTTTTAG TCTTTCCATC AGCCAGGCCA
36151 TCTCCCTTTA TTTATTCATT CATTCAACTA GCAGGTATCA ATTGAGCACC
36201 TACTAAGTGA AAGGTAAGAT CTTTCCCTCA AAGACTTAAT AGTTGAACGT
36251 TGGGAGTGGG AGGAGAGGCA GGCAGAGAGG AGACACAATA TAGTTGGATA
36301 AGGACCTCCA AGGAGAGTGT TACAGGCTGA GAGGAGGATA TACTTAGGTT
36351 GTCTTTAGGG AATCAGAAAA GGAGACTCTG GAATAGGCTG GCAGAGAGAG
36401 GGGCTACCTC CTATACCTGC TCTGGACAAA CGACTTTAAG CATAGTGACA
36451 GATTTGCCAA CCCTGTATTG GAAGAACTGA TCTTTTTTAG TGGGGATGAT
36501 TACTTCTGGG GATTTCTTCT CATAACTGAG ACCAAAACAG TTTTGTGCAG
36551 TCTCAGAAAT GACAGGAGGT ACCAATCTGA CACTTCCTTT GGAAGCTCTA
36601 GGGCAGAGAG TGAAAGAGTG GATTTTGACG GGGGCCTTGC TTGGAGGTCA
36651 TTCACCCACC CCTGTCTCA CTCCAGCAAC AGTGATAACT CACTTCCTTC
36701 CTCCCTTTGT ACACCTTCT CCCCACCTGC TCACAGGTGG CTGGGGAGTT
36751 CAAGTACCAC CCAGAGTGCT TTGCCTGTAT GAGCTGCAAG GTGATCATTG
36801 AGGATGGGGA TGCATATGCA CTGGTGCAGC ATGCCACCCT CACTGGTAA
36851 GATAGTGGTC CTTTGTCTAT CCTCTCCCAT ATAAGAGTGG CTGGCGGGGA
36901 GGGACAGTGG CAGGGTGAGT TGGGCAGAAG GAGTGTTAGG GTAGTCAGAG
36951 CATTGGATTG TTACCACAGC AGTGCTCTTA ACCAGCTCTT TAACTTGTA
37001 GCAGAAATGAT TTACACATGT CTCTACCCTT TTTCTTACC AACCTTGAAA
37051 ATGTCTTAC TCTGCCCTGC AATCCTCCCA GTGGGAGGCA CTCTTCAAGG
37101 ACGATCCCAG AACATTAAAG TCAAAGACCC CTTAGAGCTC ACCCTGTCCA
37151 ACCACCTTGG TTGATAAAAG AAGTCAGCCT GGGGCCCATG GAATAGAATA
37201 GTACAAGGGC AAGGTTCTCA TTGTGAGTCA AAGGTAGAGT GAAGAGAACC
37251 CAGACCATCT CACCCAACC CAGGCCAGTG TTTTCCAAA TATACCACTT
37301 GCTGCAGATC TAGCTCAGCA CCCCAGTCC CAGCCCACCC TGAGAACCCA
37351 GGCTCCTCAT TCTGAGCAGC CAGCTAGAAT CATGACAAAG AGGGTGGTAG
37401 TGAGACTATG GGTACTGTTG CTTAAAGCCA CATGGTGCAG TGGTTGCTGG
37451 GGGGCTTCTG TGTGGGACTC TAGCATCTTA TTCCCCCTG TGCCCTCTCC

FIG.3-15

37501 CCAGTGGGAA GTGCCACAAT GAGGTGGTGC TGGCACCCAT GTTTGAGAGA
37551 CTCTCCACAG AGTCTGTTCA GGAGCAGCTG CCCTACTCTG TCACGCTCAT
37601 CTCCATGCCG GCCACCACTG AAGGCAGGCG GGGCTTCTCC GTGTCCGTGG
37651 AGAGTGCCCTG CTCCAACCTAC GCCACCACTG TGCAAGTGAA AGAGTAAGTA
37701 TTTTGAGAAC CCTTCAGCAG GGGTTCTTGA GCAGAGTCTG TAAATGGGCC
37751 TCAGAGGGCT TAGACCTCCA AAGTCTCATG CAGAACTCCC TTTATTCTCA
37801 TCTCATATCT TTCTCCTGGA CCCCACTATG CTGTAACCGT ACCTGGGCCCT
37851 TGGCACTTAC TGTTCCTCTCT GCCCAGGCTA CTTCTACCC GATACTTAAG
37901 GCAAGAATCA CTCACCTTTC AGGTGTCAGG TTTCAGGTCA TGTTCGTCT
37951 TTGAAATCAT CTGGCTTGAT TATGTGTATT AGTTGTTTAT CTTCTATCCC
38001 CTCCACTAGA ATGTAAATTC CAGAAGAAAC TTGCTGTCTT ATTCAGTGCT
38051 GCATGCCCAG GGCTTGGAAG AGTACCTGGC ATATAGTAGG AGTTGATTGA
38101 TTATTATTTT GTCAGTCGAG AGAATGAATG GAGAAAATGT GGTCCATGGC
38151 CCAAAAGAAG TTAAGACCCT ATCCTAGATT CAGGCCAGAG ACCAGTGGGA
38201 GAAAGAGTCT GTGTCTATCT AATACCAGTA ATGTCGTACC TCTGGCCGCT
38251 TACCATGTAA ATATTGATTG TGTATCTACC ATGTGTTGGA CACTAGGCTA
38301 GTGCTTGACAG AGCAGGTGAA AGATACTAGA GTTTGGGAAG TCAGGAGGAG
38351 CTAAGGTCTG TTCTACAACC TTATTAGATG AAGAGGAGAG GGAATTGTGT
38401 TCAGGGCAGA GGGAGAAGCA TTTCTCCAAA AGTAGGAGTC TTAATCATGT
38451 CTGATGTAGG TTGAGTGTGG CCAGAAAAGG GGCTGTTAAG TATAGAGGGC
38501 CTGGATTATG AAAATCCAGC AGATCCATTG AGAGTTTAAG CAGCAAGGTG
38551 TTGTGACCAA GTTAACATTT TAGAAGGATC ACTGGTATGG AGGTTGGATT
38601 GGAGAGGGGA AAGCCTAAAG GTATAGAGAC TAGTTAGGAA GCTATTGTAG
38651 GCTGGGCATG GTGGTTCATG CCTGTAATCT CAGCACTTTG GGAGGCTGAG
38701 GTGGGAGGAT TGCTTGAGGC CAGGAGTTGA AGACCAACCT GGCCAACATA
38751 GCAAGACCCC GTCTCTGTTT TTCTTAATTA AAAGAAAAGT CCAGACGTAG
38801 ACATAGTGGC TCACGCCTGT AATGCCAGCA CTTTGGGAGG CCAAGGTGGG
38851 CAGATTGCTT GAGGTCAAGA GTTTGGGATT AGGCCAGGCG CAGTGGCTCA
38901 CGCCTGTAAT CCCAGCACTT TGGGAGGCCG AGGTGGGCGG ATCACAAGGT
38951 CAGGAGATCA AGACCATCCT GGCTAACACA ATGAAACCCC GTCTCTACTA
39001 AAAGTACAAA AATTAGCCGG GCATGGTGGC GGACGCCTGT AGTCCCAGCT
39051 ACTCGGGAGG CTGAGGCAGG AGAATGGCGT GAACCTAGGA GGCGGAGCTT
39101 GCTGTGAGCA GAGATCACGC CACTGCACTC CAGCCTGAGC GACAGAGCGA
39151 GACTCCATCT CAAAAAAAAA AAAGAGTTTG GGATTAGCCT GGCCAACATG
39201 GCAAAACCCC ATCTCTACAA AAAGTACAAA AAAATTAGCT GGGTATGGTG
39251 GTGCGCGCCT GTAATCCCAG TTAATCAGGA GGCTGAGGCA TGAGAATTGC
39301 TTGAGCCTGG GAGGTGGAGG TTGCAGTGAG CCCAGATCAT GCCACTGCAC
39351 TCCAGCCTGG ATGACAGAGT AAGATGCCAT CTCAAATAAA AATTAATAAAC
39401 AAAGTTTAAA AAAAAAATAG AAGCTATTAC CGTGATCCAG GTAAGAGATG
39451 TGAATAACTA CAATGATGGA AAGAAGGCAG AGTTCTTAGA GATGGGAGTA
39501 GGAGAGATGA GGGAACTCCA GATTGGGAAG ATGATGTTCA AGTTTCTGGC
39551 TTAGGCCACA GGGTGAGTGG CAATTCCCTT CACTGAGATG GGGCATCCTG
39601 GAAAAGGTGT TGCCTTTCTG TGTGGGTATC CTGGGCCCTT TAGGGGCCAC
39651 TGGTGGCCTG GGACCTGGTA AACCTTCCCT GCACAAGCAG AATTGGTCAA
39701 GCAGGTTTTT AGGACATCTT TACCCTGCCT CAACTCTTGT CTGGCCAGG
39751 GTCAACCGGA TGCACATCAG TCCAACAAT CGAAACGCCA TCCACCCTGG
39801 GGACCGCATC CTGGAGATCA ATGGGACCCC CGTCCGCACA CTTGAGTGG
39851 AGGAGGTAGA GTGTGTGTCT AATCTGTCTT GTGAGGGTGG GACATGGAAC
39901 AGATCCTCTG GGAAATCAGG CTGTAGCCTT TACCTTTTCC TACCCCCAGC
39951 CCATCTCTTT GTCTTAGCAT TGAGCCTGTG ACCACTGGTG ACCTATTTC

FIG.3-16

40001 GCGTAACAGG TTCCCAGGGT AGCAGGGATG GTTGATGGAC GGGAGAGCTG
40051 ACAGGATGCC AGGCAGAGGG CACTGTGAGG CCACTGGCAG CTAAAGGCCA
40101 CCATTAGACA AGTTGAGCAC TGGCCACACT GTGCCTGAGT CATCTGGGTT
40151 GGCCATGGGT GGCCTGGGAT GGGGCAGCCT GTGGGAGCTT TATACTGCTC
40201 TTGGCCACAG GTGGAGGATG CAATTAGCCA GACGAGCCAG ACACTTCAGC
40251 TGTTGATTGA ACATGACCCC GTCTCCCAAC GCCTGGACCA GCTGCGGCTG
40301 GAGGCCCGGC TCGCTCCTCA CATGCAGAAT GCCGGACACC CCCACGCCCT
40351 CAGCACCCCTG GACACCAAGG AGAATCTGGA GGGGACACTG AGGAGACGTT
40401 CCCTAAGGTG CCACCTCCCA CCCTGGCTCT GTTCTGTCCT ATGTCTGTCT
40451 CTCGGATGAA GCTGAGCTGG CTTTCAGAAG CCTGCAGAGT TAGGAAAGGA
40501 ACCAGCTGGC CAGGGACAGA CTATGAGGAT TGTGCTGACC CAGCTGCCCC
40551 TGTGGGGATC ACAGTTTACA GCCAGAGCCT GTGCGGACCC AGCTGTCTGC
40601 CAGGTTTCCT TAGAAACCTG AGAGTCAGTC TCTGTCCACT GAACTCCTAA
40651 GCTGGACAGG AGGCAGTGAT GCTAAACCCT GAAGGGCAAC ATGGCCTATG
40701 GAGAAAGCAT GGAGCTCAGA GCCTGGAGTA CGGGCACAGA TAGGATTGAA
40751 TAAATTGTGT AGAAAGACTT TGAACAAT AAAGCAAAAG ATGAATGAAC
40801 GTTTTTTTTA GACTTGAGGG ACCAACAACC CCCAAACCCC AGATTCTGCC
40851 AGGTCCATGG GGAAGGAGAA GTTGCCTTGA GTGGAAGCCC CAAGTAGGGA
40901 GACTTACAGA AAAGAAGTCA AGAGCACTGG CTCCCAGGCA GAAATACTGA
40951 TACCCTACTG GGGCTTCAGG CTGAGCTCCT CCCTTCACAA ATCACTTCAT
41001 CTCTCTGAGC CTGTTTCTGC ATCTGTGACA TAAGATGGTA AGATAAAGGT
41051 GGCTGTCTCA CCAATTATGT AAGGATTAAA TGTGGAAAAG GACATAAAGT
41101 TGTATAGTGC TGCCATAGGG ACAGTGTTCA GTAAACGTGA CACATTCTTA
41151 GTATCACTAA GAATCAGGTT CTTGGCCAGG CACCGTGGCT CATGCCTGTA
41201 ATCCCAACAC TCTGGGAGGC CTAGGTCGGA GGATGGCTTG AACACAGGAG
41251 TTTGAGACCA GCCTGAGCAA CATAGTGAGA CACTGTCTCT ACAAAAAAAA
41301 AATAATAATA ATAATTGTTT TTAATTAGAT GGGCAGGGCA CTGTGGCTCA
41351 CACCTGTAAT CCCAGCACTT TGGGAGGCCA AGGCCGAGG ATTGCTTGAG
41401 GCCAGGAGTT CAGGAGCAGC CTGGGCCACA TTCCTGTCTC TACAAAGAAT
41451 AAAAAAGTTA ACTGGGCATG GTGGCACATG CCTGTAATCC CAGCTACTCA
41501 AGAGGCTGAG GAGGAGGATT GCCTGAGCCC AGGAGTTCAA GACTGCAGTG
41551 AGCCTTGATC ACACCACTGT ACTACAGCTT GGGCAACAGA GTGAGACCTT
41601 GTCTCCAAAA AAAAAAGTTT GTTTTTTTTT ATCCACTCTC CTCACCAAAC
41651 AAACCTGAGTA AGTTAGAGCC CTCTCAGCTG GCATGTGTTG GAAACAGTGC
41701 CCTCTCATT AAGTGCTGCC CTCACTCCCA TTGCCTCTTG GCCTTGGTCA
41751 GTATGATGAA ATTAGTGGGA GGCAGGGCAA CAGAGGGCAG GGAAGAGCTA
41801 GAAATCCATG GCCTGGAAAA GGAAGATTT GGGAGTGGCC AGGTATCTGT
41851 AGAGCCACCA TGCAGAGGAG GGGGGCAGCT AGCCTTGTGT GCTCTGGTGG
41901 GCATGGTCAG CAGGAGGCAG AGCAAAAGGA CAAGGGTAAG TAAACCTGTA
41951 GGTGCGGACA AGCCAAGAGC CATCCAGCGT CAGTCCTCTC TGGGTAGCCC
42001 AAGTAAAGCA GGAGCATACC CCAGAGAGAA AGTTCGCAGG GCTGTTCAAC
42051 TGCAGTGCTG TGGACTTCAA CCTTCTTGTT CCTTCTTCAG TAAGTAAAAA
42101 TAACAGTCAT TGACCATGAC TATTATCGAC CGCTTTTGAA AATGTAAACA
42151 TAGTGACTTT ATTGCTGTAA AAATCATACG TGTTTATCAT CTTAAAATTC
42201 AGGAAACATG GACAGGTACA AAGATGTGCA AAATATCATC CAAAATCCCA
42251 TTTGCTGGCC AGGCACGGTG GCTCACGCCT GTAATCCCAG CACATTGGGA
42301 GGCCGAGGCG GGCAATCAC TTGAGGTCAG GAGTTTTGAGA CCAGCCTGGC
42351 CAACATGGTG AAACCCTATC TCTACTAAAA ATACAATAAT TAGGCTGGGC
42401 GCAGTGGCTC ACGCCTATAA TCCAGCACT TTGGGAGGCC GAGGTGGGCG
42451 AATCACAAGG TCAGGAGTTT GAGACTAGCC TGGCCAATAT GGTGAAACCC

FIG.3-17

42501 CATCTCTACT AAAAATACAA AAATTAGGGC CGGGTGTGGT GGCTCACGCC
42551 TGTAATCCCA GCACTTAGGG AGGCCGAGAC AGATGGATCG CGAGATCAGG
42601 AGTTCGAGAC CAACCTAGCC AACATGGTGA AACCCCATCT CTAATAAAAA
42651 AATACAAAAA TTATTGCGTT GTGGTGGCAC ACGCCTGTAA TCCCAGCTAC
42701 TTGGGAGGCT GAGGCAGGAG AATCTCTTGA ACCTGGGAGG CAGAGGTTGC
42751 AGTGAGTGGA GATCCCGCCG TTGCACTCCA GCCTGGGCGA CAGAGTGAGA
42801 CTCCATCAAA AAAAAAAAAA AAAAAAAAAA AAATTAGCCG GGCGTGGTGG
42851 CGTGACACCTA TACTCCAGC TACTTGGGAG GCTGAGGCAG GAGAATCGCT
42901 TGAACCTGGA AGGCGGAGGT CGCAGTGAGC CGAGATCGTG CCATTGCACT
42951 TCAGCCTGGG CGACAGAGCG AGACTCTGTC TCAAAAATAA TAATAATAAC
43001 AATAACTAGC CGGGCCTGGT GGCACATGCC TGTAATCCCA GTTACTCAGG
43051 AGGCGGAGGC ATGAGACTCA GGTGAAC TAGGAGACAGAG GTTGACAGTA
43101 GCCAAGATCA CACCACTGCA CTCCAGCCTG GTTGACAGAG CGAGACTCTG
43151 TCTCAAAAAA AAAAAATCC CATTTGCTCA TTTTTTGGAT ACTAGTATAA
43201 CTATCACTCT AAACCACTTA GTACTTAAAT CAAGCAGATA TGGGAGATGG
43251 TGAATTACCA TCTACAGTGT TGTCATATAT GTCACATACT GAGCATTATC
43301 AGCTAGTAGA ATCTAGTTAA TTGTTCTATG TGTGATGTAT GCAGAGTTCC
43351 CATTTTGAAT GTGTTTTTAC TATGCTTAAA TAAATGACTG ATGTCAGCAA
43401 CCCCAAATG ATACATCTGA TGTAAGAGCC CCTGTTCCCC AATAATAACA
43451 TCTAAACTAT AGACATTGGA ATGAACAGGT GCCCCTAAGT TTCCTCCCTC
43501 CAGGGTTTCT TGGCCGGTCT CTGAGGACTA CACATCCCTA CTCCCGTCTT
43551 TCCTCATCTT CAGGCGCAGT AACAGTATCT CCAAGTCCCC TGGCCCCAGC
43601 TCCCCAAAGG AGCCCTGCT GTTCAGCCGT GACATCAGCC GCTCAGAATC
43651 CCTTCGTTGT TCCAGCAGCT ATTCACAGCA GATCTTCCGG CCCTGTGACC
43701 TAATCCATGG GGAGGTCCTG GGAAGGGCT TCTTTGGGCA GGCTATCAAG
43751 GTGAGCGCAG GCAACAATTG CTTTGCTCTT CTGCCCCAG TCCCTGTGTC
43801 ACTGTCTTTC GGGGATTTCT CATCACTTGG CCCACCCCA CACCATGCAG
43851 GATGCCAGGC CTCCTTCCTG GCTTTGGGTG TTGGTGTGAG AGGTATCCTT
43901 CACCCCCACC CAGGCCACCT AAGGTCAATG TTGCTGTTAC AGTGAGCTTG
43951 TGGACCTGGA GATCCAGGTT GGGTTGAGCT GTGCCTGTGG CCCTCCTGCC
44001 TCCAGTCAGT GGGTGTGTTG TAGGTGCCTG CAGACCTCAG TACCGGCGAT
44051 GCTACAAGGA GCACACAGGG GAATGGCTCC TGCTCCCTG GTGAACAGTC
44101 TCAGGGACTA ACCTCTCTCT TTCTCTCCTC CTCCTCCTCT TCTGCTGAGA
44151 ACTGGGAGGG GGGGTCAGGT AAGACGTGTG TCTCAGCTTG GGGGCAGCAG
44201 GGCTGGAGAG CTCACCCCGG ATCCACCCAG CTCCCTGGTG CATGTCTTTG
44251 GCACTGACCT TCCTGCCCCC AGACTTCTGT TCACTCAGGA GACTCACTTC
44301 TATGCCAAAT GACCAGAGCC CCTGCTTGGC TTGGCAGCAT CCCCTCCTGC
44351 CTTCTTCCCC ACTTCCCTTT TCTGGGTTCT TGCTGTCTCT CTGTGCATGC
44401 CCAGCTCTCC AGGAAAGAGG GTTTGCTTCC GTGTGAGTCC CATGTTGCTC
44451 CACGCTGCAT CTTCCACACA TGAACCTCTG CATTCTGACC CGGCTCAGTG
44501 TGCCCTCCAA GGGATGGGAT GGCCAGCTGC ATAGATTTTC TCAAACAGTT
44551 CTCCAGAACT TCCTCTGGTC TCAGCACCAT TAACAGTCAC CCTCCCTGTA
44601 GGTGACACAC AAAGCCACGG GCAAAGTGAT GGTGATGAAA GAGTTAATTC
44651 GATGTGATGA GGAGACCCAG AAAACTTTTC TGACTGAGGT AAGAAGATGG
44701 AGGGGGCCCC GGAGGTTGGT GTCACCATTG GAAGAGAGAA GACCTTACAA
44751 ATAATGGCTT CAAGAGAAAA TACAGTTTGG AATTACTGTC TTAAGACTA
44801 AGCAGAAAAG AGCCCTAGAG GAATATCCCA CTCCCTCTAA ATTACAGCGT
44851 AATTATTTGT TCAATGAACA CTTACTAAAA GCAACACAAA CAGGGTACAA
44901 GGGATGCAGT AACAAAAGAT ACAGGGTTCA GAAGAGCTCT CAGGTTATGA
44951 GGATGATGGA CATGAAAACA CTCCAATTTA GTACAACCTCA ATGTTATAAT

FIG.3-18

45001 CCTCACCTGA ACGCCCTGCT AAGGGAGCCT GGAGGGGAGC TCCCTGAGCA
45051 CTCACACTCC TTGGGCATTT ACAGTTTTCA CTACCCCTCC CAAGTTACTT
45101 CATGGAGTAA CTTAAGTTGG GGACACCTGT GGTCTGGGTA TTGCCCTCCA
45151 AGCCACTTGG CCACTCCAC CCCAGTTCTC CCAATGCAGT TCCAAGGGTA
45201 AGGCCTATGA AGCCATCTCC ATCTATATGG TGGTGGTCTT CCCTCATCCT
45251 GATCTTAGTG CCCTGTCATA TCACAAGATA GGAGGTAGGA GATACAGGTG
45301 GTAACACTTG TCAAGCTGAT TCCTTGAGG GAAGAGGTAA GGAAGACAGT
45351 GAGAAGTTAA CCACCAGCTT TCCTTGCTT CCCCCACCC CAGGTGAAAG
45401 TGATGCGCAG CCTGGACCAC CCCAATGTGC TCAAGTTCAT TGGTGTGCTG
45451 TACAAGGATA AGAAGCTGAA CCTGCTGACA GAGTACATTG AGGGGGGCAC
45501 ACTGAAGGAC TTTCTGCGCA GTATGGTGAG CACACCACCC CATAGTCTCC
45551 AGGAGCCTTG GTGGGTTGTC AGACACCTAT GCTATCACTA CCCTAGGAGC
45601 TTAAAGGGCA GAGGGGCCCT GCTTTGCCTC CAAAGGACCA TGCTGGGTGG
45651 GACTGAGCAT ACATAGGGAG GCTTCACTGG GAGACCACAT TGACCCATGG
45701 GGCCTGGACC ACGAGTGGGA CAGGGCTCAA CAGCCTCTGA AAATCATTCC
45751 CCATTCTGCA GGATCCGTTT CCCTGGCAGC AGAAGGTGAG GTTTGCCAAA
45801 GGAATCGCCT CCGGAATGGT GAGTCCCACC AACAAACCTG CCAGCAGGGC
45851 GAGAGTAGGG AGAGGTGTGA GAATTGTGGG CTTCACTGGA AGGTAGAGAC
45901 CCCTTCCTAT GCAACTTGTG TGGGCTGGGT CAGCAGCTAT TCATTGAGTT
45951 TGTCTGTGTC ACTGAACTG ACCCCAGCCA ACTGTTCTCA GTTCACAGCC
46001 CTGTTTTCAA AGAATTACAC ATCTCTAAAG GCAAACAGGG CACGGACAAG
46051 GCAAATGGA GAGGCAAAT GTAGCCTGAG ATGGCCTGGG CTTGCCATCA
46101 CAGGTATTCA GGTGCTGAGG GCCCTTAGAC CAACTAGAGC ACCTCACTGC
46151 CTAGGAAATC AATGAAGGGG AAATGAGTTC TAGCGGAGCC CTGAAGGATC
46201 AGAATTGGAT AAAGTCTTA TTGGCAGAGA GGCACCAGGA TTGAAGTGAC
46251 AGGAGCAAAG ACCTGGGAGG AAAGAGGAGA AAATCATCTA TTTCACCTGG
46301 AAACAAATGA TTCCAAGCAT AGAAATAATA ACAGCTGACA AGTACTGAGT
46351 GCCCTCTATA TGCTAGGCAC TGGGCTGAGG GATTAACATG CATGTGCATG
46401 TTTATTCTC ATGACAACCT TGGTTTCCAG ATAAGCTGGA CTGGAAAGGG
46451 ACAGAGCTGG GATCCTGGGC TAATCAGTCT GGTGCGCAAG CCTGAGACTT
46501 TAGCCACTGC CCTTCACATG GGGGTCCATG AAAATAGTAG TAGTCTGGAA
46551 CAGTTTGGGG GTACATCAAG GTCGCTGTGT TTAAAGCTAT GGAGTCTGGA
46601 CTATAGGAGA CAAATGTAAA AGAGTTTTTT GGTGACTGG CTTTTTGGTT
46651 TTTTGTGTTG TTTGTTGTT TGTGTTGTTG TTTGTTGTT TTTTCTGTT
46701 TCTGGGGCTT GAATCAGGAA GGAGGTTTTT TTGTTGTTGT TGTTTGGAGA
46751 AAGGATATTG CTCTGTTGCC CAGACTGGAG TGCAGTGGCA CGATCATGGC
46801 TCACTACAGC TTCGACCTCC TGGGCTCAAG CAATCCTCCT GCCTTAGCCT
46851 CCAAGTAGC TGGACTACAG GTGTGTACCA CCACACCTAA TTTTTGAAT
46901 TTTTTTTCT TTTTTTTTT TTTTTTTTT GGTAGAGACA GGTCTCACT
46951 TTGTTGCCCA GGCCTGAATC TCAAACCTCT GGGCTCAAGC ATTCCTCCTG
47001 CCTCGCCCTC CCAAAGTGT GGGATTACAG TTGTGAGCCA CCATGCCCGG
47051 CAGGAAAAGA TTTTAAAGCA AGAAAGCTTA AGAGCTGTGG TTTTCCAAA
47101 ATGAGTCTGG GCTGGCACAG TGGCTCATGC CTGTAATCCC AGCACTTTTT
47151 TGGGAGGCCG AGGTGAGTGG ATCACTTGAG GTCAGGAGTT TGAGACCAGC
47201 CTGGCCAACT GGTGAAACCC CTGTTTCTAC TAAAGAAAAA AATGCAAAAA
47251 TTAGCTGGGC GTGGTGGTGC ACGCCTGTAG TCCCAGCTAC TCAGGAGGCC
47301 GAGGCAGGAG AATAGCTTGA ACCTGGGAGG CAGAAGTTGC AGTGAGCCAA
47351 GATCACACCA CTGCATTCCA GCCTGGGTGA CAGAGTGAGA CTTCATCTCA
47401 AAAAAAAAAA AAAAGAGAGA CTGATATGGT TAGTACATTG GGGTGAATG
47451 CGGAGGGTCC AGGAATGGA GCCCTGCATA GGGGGCTAAT GAAACATTC

FIG.3-19

47501 AGATTTCTGA ATTAAGGTAG TGGCTGTGGG GACAGGAGCC TGGGAGGCAG
47551 GGTGGAGTCA GAATGGAGAG ACTGGTTGGC AATGAGGGAA CAGGAGGAGG
47601 AGGAGGAGGA GTTACGAGTG GCTTGAGGTG TCACTTACCA GACATTTGGG
47651 GGATGGGGGA TAGCCGTGAT TGTTGAGCAA CTGGTTTGGG AAGAGCTAGC
47701 ATTGATCCCT GCTGTTCTGT GCTAGCAGAA CCTATCAGCA TCTTCTGGGC
47751 AGGAAACTGG CTCCATGAGA CTGGCTTAGG GAGAGGCTGC TAGTCACCTA
47801 ATCTGCAGAG AAGGGGCAGC TGGAGCTGTG GGACAGAAGA GGCATCCATG
47851 TAGCTGGTGG GGGTGTCTCA GCTTGTGAAG AGGAGATGGC TTTGAGCAGG
47901 GCTGACACTG AAAAGGCTGG AAGAAAAAAA CAGACACACA AGAGTCTCAG
47951 GATCAGGTAG CATAGGAAAG TTGTGGACAG TCTTTGAGGA GCACTCCCTC
48001 AGGCAGGCAG GCAGGCAGGT CATGAGCTAT AGCGATTGAG GAAGAGCTCC
48051 CTGGGTGTGT GAGCAGCTCC AGGAGCCTAA GGGATGAAAG TAGTATTGCA
48101 GGGGGCTGGA GAGCAAGGAG TGGCTCCTTC TACATTTGCA AGGGAAGGAG
48151 AAAGGAAGTT GCTCCTGAGA GTGGTAAGAG TCAGTGGTGG AGGCCTGGAG
48201 AGGAGACATA ACAAACAAAT TTGTTGACAA ACATTTTGGT AGGAAGGGGG
48251 AGAGCTTAAA GTTTAGACAG TGGGGAAGGT GGAGTCTTAG AGGAGGTGAA
48301 TGTCTGAAAG ACAGAGCTAG CTGGAGCAAG AAGTCACTTC TCTGTTGCAG
48351 GCAGGAAGGA TCCAAAGTGG CTCAAGCCAG AGATTGGGAG AGTGGGGAGG
48401 AGGGAGCAGC CTGGATCTAA GTAAATGGG TAGAGGTGGA GGGGGTGTCTG
48451 CAACGGCCAG GGTTTTCTGA AGTTGGGGAC ATTAGGAGAG AGCTGTGAGG
48501 GCTTTGGCCA GCCACTGTGC TAGTGATTGG TGAACCAAAG GATGGGCAGG
48551 AGATGGCAGC AGGGAAGCAG AGGAAGTCCA GGCTTCCTGT TGGTATTGGG
48601 ACAAGGGAGA GGCCATAGGA GGCCCTGGCC CTGTTGTCCA GGTGGGTTTC
48651 TGAAGCTGGG TGGGCATGGC CTGGTAGGAG AGCATCTATG GCGCCCAATT
48701 CCAGATTGAG GGTCTAGTTG ATTTGCTGGC CCTGTAGCCT CAGTCATGC
48751 TTCTGTTCCA GGCTATTTG CACTCTATGT GCATCATCCA CCGGATCTG
48801 AACTCGCACA ACTGCCCAT CAAGTTGGTA TGTCCCACTG CTCTGGGCCT
48851 GGCTCCAGG GTCCTATCCT TCCTGGCTTC CTTGTACAA AGGAGGCTGA
48901 CTTGTCCCCT CTGGCTAGAG GGCAGAGGTG TTGCCTAGGA GCTCCTATCT
48951 TTCCCTTCCT GCTTCTTCCA ATGCCCTTCT CTGTCCTCTG GGAGCTCCGA
49001 GACACACACA GACATAATTT CACCTTCTCT CATTAGCAAC CTTTGAAATA
49051 ATTTGATTAG AAGGGACTTC AGAAGTTTGT TGAATATATG TAGAAAACCC
49101 TGTCATTTTA CCTGCTTTTG CCCCATAGTA GTCTTGTAAG ACAGTTCATT
49151 GCTGACCCCA TTTTACAGTG GTGGCACCTG AAGCCTCAGC CTGAGGCCAC
49201 CGAGCTAGTA AATTTACAGG GACCAGTTTG AGACCAGCAT TCCTCCCACT
49251 GCCCCTCAGC TGTGGTGGTT ACAATGTTGT TTGTCTTACT GACTTGCTAT
49301 CTGGCTTCCT GGGTGTCTAC CGGCTGGCCC TGGCTCTGCC CTCTAGACCC
49351 ACACCACGCA ATCTTCATTC CTTTCCACCA TGAAGTCCCT GTAGCTATTC
49401 AAAGAGCTTG TCTCCCCAA GTCTCCCCAT CTAAGTCCCT CACCTTGCCT
49451 TTTTCTGTCT TATCCTGGTT CTAGCCACTG CCTGAAATCA TTTTAGGAAT
49501 AAGACAGGAC AGGGAAAAAC AAAAGCAACC CCTGTCCCA CCTCTGAGTT
49551 CCACTCTCCA AGTCCCTGAG CCTCACCTCC AGGGCTCCAG TGGCTCTGCC
49601 ATGAACCCAC TGTGGGCTGG GAGTCTGCTG TGCACAGATA CCAGACCCTC
49651 AGAAACACAA ATGCCAAGTG TGCTGTTTT TTTGTTTTGT TTTGTTTTGT
49701 TTTTATAGTG GAGTCTCATT CTGTTTCCCA GGCTGGAGTG CAGTGGTGCA
49751 ATCTTGGCTT ACTGCAGCCT CTACCTCCCG GGTCTAGTG ATTGTTCTGC
49801 TTCAGCCTCC CAGTAGCTAG GACTACAGGC GTGTGCCACC ACGCCAGCT
49851 AATTTTTTTT TTTTTTTTTT TGTATTTTGA GTAGAGACAG GGTTTTGCCA
49901 TGTTGGCCAG GCTGGTCTTG AACTCCTGAC CTCAGGTGAT TCACCCGCCT
49951 TGGCCTCCCA AAGTTCTGGG ATTACAGGTG GAAGCCACCG TGCTGGCCT

FIG.3-20

50001 GAGTGTGTCT ATTTGATAGA GCTTTCTGCT CTGATTCTCC CTTGCTATAC
50051 ACCTTTTCTC CCCTTCTCAG TGGCTTCTCT TGCCTATGCT TCCTCCCCAG
50101 GGCCAGGTTT GAGAACATCC CCATGAAGTC CTGACCTGTC TTTTATCCTA
50151 CCAGGACAAG ACTGTGGTGG TGGCAGACTT TGGGCTGTCA CGGCTCATAG
50201 TGGGAAGAGAG GAAAAGGGCC CCCATGGAGA AGGCCACCAC CAAGAAACGC
50251 ACCTTGCGCA AGAACGACCG CAAGAAGCGC TACACGGTGG TGGGAAACCC
50301 CTA CTGGATG GCCCTGAGA TGCTGAACGG TGAGTCCTGA AGCCCTGGAG
50351 GGGACACCCG CAGAGGGAGG ACAGATGCTG CCCTTGCA TC AGAGCCCTGG
50401 GAATTCAGG GGAGGCCTGT GAAGCGTAGG ACCGGATACC CAGAGCTGAG
50451 GATATTTTTC CCTTGCCAGG TGGGGCCTCA CGATTTAGCT CCTGAGCTCA
50501 GGGGGCTGGG AACTGATCAG TGTCCCATCA TGGGGGATAA GGTGAGTTCT
50551 GACTGTGGCA TTTGTGCCTC AGGGATCGCT AAGAGCTCAG GCTATTGTCC
50601 CAGCTTTAGC CTTCTCTCTC CATGGTGAGA ACTGAAGTGT GGTGCCCTCT
50651 GGTGGATAAT GCTCAAACCA ACCAGAGATG CTGGTTGGGA TTCTTGAAT
50701 CAGGGTTGTG AGGCCTCAGA AATGGTCTGA ATACAATCCA TTTTGGAGTC
50751 TGAGGCCAG AGAAGTTCAG TGAATTGCCT AGGAGCATAC AGCTGCCTAA
50801 TGGCAGAGGC TAGATGAACC CTAGTCTGGT TCTTTTCCAC TTTAACGTGC
50851 AGTTTCATCC TAGGCAGTGT TATGTTATAA GGGCTCTCCA AGGCAGTTCA
50901 CCTACGGCTG AGGAAGGACT ATTTTCAGGT GGTGTCTGCG CAGGACAGCC
50951 TGTGGGGTGT CCCTACAGAA CCTGTTCTAG CCCTAGTTCT TAGCTGTGGC
51001 TTAGATTGAC CCTAGACCCA GTGCAGAGCA GGTAAAGGAT GTAAACTTAA
51051 CAGTGTGCTC TCCTGTGTTT CCCAAGGAAA GAGCTATGAT GAGACGGTGG
51101 ATATCTTCTC CTTTGGGATC GTTCTCTGTG AGGTGAGCTC TGGCACCAAG
51151 GCCATGCCCG AGGCAGCAGG CCTAGCAGCT CTGCCTTCCC TCGGAAGTGG
51201 GGCATCTCCT CCTAGGGATG ACTAGCTTGA CTAAAATCAA CATGGGTGTA
51251 GGGTTTTATG GTTTATAACG CATCTGCACA TCTTTGCCAC GTTCGTGTTT
51301 CATTGGTCTT AAGAGAAGGA CTGGCAGGGT TTTTTTGTT TAGATGGAGC
51351 CTCACCTCGT TGCCCAGGCT GGAGTGCACT GGCACAATCT GGGCTCACTG
51401 CAACCTCTGC CTTCTGGGTT CAAGTGATTC TCCTGCCTCA GCCTCCCAAG
51451 TAGCTGGGAC TACCGGCACA CACCACCATG CCCGGCTAAT TTTTGTATTT
51501 TTAGTAGAGA CAGGGTTTCA CCATGTTGGC CAGGCTGGTC TTGAACTCCG
51551 GACCTCAGGT GATCCGCCTG CCTCAGCCTC TAAAGTGCT GGAATTAATA
51601 GGCGTGAGCT ACCTCGCCCG GCCAGGTTTT TTTTTTTTTT TTTTAGTTG
51651 AGGAACTGA GGCTTGGAAG AGGGCAGTGG CTTGCACATG GTCGATAAGG
51701 GGCAGATGAG ACTCAGAATT CCAGAAGGAA GGGCAAGAGA CTGTTTATGT
51751 GGCTGTCTAG CTAGCTCTTG GGCCAAATGT AGCCCTTCTC AGTTCCCTTC
51801 AAGTAGAAGT AGCCACTCTA GGAAGTGCA GCCCTGTGCC AGGTACCACG
51851 TGGACAGAGT GAGGAATCTT GGAAAGATTC CTACCTTTAG GAGTTTAGTC
51901 AGGTGACAGC ATATCTCAGC GACTCAAACA CACACACATT CAAAGCCTTC
51951 TGTAATTCCT ACAAAGTTGT GAGGGGTAGA GGAGAGGAGA GACAAGGGAT
52001 GGTTAGGATA ATGAAGGAAT GTTTTGTTTT TGTTTTTGTT TTTGAGATGG
52051 AGTTTCACTC TGTCACCCAG GCTGGAGTGC AGAGGTGCAA TCTTGGCTCA
52101 CTGCAGCCTC CGCCTCCAG GTTCAAGCAA TCCTCCTGCC TCAGCCTCCC
52151 AAGTAGCTGG GACTACAGGT GTGCGCCACC ACGCCTGGCT AATTTTTGTA
52201 TTTTCAGTAG AGACAGGGTT TCGCCATATT GGCCAGGCTG GTCTCAAATG
52251 CCTGACCTCA GGTGATACAC CCGCTTCAGC CTCCCAAAGT GCTGAGATTA
52301 CAGGCATGAG CTACCGTGCC TGGCCATGAA GGAAGATTTG TTTTAAAAAA
52351 TTGTTTTCTT TAATATTAAT TGAACACCTC GTTTCAGAGC ACTGGGCTGG
52401 TGCCAGAGGG TTTCAGACAT GAATCAGATC CAGCACCTCA TAGAGCCTTA
52451 ATCTGGCACA CACACACAGC CACAAGGAGA CACAGACAAG GCAGGGTAGG

FIG.3-21

52501 ATGAGTGGAA GCTAGGAGCA GATGCTGATT TGGAACTT GGCTTCTGCA
52551 GTGAAGCCCC TTCTTAGTCC TCTTCAGTAA CCCAGCTCTC AGTGGATACA
52601 GGTCTGGATT AGTAAGATTT GGAGAGATGA TTGGGGATTG GGGAGAGCTC
52651 TCTAACCTAT TTTACCACCT CCTCTTCTGC CATTCTTCCT GTCCACATCC
52701 CCAGCATCCC TTTCCCTTGC CAAGTATCTG TGGCCTCTGT AGTCCTTTGT
52751 AAACAGCTGT CTTCTTACCC TACAGATCAT TGGGCAGGTG TATGCAGATC
52801 CTGACTGCCT TCCCCGAACA CTGGACTTTG GCCTCAACGT GAAGCTTTTC
52851 TGGGAGAAGT TTGTTCCAC AGATTGTCCC CCGGCCTTCT TCCCCTGGC
52901 CGCCATCTGC TGCAGACTGG AGCCTGAGAG CAGGTTGGTA TCCTGCCTTT
52951 TTCTCCCAGC TCACAGGGTC CTGGGACGTT TGCCTCTGTC TAAGGCCACC
53001 CCTGAGCCCT CTGCAAGCAC AGGGGTGAGA GAAGCCTTGA GGTCAAGAAT
53051 GTGGCTGTCA ACCCCTGAGC CATCTGACAA CACATATGTA CAGGTTGGAG
53101 AAGAGAGAGG TAAAGACATA GCAGCAAGTA ATCTGGATAG GACACAGAAA
53151 CACAGCCATT AAAAGAAAGT TAAAAGAAG GAAATTCACC CAAACCATTT
53201 GAATACAGTA AGTGATTCA TCTTTCGATA TTCCCTGTG CATATCTACA
53251 CATATACTTT TTTTATAGT AAATAGTTCT GTATTTTGCC CTGCATTTCC
53301 CTTGTGTTTA CTATCCAGTC TTCCTGTTTA TCATTTTGT CGACAACATG
53351 AAATTCTATT GAGAGACTGT CTGAACATAT TGAATGTAG ATGTTCAAGT
53401 TTTTCCAGTT TCTCTTTACA ATAGGTATTT AACTACAGTG AGCAGTTTTA
53451 TGCATTTAGC TAATTTCTCC TTTGAGGAAG TATTTTCAA ATTACCTTA
53501 TTCTTCTCAG GTAATAATT CATTATTACC AAAGTTACCC TAGGTCTTTT
53551 CAAGTGTGTG GTTAAAAAAC GAGAATCTGG CTGGGCGCGA TGGCTCACAC
53601 CTGTAATCCC AGCACTTTGG GAGGCTGAGG CTGGTGGATC ACCTGAGGTC
53651 TGGAGTTTCA GACCAGCCTG GCCAACATGG TGAACCCCA TCTCTACTAA
53701 AAATACAAAA CTTAGCCAGG CATGGTGGCA GGTGCCTGTA ACCCCAGCTA
53751 CTTGGGAGGC TGAGGCAGGA GAATTGCTTG AAGCCAGGGG CGGAGGTTGC
53801 AGTGAGCCGA TATCACGCCA TTGCACTCCA GCCTCGGCAA CAAGAGTGAA
53851 ACTCTGTCTC AAAAATGGGG TTCTTTTCTT GCCATCAAAA ATCATGTTTC
53901 TTTTAAAAAC AAGTTCAAAC ATTACCAAAG TTTATAGCAC AGGAAATACG
53951 TCTTCTGTAA TCTCCCTTAA CCAATATATC CCTCAACATT CTCCTCACCC
54001 CCAACTCCAC CCTCCCAGGA TAACCAAGTTG GGACATAATC TTTATTTAAA
54051 AATGGTTTCC GGATAGAGAA AGCGCTTCGG CGGCGGCAGC CCCGGCGGCG
54101 GCCGCAGGGG ACAAAGGGCG GCGGATCGG CGGGGAGGGG GCGGGGCGCG
54151 ACCAGGCCAG GCGCGGGGCG TCCGATGCT GCAGCTGCCT CTCGGGCGCC
54201 CCCGCCGCGG CCCTCGCCGC GGAGCCGCGG AGCTAACCTG AGCCAGCCGG
54251 CGGGCGTCAC GGAGGCGGCG GCACAAGGAG GGGCCCCACG CGGCGACGTG
54301 GCGCGGAGG CCGCGTGGC GGACAGCGGC ACCGCGGGG GCGGCGGTT
54351 GCGGCGCCG GCGCGGCC CCAGGCCAGG CAGTGGCGGC CAAGGACCAC
54401 GCATCTACTT TCAGAGCCCC CCGGGGGGCC GCAGGAGAGG GCGGGGCTG
54451 GCGGATGAT GAGGGCCAG TGAGGCGCCA AGGGAAGGTC ACCATCAAGT
54501 ATGACCCCAA GGAGCTACGG AAGCACCTCA ACCTAGAGGA GTGGATCCTG
54551 GAGCAGCTCA CGCGCTCTA CCACTGCCAG GAAGAGGAGA TCTCAGAACT
54601 AGAGATTGAC GTGGATGAGC TCCTGGACAT GGAGAGTGAC GATGCCTGGG
54651 CTTCCAGGGT CAAGGAGCTG CTGGTTGACT GTTACAAACC CACAGAGGCC
54701 TTCATCTCTG GCCTGTGGA CAAGATCCGG GCCATGCAGA AGCTGAGCAC
54751 ACCCCAGAAG AAGTGAGGGT CCGGACCCA GGCGAACGGT GGCTCCATA
54801 GGACAATCGC TACCCCCGA CCTCGTAGCA ACAGCAATAC CGGGGGACCC
54851 TGCGGCCAGG CCTGGTTCCA TGAGCAGGGC TCCTCGTGCC CCTGGCCAG
54901 GGGTCTCTTC CCCTGCCCCC TCAGTTTTCC ACTTTTGGAT TTTTTATTG
54951 TTATTAAACT GATGGGACTT TGTGTTTTTA TATTGACTCT GCGGCACGGG

FIG.3-22

55001 CCCTTTAATA AAGCGAGGTA GGGTACGCCT TTGGTGCAGC TCAAAAAAAA
55051 AAAAAAAAT GATTTCCAGC GGTCCACATT AGAGTTGAAA TTTTCTGGTG
55101 GGAGAATCTA TACCTTGTTT CTTTATAGGC CAAGGACCGC AGTCCTTCAG
55151 TAACACCAGT GTAAAAGCTT GAGGAGAAAT TGTGAAGCTA CACAGTATTT
55201 GTTTTCTAAT ACCTCTTGTC ATTCTAAATA TCTTTAATTT ATTAATAAAT
55251 ATATATATAC AGTATTGAAT GCCTACTGTG TGCTAGGTAC AGTTCTAAAC
55301 ACTTGGGTTA CAGCAGCGAA CAAAATAAAG GTGCTTACCC TCATAGAACA
55351 TAGATTCTAG CATGGTATCT ACTGTATCAT ACAGTAGATA CAATAAGTAA
55401 ACTATATTGA ATATTAGAAT GTGGCAGATG CTATGGAAAA AGAGTCAAGA
55451 CAAGTAAAGA CGATTGTTCA GGGTACCAGT TGCAATTTTA AATATGGTCG
55501 TCAGAGCAGG CCTCACTGAG GTGACATGAC ATTTAAGCAT AAACATGGAG
55551 GAGGAGGAGT AAGCCTGAGC TGTCTTAGGC TTCCGGGGCA GCCAAGCCAT
55601 TTCCGTGGCA CTAGGAGCCT GGTGTTTCCG ATTCCACCTT TGATAACTGC
55651 ATTTTCTCTA AGATATGGGA GGAAGTTTTT TCTCCTATTG TTTTAAAGTA
55701 TTAACCCAG CTAGTCCAGC CTTGTTATAG TGTTACCTAA TCTTTATAGC
55751 AAATATATGA GGTACCGGTA ACATTATGCC CATTTCTCAC AGAGGCACTA
55801 CTAGGTGAAG GAGTTTGCCCT GACGTTATAC AACCAGGAAG TAGCTGAGCC
55851 TAGATCCCTT CCACCCACCC CATGGCCCTG CTCATGTTCC ACCTGCCTCT
55901 AATTTACCTC TTTTCTTCT AGACCAGCAT TCTCGAAATT GGAGGACTCC
55951 TTTGAGGCC TCTCCCTGTA CCTGGGGGAG CTGGGCATCC CGCTGCCTGC
56001 AGAGCTGGAG GAGTTGGACC AACTGTGAG CATGCAGTAC GGCCTGACCC
56051 GGGACTCACC TCCCTAGCCC TGGCCCAGCC CCCTGCAGGG GGGTGTCTA
56101 CAGCCAGCAT TGCCCTCTG TGCCCATTC CTGCTGTGAG CAGGGCCGTC
56151 CGGGCTTCTT GTGGATTGGC GGAATGTTTA GAAGCAGAAC AAGCCATTCC
56201 TATTACCTCC CCAGGAGGCA AGTGGGCGCA GCACCAGGGA AATGTATCTC
56251 CACAGTTCT GGGGCCTAGT TACTGTCTGT AAATCCAATA CTTGCCTGAA
56301 AGCTGTGAAG AAGAAAAAA CCCCTGGCCT TTGGGCCAGG AGGAATCTGT
56351 TACTCGAATC CACCAGGAA CTCCCTGGCA GTGGATTGTG GGAGGCTCTT
56401 GCTTACACTA ATCAGCGTGA CCTGGACCTG CTGGGCAGGA TCCAGGGTG
56451 AACCTGCCTG TGAACCTGA AGTCACTAGT CCAGCTGGGT GCAGGAGGAC
56501 TTCAAGTGTG TGGACGAAAG AAAGACTGAT GGCTCAAAGG GTGTGAAAAA
56551 GTCAGTGATG CTCCCCCTT CTACTCCAGA TCCTGTCTT CCTGGAGCAA
56601 GGTGAGGGA GTAGGTTTTG AAGAGTCCCT TAATATGTGG TGAACAGGC
56651 CAGGAGTTAG AGAAAGGGCT GGCTTCTGTT TACCTGCTCA CTGGCTCTAG
56701 CCAGCCCAGG GACCACATCA ATGTGAGAGG AAGCCTCCAC CTCATGTTTT
56751 CAACTTAAT ACTGGAGACT GGCTGAGAAC TTACGGACAA CATCCTTTCT
56801 GTCTGAAACA AACAGTCACA AGCACAGGAA GAGGCTGGGG GACTAGAAAG
56851 AGGCCCTGCC CTCTAGAAAG CTCAGATCTT GGCTTCTGTT ACTCATACTC
56901 GGGTGGGCTC CTTAGTCAGA TGCCTAAAC ATTTTGCTA AAGCTCGATG
56951 GGTTCTGGAG GACAGTGTGG CTTGTCACAG GCCTAGAGTC TGAGGGAGGG
57001 GAGTGGGAGT CTCAGCAATC TCTTGGTCTT GGCTTCATGG CAACCACTGC
57051 TCACCCTTCA ACATGCCTGG TTTAGGCAGC AGCTTGGGCT GGAAGAGGT
57101 GGTGGCAGAG TCTCAAAGCT GAGATGCTGA GAGAGATAGC TCCCTGAGCT
57151 GGGCCATCTG ACTTCTACCT CCCATGTTTG CTCTCCCAAC TCATTAGCTC
57201 CTGGGCAGCA TCCTCCTGAG CCACATGTGC AGGTACTGGA AAACCTCCAT
57251 CTTGGCTCCC AGAGCTCTAG GAACTCTTCA TCACAACTAG ATTTGCCTCT
57301 TCTAAGTGTC TATGAGCTTG CACCATATTT AATAAATTGG GAATGGGTTT
57351 GGGGTATTAA TGCAATGTGT GGTGGTTGTA TTGGAGCAGG GGAATTGAT
57401 AAAGGAGAGT GGTTGCTGTT AATATTATCT TATCTATTGG GTGGTATGTG
57451 AAATATTGTA CATAGACCTG ATGAGTTGTG GGACCAGATG TCATCTCTGG

FIG.3-23

57501 TCAGAGTTTA CTTGCTATAT AGACTGTACT TATGTGTGAA GTTTGCAAGC
57551 TTGCTTTAGG GCTGAGCCCT GGACTCCCAG CAGCAGCACA GTTCAGCATT
57601 GTGTGGCTGG TTGTTTCCTG GCTGTCCCCA GCAAGTGTAG GAGTGGTGGG
57651 CCTGAAGTGG GCCATTGATC AGACTAAATA AATTAAGCAG TTAACATAAC
57701 TGGCAATATG GAGAGTGAAA ACATGATTGG CTCAGGGACA TAAATGTAGA
57751 GGGTCTGCTA GCCACCTTCT GGCCTAGCCC ACACAACTC CCCATAGCAG
57801 AGAGTTTTCA TGCACCCAAG TCTAAAACCC TCAAGCAGAC ACCCATCTGC
57851 TCTAGAGAAT ATGTACATCC CACCTGAGGC AGCCCCTTCC TTGCAGCAGG
57901 TGTGACTGAC TATGACCTTT TCCTGGCCTG GCTCTCACAT GCCAGCTGAG
57951 TCATTCTTCA GGAGCCCTAC CCTTTCATCC TCTCTATATG AATACTTCCA
58001 TAGCCTGGGT ATCCTGGCTT GCTTTCCTCA GTGCTGGGTG CCACCTTTGC
58051 AATGGGAAGA AATGAATGCA AGTCACCCCA CCCCTTGTGT TTCCTTACAA
58101 GTGCTTGAGA GGAGAAGACC AGTTTCTTCT TGCTTCTGCA TGTGGGGGAT
58151 GTCGTAGAAG AGTGACCATT GGGGAAGGACA ATGCTATCTG GTTAGTGGGG
58201 CCTTGGGCAC AATATAAATC TGTAACCCCA AAGGTGTTTT CTCCCAGGCA
58251 CTCTCAAAGC TTGAAGAATC CAACTTAAGG ACAGAATATG GTTCCCGAAA
58301 AAAACTGATG ATCTGGAGTA CGCATTGCTG GCAGAACCAC AGAGCAATGG
58351 CTGGGCATGG GCAGAGGTCA TCTGGGTGTT CCTGAGGCTG ATAACCTGTG
58401 GCTGAAATCC CTTGCTAAAA GTCCAGGAGA CACTCCTGTT GGTATCTTTT
58451 CTTCTGGAGT CATAGTAGTC ACCTTGCAAG GAACTTCCTC AGCCCAGGGC
58501 TGCTGCAGGC AGCCCAGTGA CCCTTCCTCC TCTGCAGTTA TTCCCCCTTT
58551 GGCTGCTGCA GCACCACCCC CGTCACCCAC CACCCAACCC CTGCCGCACT
58601 CCAGCCTTTA ACAAGGGCTG TCTAGATATT CATTTTAACT ACCTCCACCT
58651 TGGAAACAAT TGCTGAAGGG GAGAGGATTT GCAATGACCA ACCACCTTGT
58701 TGGGACGCCT GCACACCTGT CTTTCCTGCT TCAACCTGAA AGATTCTGA
58751 TGATGATAAT CTGGACACAG AAGCCGGGCA CGGTGGCTCT AGCCTGTAAT
58801 CTCAGCACTT TGGGAGGCCT CAGCAGGTGG ATCACCTGAG ATCAAGAGTT
58851 TGAGAACAGC CTGACCAACA TGGTGAAACC CCGTCTCTAC TAAAAATACA
58901 AAAATTAGCC AGGTGTGGTG GCACATACCT GTAATCCCAG CTA CTCTGGA
58951 GGCTGAGGCA GGAGAATCGC TTGAACCCAC AAGGCAGAGG TTGCAGTGAG
59001 GCGAGATCAT GCCATTGCAC TCCAGCCTGT GCAACAAGAG CCAAACCTCA
59051 TCTCAAAAAA AAAAA (SEQ ID NO:3)

FEATURES:

Start: 3000
Exon: 3000-3044
Intron: 3045-45393
Exon: 45394-45525
Intron: 45526-45761
Exon: 45762-45818
Intron: 45819-50154
Exon: 50155-50329
Intron: 50330-51076
Exon: 51077-51132
Intron: 51133-52775
Exon: 52776-52933
Intron: 52934-55922
Exon: 55923-56064
Stop: 56065

FIG.3-24

CHROMOSOME MAP POSITION:
Chromosome 22

ALLELIC VARIANTS (SNPs):

DNA Position	Major	Minor	Domain
941	A	T	Beyond ORF(5')
2612	G	A	Beyond ORF(5')
5080	G	A	Intron
6599	-	A C	Intron
6983	C	G	Intron
9885	A	-	Intron
12538	G	T	Intron
17707	T	C	Intron
18219	-	A	Intron
19670	C	T	Intron
21153	G	T	Intron
24566	C	-	Intron
26604	G	A	Intron
27255	C	G	Intron
27399	T	C	Intron
28088	G	A	Intron
28734	G	A	Intron
29246	-	T	Intron
29490	G	A	Intron
29934	T	C	Intron
34480	A	G	Intron
38812	T	C	Intron
40731	C	G	Intron
41303	T	A	Intron
41305	-	A	Intron
41457	G	C	Intron
43168	A	- T	Intron
43357	T	G	Intron
45664	T	C	Intron
47549	A	C	Intron
47908	C	A	Intron
52267	C	A	Intron
54654	T	C	Intron
54679	C	G	Intron
54693	A	C	Intron
54706	T	C	Intron
54712	T	C	Intron
54799	T	C	Intron
54819	G	A	Intron
55499	C	T	Intron
56825	C	A	Beyond ORF(3')
58871	T	A	Beyond ORF(3')

Context:

FIG.3-25

DNA
Position
941

GAGTAAGTGGGTGGTCAGGTTACAGACTTAATTTTGGGTAAAAAGTAAAAACAAGAAAC
AAGGTGTGGCTCTAAAATAATGAGATGTGCTGGGGGTGGGGCATGGCAGCTCATAAACTG
ACCCTGAAAGCTCTTACATGTAAGAGTTCCAAAAATATTTCCAAAACCTTGAAGATTCAT
TTGGATGTTTGTGTTTATTAAAACTCTCTACTAATTCATTGTCTTGTCCACTGTCCGTAA
CCCAACCTGGGATTGGTTTGAGTGAGTCTCTCAGACTTTCTGCCTTGAGTTTGTGAGAG
[A,T]
GATGGCATACTCTGTGACCACTGTCCACCTAAAACCAAAAAGGCCCTCTTGACAAGGAG
TCTGAGGATTTTAGACCCAGGAAGAATGAGTGATGGGCATATATATATCCTATTACTGAG
GCATGAGAAGAGTGGAATGGGTGGGTGGAGTGGTGTGTTTAAGGCCTCTTGCCAGCTTGT
TTAACTCTTCTCTGGGGAACGAGGGGGACAACCTGTGTACATTGGCTGCTCCAGAATGATG
TTGAGCAATCTTGAAGTGCCAGGAGCTGTGCTTTGTCTATTCATGGCCCCTGTGCCTGTG

2612

TGAGTTGGAACAGTTTGATACCAAAACCATCCCCCGCCCCCAACCCCAGCCTAGGGT
CCGTGGAAAAATTGGCCCCGGTGCCAAAAAGGTTGAGGACTGCTGATCTAGAGGACCAA
TTTATTCAATGTTGGTTGAGTAAATGAGCTCTTGATTAGGTGATGGAATAATCTGAAAA
AACAGGGCTTTTGAGGAATAGGAAAAGGCAGTAACATGTTTAACCCAGAGAGAAGTTTCT
GGCTGTTGGCTGGGAATAGTCATAGGAAGGGCTGACACTGAAAAGAAGGAGATTGTGTTT
[G,A]
TTTCTTCTCTCAGAGCTATAAGCAAAGGCTGAAAGTTCTAGAAAAAGGCAAGTTTGT
TCAGTAGAAAAAAGGATAATCAGAACCATTTTGTAGAAAATGGAATGAGACTACTTTTGTG
GCCATGAGTTCCTTGTCCCTGGAGAGATGAGCAGAGGTTGGACAAGTGCTTACCAGAGAT
CTTGTGGAGGCAGAACTGTGCATCTAGCAGAGCATTGGCCTAACCTTTCAAATGAGAT
GCTGTAACTCAGTCTTATTCTACATGGTAGGAATCCTGTCCCTTTGCCTCCTGCTACTT

5080

ACAACGTAAAATAGTTGAAATTTGTTGGTGGAAAGAAGAGCAGTCCACTCCAGAGGCTGG
ATGGGCATGCCTGGCCCCAAGGTCTGAAGTGGTAGGGCTGTGCCTATATCCTGAGAATG
AGATAGACTAGGCAGGCACCTTGTGCTGTAGATTCCAGCTCCTGCACATAGCTCTTGTG
TAAACATCCCTGTGCTTATACCAAGTAATTGAGTTGACCTTTAAACACTTGCCCTTTCC
CTGGGAACCATATAGGGGATTGGCCTGGAGACGTCTGGCCTCTGGAAGAGTTGGAAAGCA
[G,A]
CCATCATTATTATCCTTTCTTTTCTAGCTATAACTCAGAGCTCTCAAGTCTTTTCTGTGGA
TCTTATTGCCTTGGTTCTTGCCCCCTTTTACTCCCAGGGAAGTTGATTCTGTCTTTTCTGT
TCCATTTAGTATGACAGGAGCAGAGAATGTCAGAGCTGTAAGGGACCTTATAGTTAAAGC
CTTTGGCTGGTCTTTTCAATTTTATAGCTGGGACTAATAAGTAACGTCAAAACCCAATGAG
TTCACAGATTGGGTCTCGCCTTGGCATGTAACCCATATGTTTATATTCTTGTGTTTTCC

6599

CTGTAATCCTAGCACTCTGGGAGGCCGAGGCAGAGGATCGCTTGAGCCCATGAGCCCAG
GAGTTTGAGACCAGCCTGGCCAACATGGCAAACTCCACCTCTACAAAAATACAAAAAT
ATTAGCCAGGCGTGATGGCACACACCTGTAGTCCCAGCTACTTGGGAAGCTGAGGAGCGA
TGATTACCTGAGCCAGGGATATCAAGGCTGTAGTGAGCTGTGATCATGCCACTGTACTC
CATCCAGCTGGGGACAGAGTGAAACCCCTGTCTCAAAACAAAACAAATGAAAAAAAAA
[-,A,C]
CCTTAATAATCAGTAACTGTCACTTTATATTATGTTGTGAGTGTGTGTCTATATACACT
ATATGTATACATTTCTTATTACACATTCATTGGTGATCTGATGTGGAGCCCCAGGGAT
TAAGGGCAACTTTGAACTACCCTGACACAATCAAGCCAAATATCATTTCCCGTGGAGGAAG
TAGAGTATCTAGGTTCTGTCTCCTAGTTGCAGCTTTACCTTGAGGACAGAGACTCTAATC
CAGCTGTGCTGAAGGAGCACATCTCCTGACTTCTGAGCTTTCCCTGGTAAATTCAACT

FIG. 3-26

6983 CACATTCATTGGTGATCTGATGTGGAGCCCCAGGGATTAAGGGCAACTTTGAACTACCCT
GACACAATCAAGCCAAATATCATTCCTGGAGGAAGTAGAGTATCTAGGTTCTGTCTCC
TAGTTGCAGCTTTACCTTGAGGACAGAGACTCTAATCCAGCTGTGCTGAAGGAGCACATC
TCCTGACTTCTGAGCTTTCCCTGGTAAATTCAACTGGATGTCACGGCGCCCTCAGATA
GAGCCTGGTAATTTGCCCTGGGAGAGTGACTGTCTTTGGATCTAATTTGACTTTTGCC
[C, G]
CAGTTGGAGGAAAATCTTCAGGGCTAGGAAGGATTGTATTTGTCTGACCCAGAGATAAC
CTGGGTTTTGAGGAACATGGGGCATCAACCTGAATGGTCTTGTAAGATCTCTCCACGCC
AGCTTGCCAGTGTTTCTCTGATGAATTTAGAGTACCTGAGTAGTGCAGGCCTGCTGGGAG
GAGGACTCTCCCTCTGTGCTACTCAGAGAAATTCATTCTCAAGGCCCCCTTCCAGCCTT
GCTCTTACCCAGCTGGGCTACAGTTACAATAAAGGAAATGACTTTTCTCTCCCTTCCC

9885 GGCGTGCCACCACACCTTGCCATTTTTTTTTATTTTAAGTAGAAACAAGGCTTTATTAAT
ACTATGTTGCCCAGGCTGGTCTTGAATCCAGCGATCCTCTGCCCCAGCCTCCCAAAGT
GCTTGGGATTACGGAAGTAAGCCACTGTGCCTGGCCAGTGCAACCCCCATTTTATACTAA
AACAGGAAGGCCAGAAAGGTTTGGAGTAAC TTGTCCAGGGTCACACAGATGATATTTGA
ACTCAGGTCTCCCTGGCTCCCAAGAGAGTCTGCTTTCCTAGGACTCCCAGGAGAAAAA
[A, -]
AAAAAAAAAACAGTAGACTTGGAGACAGAAAATCTGATTTGAGTCTTAGTTGAGCTAGG
CTAACTGTGTAACGTGGGCAAGTTCCTTAGCCCCGTGAGCCTCAGTTTCTTATCTGTA
AAATGTCATAAAAGAAATCCATCTCATGGAGTAGTTGTGATGATCAAGGACTCTGAAAC
ATTAGAATGGTTTAAATGTGAAGGATTAGCAGCAGCACATGGCAACATTGTGCATCTTATA
TTAACTATCCAAATATATCAAGCGTCATTTGCTATATATAAAAGTCATCAAATTAGGCAC

12538 ACTTGGGAGGCTGAGGCAGGAGAATCACTTGAACCTGGGAGGCAGAGGTTGCAGTGAGCC
CAGATCACGCCACTGCACTCCAGCCTGGTGACAGAGTAAGACTCCATCTCAAAAAAAAAA
AAAAAAAAAAAAATTCCTTAATTTGGCCTACAGTAGAGCCCTCCGTAATGTGGCCTCTCT
CCACATCTCCACAACCTCCTGCTCCCTGCACTTCAGCCTCACCTCTCTTCTGGACAGGCC
CTCCTTCTGACAAGGGCTTTGTTCAATCTGCTCCCTCTGCCTAGAATGCCCCCTTACTCT
[G, T]
TTCCTTAACCTCCTGCTTATCGTTTAGATCTTTACCTGGATGGCTCAGAGAAATATAGAA
GTAATTCCTCACCCTGAAAAATAGGTTAGGTCCCTGTTTTATGTTTTTCATAGACCTTTCC
TTTGAGGCTTTTTTTAAAAAAGTAGTTTTAATCTCACATTTATTCAATGTGATCATCTCCT
TAATGATATCTTAAGACCTCTAATAGAACAATTTGGTCATGGACTGTGGGGTTTTTGCCC
CTCATTGTGTCAGCACTGAGCATATTGTTGGCATAGGAGGGATATTTGTTGAATGAATTG

17707 GTAGTGGGTGCTCAGAGTGTTTGTGGGTGAATGATGTATTTGTTGAACGACTCTTTGGA
CACTTGAATAAAGTCCATCCAGTATGCACCATTACCATCTCTTCGCTCTACAATATTCTT
TAGGCAAGAGCTTATCTTTTGAGGTGATAAGATAAGCTCAAACCTATGTAGACTAAGAC
CTCAGTCTGTAAATGTCATCCCTAAGTCTTAAACCATCAAACCCAGGGCCTCAAGGAATG
GCATGCCTTCTGCAACTGTAGCAACCTGCTGTGCTTATTTGCCGTGTTTTTCATTTTTTC
[T, C]
CCCCAAAGCTAGAGTCCCTTCTCCCATGGGCAGTGCTGGAAGTGTGCTAACAATTCCTT
CTCCATACTGCTTACGATTACAAAAAAACCTCAGCATCTCATGCCAGACTTGAGTTAA
GGTTGTTTTCTTTGTGTGTCAGCTGTATTCTGGTCATGACTTCCTGATGATGCCCTATA
GAGATTTTGTGATCAGAGGTGCTCCACTGCCATCAGTAGCACTGACTCTTGAGAA
GCACCGTTTCTGAAGTTGGCTAATGTATCCCTCACGTTTGTTGTTTGAATTTGTTTT

FIG.3-27

18219 TGCCATCAGTAGCACTGACTCTTGCAGAAGCACCGTTTCTGAAGTTGGCTAATGTCATCC
CTCACGTTTGTGTTGTTTAAAATTTGTTTTAGTTCCAGAGATAGCACTTTCATGGAATGAC
GCTATCTTCTAGAATCACTTTTTTTTTTTTTTTGAGTTGGAGTCTCGCTGTGTGCCAGG
CTGGAGTGCAGTGGCACAATCTCAGCTCACTGCAATCTCCACCTTCGGGTTCAAGTGAT
TCCCTGCCTCAGCCTCCCGAGGAGCTGTTACTACAGGCGCACACCCCCACTCCTGGCTA
[-,A]
TTTTATGTGTTTTAGTAGAGACGGGGTTTACCCTGTTGGCCAGGATGGTCTCGATCTCC
TGACTTTGTGATCTGCCTGCTTCAGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGTCAC
CGCGCCTGGCCTAGAATCACCTTTTTATACCATAACGTGAGCACCCTGCCGCGTCACCA
AGGAAAGAGAGAGGCAGCTACTGTGGGGTTACAAATGGGTAAGAGTGGCACCAGGAAGGT
GAAAGTCTCTACTTAGCCAAGGCTTAACAAAATGTCAATACCAAACATTTATTTATTA

19670 GACCCCCATGATGAGCAACTATAGCACTAGAACAGTGATAATACTAATGTTTATAATGC
ATCTTCAGTTTACAGAGGGCTTTTGTACTCATCATCTAGTTTGTTCCTGCAACAACCTC
TTGAGGAATATAGCACAAGCAGGACAAGGGAAGCCAGAGATGTTAAATAATTTATCCAA
GTTTATGCTGCTGGGAAGGGCAGCACTGAAATTTAAAGAAAAGTTTTCTGAGCTCAAATC
CCATGCCCTTTCTCAATGTGAGCTCTAGCAAGGTATTCAGGAATCCTGCCTCTACAGTT
[C,T]
AGAGCCTCAAATTGCTGGGTATGTTGAGTTCTTGTATCTGATTTTTCTAGATTTCTGCC
CACATTTCTACTGTCTGGATATCAGGAAAGAGTTTATCAAATGCCTGTGGAAATCCAAGA
TAAGGTCTCATGATGAGTAACCCAGTGAAACATGAAGTCAAGTCTAACTAGTCACTACT
ATTTCACTACTGCTGACTCCTGATGATCAGCTCCTTTTCTAAGTGCTTACTGTCCACTTA
TTCCATCATCTGCCTAGAATTTATGTGAAGGAATCAAAGCAAAAGGATCATAAGGCTTCC

21153 GGACCTTGTTTTAGAAGGATGACTGCTGCTATAATGTAGAAAGTGATTTGGAAGAGGGG
AGGAGTGGGGCACGAAAGATGGTTAGTAGATGGGGTGGTAATGCTTACCTTTCACTATT
TGGAGGCTTCGGAGTCTCAAAAATCTCTTCTTGATTGGAGTCTCCAGCCAATAGA
GGGCTTCACACAAACAGTTTCTTGGGTTTTGAATTGTTTGACCAGAGCTTTCTTCCGACA
AAAGGTTGGGGTGATTCATTCACCTACCACACCTGCCTGAACATTCACTTGGGGCTGCC
[G,T]
GTTATGAAGGCTATTGTTCTCCAGCCTGTCACAGACGCTTTGAAGACCTGTGCCTCAGCT
GGTTCTAAGGAGTCAGTTTGTTCAGCTCCGTGCCAGGTTTCAAATTTATGAAATGTGCTG
GAGATTAACACCTCTCTGCCATTTTATCCCTACTATAATTGCCAGTCAAAGGATTCCTG
CAGTTGCCTCTGGCAGCCATAACTGATGAATGTTCTGCCAGCTGCTCTGAGGACCTAGAA
GAGCAGTTTTCTATCCAGGACCAGTTTCAAGGGTGGGAGGGTGAAATATATCTCCAGT

24566 CTA CTCTGGAGGCTGAGGTGAGAGGATCACTTGAGTCCAGAAGGTCGAGGTCAAGATTGT
AGTGAGCCATGATGGCATCACCGCACTCCAGCCTGAGTGACAGAGAGAGCCCTGACTCA
AAAAAAAAAAAAACAAAAAAAAAAAAACACCCTCACCCTTATCAGCTATTTGTCTTGAGAA
TAGTGACATAACCCCTCAGAACCTATTTCTAATCTGTTAAATGAGGCTGATGACGTTTC
CTCCTTTTACTGGCAATTTAAACATGATGGATAATAAATGCTAAGCACTTAACACAGGGC
[C,-]
TAGAAGATATTAAGTCTCAATAAATGGTAGCTTCTTAACAGTATTCAAACCATGTGCT
CTTATCACATGCATTGTTGTCCCTGTGTCCAGTTGGTGGAAATGGGAAAAGGCTCCCTTGT
AACCCCATCTACCCTTTATCAGACTTTCTGCCATGGTTACAGTAAGAGATAGAAGC
TGACCGGTGACTTCTGGCTCTTTACAATGGTGAGCGGTGTGTGCCTGGTAAGGGAGAGCT
GATGTCAGTGGCCCAATCCAGTAGTGAGATCTGAGTGTTCTGGTTTCTCCAGCAGCT

FIG.3-28

26604 GATTTGCAGCTGAGCCTGTCTATCTGGTGTGGGAAGAAGATGGGGAGTTACTTGTCACTC
CCGGCTTACTTCACCTCCAGAGACCTGTTTCGGTGAGTTGGTCTCCGAGTTCCCCTCTCC
ATCTCTCCTGGCCCCCTGGTCTGAGAGGAGGGTGGTCTCCCTAAATCTCCTTCTCACTTA
GTCCTTTACCATCGGTTCTGCCGGGCAGAAGCCAGCGGAGGTTATACCAAGGAGAATCG
GCCTTGTGAGGTACCCCATATTATGCTCTGGAAGTGGTGAGGGGAGGGATATACCCAGAAG
[G,A]
AACTTCTTAGGGAGCTCCAGCTCCCCTTCTATCCAGACAAACCTGAAGGAGCCTCCAAA
AGATGCCACTGACCTGCCCATTGTAGATGTTACTGCTTCCGGGGGAATAGCCCAAATAG
AGTGCTGTTTCCAGCTCTCACATGCTTACCTGCGGGCCATGCTGCCTGCCCAGGAATTT
GTCCCAACAAGCAGGATGGGCAGGTTTTGCCAACTGTGAAACTGGCAAGTCCTGGGTG
TGGGTAGCCTGGTACACAGTAGGCACCTTATAAACGTTTGTCTCTTAATGGCAGGCACA

27255 TGGGGAAAGACCTGGGCGAGTGCTTCTAAGACTGGAGCAATGGGCTTTAGAGTGTTCTTG
AGCTGCTGGGCCAGCCCCACACCTCCTCAGTCCCTAGGCCTAAGTACCTCCACGAGCCT
CTCTCTGTGGGGCTTCTCAGAGGGAGATGTGGAACCTCTACCTCTAACCTGGCTTTCTTT
GCTCATTGCCCACTCCACCTCCCATAGAACTCCCCAGGGGTTTCTGGCCCTCTGGGT
CCCTTCTGAATGGAGCCATTCCAGGCTAGGGTGGGGTTTGTTCATTCTTTGGGAGCAG
[C,G]
CTGTTGTTCCAAAAGGCTGCCTCCCCCTCACCAGTGGTCTGCTCGACTTTTCCCTTCT
GGCTTCTCTAAGCTAGGTCCAGTGCCAGATCTTGCTGCCGGGATACTAGTCAGGTGGCC
AGGCCCTGGGCAGAAAAGCAGTGTACCATGTGGTTTTGTGGAATGACCGGACCCTGGTAG
ATTGCTGGGAAGTGTCTGGACAGGGGGAAGGGGAAGGGAAGTGGTCTCAATGCTGACT
CTACCAAGCGCCTGCTAGACACTTTATCCTTTAATCTCTCAACAGCCTAAAGAGATTAT

27399 AGATGTGGAACCTCTACCTCTAACCTGGCTTTCTTTGCTCATTGCCCCACTCCACCTCCC
ATAGAACTCCCCAGGGGGTTTCTGGCCCTCTGGGTCCCTTCTGAATGGAGCCATTCCAG
GCTAGGGTGGGGTTTGTTCATTCTTTGGGAGCAGCCTGTTGTTCCAAAAGGCTGCCT
CCCCCTCACCAGTGGTCTGGTCGACTTTTCCCTTCTGGCTTCTCTAAGCTAGGTCCAGT
GCCCAGATCTTGCTGCCGGGATACTAGTCAGGTGGCCAGGCCCTGGGCAGAAAAGCAGTG
[T,C]
ACCATGTGGTTTTGTGGAATGACCGGACCCTGGTAGATTGCTGGGAAGTGTCTGGACAGG
GGGAAGGGGAAGGGAACCTGGTCTCAATGCTGACTCTACCAAGCGCCTGCTAGACACT
TTATCCTTTAATCTCTCAACAGCCTAAAGAGATTATATCCCCATTTTACAGATGAGGC
AACCAGTTTCAACAGAGTTAACATATGGAGCCTCACTGGGCAGCTTTTCTGTCTTCCTG
ACTTCTCTCATCCTTCAGGGGGCTGCAGGTTTGTTCCTTCTCCTAGTGGAGAGGAAAT

28088 AAGAGCCAATGGAAATTGATCTTGAGTTTAGGAGAAAGCTTTTACATGTGGAATTAAGAT
GCCAAGTGTTGAAGTAGCCACATTTAGGTCTCATTAAATTTCTCTTAATCCTGGGAAGG
CAGCTTAGGAGAAGGGTTGTTCTTTAGGAGCCAGGAACTATACCCCTTTTACCCTTGGA
GAGGCAGGGAAGCCAGGGAGGACACAACCTTCTCAGGAAGAGGAGAAGCTAGAGCAGATAG
TGAACCTCAACCTGAACCTTTAAGGGCCAGACCACTAATGCCACCCAAGTCCACCTGCC
[G,A]
TTTGTCTTGTCTGTCCCAGGCTTTCTGGAGAACCTGATCTTCTTGCCCTACCCCCAAG
CTCCGTTTGCCAGCTAGAGTCTGGGGGGTACTGACTGACTTTCTGAGACATTCTCCCT
TCCCCAAATAAGAGGCCACATTCCTGAAGTCACTTCTGAAGAGATAGCTGCCACACAGGG
CTCTTCCCCCAGGGAGGGACCACCCAGACCTCTGCTCTCCAGGTATCCGTTACCAC
ATCACTACCTGGTCAGAAAGCTGTTCTGCCATTAGCCCTCCCTCTTTTATTATAGGAT

FIG.3-29

28734 AAGTAGAAGCTAGACTTCTTGGGCTCCTGAACAGGGTCCTTGCTGGATTCTGTGAAACAA
ATTAAGTTCTTGACCCTAGGCCTCTGGGGGAGTACAAAGTCTATGGGAGTTCTGGGGCTG
TGGTTGCAAGGAAAGTGACGCAACCAGATTCCATGGGGACATGATCAGGCGTGACATGTG
AGGGAGGAAGAGGGAGCAAGGGAATGAAGAATACTTCTGTGTCCCATACACCCCTGC
CTGACAGGCCATACATACTCAGCAGAGAATGCACTGTCTTCTACCACACTAGCGTGAG
[G,A]
AGTGAGCTGCAATTACCACTGTGCTTCCAAGTAAGAAAATACCTCAAATTGGAATTTACA
AAAGAGGTAAATTAGGGAGTGGCTTTTGTGCGACATCTTTAAAGCATTTTTCTTTTATA
GAATTTCACTTAATGTCCAATACTGATTTAATGAGCTTGGGTTTACACATTATCTCTTGA
AGAAAACAAATGAACCTTTGTGTTCCAAAGCAATCCATGTTTAAAGGGAAAAAATTATGC
ATAACTCTGCCAGCTTCACAGTAACCTTTGGCAGGTGCCCTTAGGTCTCTGGGACTCTT

29246 AATCCATGTTTAAAGGGAAAAAATTATGCATAACTCTGCCAGCTTCACAGTAACCTTTG
GCAGGTGCCCTTAGGTCTCTGGGACTCTTTTCTTATCTGAAAAATGAAGGACTTGGATC
AGGTGAATGGTTCCAGCTCTGCAACTTATGTGGCTCCTCAGAGGCACACAAGCTCTTTT
CCATTATTTGCCAAATAATGGAGGCCCTGTCTTTAACTGCAGTACAACACAAAAATAC
TTGAACTACAGTCTTCTGGTTTTTGGTTGGAAGTGAATCAGTGCACTCTAGCAACACT
[-.T]
ATTTCTTGCTGTTCTGAGGCTTCATTATGTGTTTGGTTAATTTTTTAAACAACAATAAC
ATATCCATAATAATTACAGCTTAATTGGCAGACTGTTTCAGTCTATAGGATCTGCAGGA
AGGAGGAGTAATAAAGGGATTTTTGACTGAGCTCTTATGGAACAGAGTCTCTTAGGCC
CTGTCATATCTGCCCTTCTGGGCCCTGGGGAAAAGTTGGCATCCCCAGTTGTGGTGCTCT
CCAGGTGCCCTCAGGCTGTGGTGGAGGGAGCTTCCATTCTCTCCTTCAGCCCACTCAAT

29490 AACTACAGTCTTCTGGTTTTTGGTTGGAAGTGAATCAGTGCACTCTAGCAACACTTATT
TCTTGCTGTTCTGAGGCTTCATTATGTGTTTGGTTAATTTTTTAAACAACAATAACATA
TTCCATAATAATTACAGCTTAATTGGCAGACTGTTTCAGTCTATAGGATCTGCAGGAAGG
AGGAGTAATAAAGGGATTTTTGACTGAGCTCTTATGGAACAGAGTCTCTTAGGCCCTG
TCATATCTGCCCTTCTGGGCCCTGGGGAAAAGTTGGCATCCCCAGTTGTGGTGCTCTCCA
[G,A]
GTGCCCTCAGGCTGTGGTGGAGGGAGCTTCCATTCTCTCCTTCAGCCCACTCAATTCAG
AGGCTAGGGGCTGAAAGAAGCTTCTCTACAACCTGGCTGTTCACTGGGAGGTTAAGGGATG
ACCATCCAGCCAGGCCCTTCTCAGGACATGGGAGGGCTTATGCTTTAACATGTGTAAATC
CACTGCAATAATGACTGGTTCTTTACCCATAAGGTTGAGAATTTACCTGTAAACATTT
TTGTCTGAAGAATTTGGATGTAAGTGAGGGCTGGGCCTCTATCTTATCTCACTTGGCTTC

29934 GGACATGGGAGGGCTTATGCTTTAACATGTGTAAATCCACTGCAATAATGACTGGTTCTT
TTACCCCATAGGTTGAGAATTTACCTGTAAACATTTTTGTCTGAAGAATTTGGATGTAA
GTGAGGGCTGGGCCTCTATCTTATCTCACTTGGCTTCTCTCAGCACAGCACCTTGCCTGC
TTGTTCTTACACATCCTAGATGCACAGTAACATTTCTAATTATTAGAAATCTATTAGA
ATCAATTGATTTCACTGGGCTTGGTGGCTCCTTCTGTAAATCCAGCACTTTGGGAGGC
[T,C]
AAGGCTGGAGGATCACCTGAGTCCAGGAGTTTAAAGACCAGCCTGGGCAACATAGGGAGAC
CCTGTCTCTACAAAAAATAAAAAATTAGCCAGGCATGGTGGTGTGCACCTGTAGTCCAG
CTACTCAGGAGGCTGAGGCAGGAGGATCTCTGAGCCTGGGAGGTGAGCTACAGTGAGC
AATGATTGTCCACTGCACTCCAGCCTGGGTGACAGAGTAAGACTCTGTCTCTTAAAAA
AAAAAAAAAAAAAGTTGATTTCTATTTGGATAGATAAATAATTCATTTTAGGACCTTTCTT

FIG.3-30

34480 CTGACTTCAAGTGATCCACCCGCCCTCGGCCTCCCAAAGTGCTGGGATTATAAGCATAAGC
CACTGTGCCCAGCTGCTCTCTATATTTTAAATACATATTATTTCCATTAATTTTCACAGC
AGTTCATTTTATAGATGAGGAACTAGGCCAGAGAAGTAAATATCTTGCCCAAGATGAT
GTAAGTAGTAAGTGGCAGGATCAAGATTCAAACCAAGCAATGTTCAAACCTCTTGGAAGC
AAGAATGTGGCCACTGTGGAAGGTGCAAGGCCCTTGACAACAAGAATAGGGAAAAGAAGGA
[A, G]
CTAGAAGGAAAGAGATGGCATGGGCTCAGCAGGCCAGGGAGCTCTTAGCTGTGTGTGTG
GGAAGCTCAGAAGGGAGGAAGAGGTTGTCTGTGCAGGTAAGTCTGAGAACACACCAGAC
TTTTGAGAGGTGGAGCTTCATAGCCAGGTCATTAGGGGAGAAGGGAGCTATAGATTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTAGAGACGGGGTCTTACTATGTTGCCAGGCTG
GTCTTGAACCTCTGGGCTCAAGTGATCCTCCACCTCAGCCTCCCAAAGTGCTGGGATTA

38812 AAATCCAGCAGATCCATTGAGAGTTTAAGCAGCAAGGTGTTGTGACCAAGTTAACATTTT
AGAAGGATCACTGGTATGGAGGTTGGATTGGAGAGGGGAAAGCCTAAAGGTATAGAGACT
AGTTAGGAAGCTATTGTAGGCTGGGCATGGTGGTTCATGCCTGTAATCTCAGCACTTTGG
GAGGCTGAGGTGGGAGGATTGCTTGAGGCCAGGAGTTGAAGACCAACCTGGCCAACATAG
CAAGACCCCGTCTCTGTTTTCTTAATTAAGAAAAGTCCAGACGTAGACATAGTGGCT
[T, C]
ACGCCTGTAATGCCAGCACTTTGGGAGGCCAAGGTGGGCAGATTGCTTGAGGTCAAGAGT
TTGGGATTAGGCCAGGCGCAGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAG
GTGGGCGGATCACAAGGTCAAGAGATCAAGACCATCCTGGCTAACACAATGAAACCCCGT
CTCTACTAAAAGTACAAAATTAGCCGGGCATGGTGGCGGACGCCTGTAGTCCCAGCTAC
TCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCTAGGAGGCGGAGCTTGCTGTGAGCAGA

40731 GTTCTGTCCTATGTCTGTCTCTCGGATGAAGCTGAGCTGGCTTTTCAGAAGCCTGCAGAGT
TAGGAAAGGAACCAGCTGGCCAGGGACAGACTATGAGGATTGTGCTGACCCAGCTGCCCC
TGTGGGGATCACAGTTTACAGCCAGAGCCTGTGCGGACCCAGCTGTCTGCCAGGTTTCT
TAGAAACCTGAGAGTCAGTCTCTGTCCACTGAACTCCTAAGCTGGACAGGAGGCAGTGAT
GCTAAACCTGAAGGGCAACATGGCCTATGGAGAAAGCATGGAGCTCAGAGCCTGGAGTA
[C, G]
GGGCACAGATAGGATTGAATAAATTGTGTAGAAAGACTTTGAAAACAATAAAGCAAAAAGA
TGAATGAACGTTTTTTTTAGACTTGAGGGACCAACAACCCCAACCCAGATTCTGCCA
GGTCCATGGGGAAGGAGAAGTTGCCTTGAGTGGAAAGCCCAAGTAGGGAGACTTACAGAA
AAGAAGTCAAGAGCACTGGCTCCCAGGCAGAAATACTGATACCTACTGGGGCTTCAGGC
TGAGCTCCTCCCTTCACAAATCACTTCATCTCTGAGCCTGTTTCTGCATCTGTGACAT

41303 CTCTGAGCCTGTTTCTGCATCTGTGACATAAGATGGTAAGATAAAGGTGGCTGTCTCACC
AATTATGTAAGGATTAAATGTGGAAGGACATAAAGTTGTATAGTGTGCCATAGGGAC
AGTGTTTCAGTAAACGTGACACATTCTTAGTATCACTAAGAATCAGGTTCTTGCCAGGCA
CCGTGGCTCATGCCTGTAATCCCAACACTCTGGGAGGCCAGGTGGGAGGATGGCTTGAA
CACAGGAGTTTGAGACCAGCCTGAGCAACATAGTGAGACACTGTCTCTACAAAAA
[T, A]
AATAATAAATTGTTTTTAATTAGATGGGCAGGGCACTGTGGCTCACACCTGTAATCCC
AGCACTTTGGGAGGCCAAGGCCGGAGGATTGCTTGAGGCCAGGAGTTCAGGAGCAGCCTG
GGCCACATTCTGTCTCTACAAAGAATAAAAAAGTTAACTGGGCATGGTGGCACATGCCT
GTAATCCCAGCTACTCAAGAGGCTGAGGAGGAGGATTGCCTGAGCCCAGGAGTTCAAGAC
TGCAGTGAGCCTTGATCACACCACTGTACTACAGCTTGGGCAACAGAGTGAGACCTGTG

FIG. 3-31

- 41305 CTGAGCCTGTTTCTGCATCTGTGACATAAGATGGTAAGATAAAGGTGGCTGTCTACCAA
TTATGTAAGGATTAAATGTGGAAAAGGACATAAAGTTGTATAGTGCTGCCATAGGGACAG
TGTTTCAGTAAACGTGACACATTCTTAGTATCACTAAGAATCAGGTTCTTGCCAGGCACC
GTGGCTCATGCCTGTAATCCCAACACTCTGGGAGGCCCTAGGTCGGAGGATGGCTTGAACA
CAGGAGTTTGAGACCAGCCTGAGCAACATAGTGAGACACTGTCTCTACAAAAAAAATA
[-.A]
TAATAATAATTGTTTTTAATTAGATGGGCAGGGCACTGTGGCTCACACCTGTAATCCCAG
CACTTTGGGAGGCCAAGGCCGGAGGATTGCTTGAGGCCAGGAGTTCAGGAGCAGCCTGGG
CCACATTCTGTCTCTACAAAGAATAAAAAAGTTAACTGGGCATGGTGGCACATGCCTGT
AATCCCAGCTACTCAAGAGGCTGAGGAGGAGGATTGCTGAGCCCAGGAGTTCAAGACTG
CAGTGAGCCTTGATCACACCACTGTACTACAGCTTGGGCAACAGAGTGAGACCTTGCTCTC
- 41457 CTAAGAATCAGGTTCTTGCCAGGCACCGTGGCTCATGCCTGTAATCCCAACACTCTGGG
AGGCCTAGGTCGGAGGATGGCTTGAACACAGGAGTTTGAGACCAGCCTGAGCAACATAGT
GAGACACTGTCTCTACAAAAAAAATAATAATAAATTGTTTTTAATTAGATGGGCAG
GGCACTGTGGCTCACACCTGTAATCCCAGCACTTTGGGAGGCCAAGGCCGGAGGATTGCT
TGAGGCCAGGAGTTCAGGAGCAGCCTGGGCCACATTCTGTCTCTACAAAGAATAAAAA
[G.C]
TTAACTGGGCATGGTGGCACATGCCTGTAATCCCAGCTACTCAAGAGGCTGAGGAGGAGG
ATTGCCTGAGCCCAGGAGTTCAAGACTGCAGTGAGCCTTGATCACACCACTGTACTACAG
CTTGGGCAACAGAGTGAGACCTTGCTCTCAAAAAAAAAGTTTGTTTTTTTTATCCACT
CTCCTCACCAACAACTGAGTAAGTTAGAGCCCTCTCAGCTGGCATGTGTTGAAACAG
TGCCCTCTCATTAAAGTGCTGCCCTCACTCCATTGCCTCTTGGCCTTGGTCAGTATGAT
- 43168 AGCTACTTGGGAGGCTGAGGCAGGAGAATCGCTTGAACCTGGAAGGCCGAGGTGCGAGTG
AGCCGAGATCGTGCCATTGCACTTCAGCCTGGGCGACAGAGCGAGACTCTGTCTCAAAAA
TAATAATAATAACAATAACTAGCCGGGCCCTGGTGGCACATGCCTGTAGTCCAGTTACTC
AGGAGGCCGAGGCATGAGACTCAGGTGAACCTAGGGAGACAGAGGTTGCAGTGAGCCAAGA
TCACACCACTGCACTCCAGCCTGGTTGACAGAGCGAGACTCTGTCTCAAAAAAAAATA
[A.-.T]
CCCATTGCTCATTTTTTGGATACTAGTATAACTATCACTCTAAACCAGTTAGTACTTAA
ATCAAGCAGATATGGGAGATGGTGAATTACCATCTACAGTGTTGTATATATGTCACATA
CTGAGCATTATCAGCTAGTAGAATCTAGTTAATTGTTCTATGTGTGATGTATGCAGAGTT
CCCATTGTAATGTGTTTTTACTATGCTTAAATAAATGACTGATGTCAGCAACCCCAAAA
TGATACATCTGATGTAAGAGCCCCTGTTCCCAATAATAACATCTAAACTATAGACATTG
- 43357 AGGCATGAGACTCAGGTGAACTAGGGAGACAGAGGTTGCAGTGAGCCAAGATCACACCAC
TGCACTCCAGCCTGGTTGACAGAGCGAGACTCTGTCTCAAAAAAAAATAATCCCATTG
CTCATTTTTTGGATACTAGTATAACTATCACTCTAAACCAGTTAGTACTTAAATCAAGCA
GATATGGGAGATGGTGAATTACCATCTACAGTGTTGTATATATGTCACATACTGAGCAT
TATCAGCTAGTAGAATCTAGTTAATTGTTCTATGTGTGATGTATGCAGAGTTCCCATTG
[T.G]
AATGTGTTTTTACTATGCTTAAATAAATGACTGATGTCAGCAACCCCAAAATGATACATC
TGATGTAAGAGCCCCTGTTCCCAATAATAACATCTAAACTATAGACATTGGAATGAACA
GGTGCCCCAAGTTTCTCCCTCCAGGGTTTCTTGCCGGTCTCTGAGGACTACACATCC
CTACTCCCGTCTTTCTCATCTTCAGGCGCAGTAACAGTATCTCCAAGTCCCCTGGCCCC
AGCTCCCCAAGGAGCCCCTGCTGTTGAGCCGTGACATCAGCCGCTCAGAATCCCTTCGT

FIG.3-32

45664 CCAGCTTTCCTTGGCTTCCCCACCCCCAGGTGAAAGTGATGCGCAGCCTGGACCACCCC
AATGTGCTCAAGTTCATTGGTGTGCTGTACAAGGATAAGAAGCTGAACCTGCTGACAGAG
TACATTGAGGGGGGCACACTGAAGGACTTCTGCGCAGTATGGTGAGCACACCACCCCAT
AGTCTCCAGGAGCCTTGGTGGGTGTCAGACACCTATGCTATCACTACCCTAGGAGCTTA
AAGGGCAGAGGGGCCCTGCTTTGCCCTCAAAGGACCATGCTGGGTGGGACTGAGCATACA
[T,C]
AGGGAGGCTTCACTGGGAGACCACATTGACCCATGGGGCCTGGACCACGAGTGGGACAGG
GCTCAACAGCCTCTGAAAATCATTCCCCATTCTGCAGGATCCGTTCCCTGGCAGCAGAA
GGTCAGGTTTGCCAAAGGAATCGCTCCGGAATGGTGAGTCCACCAACAACCTGCCAG
CAGGGCGAGAGTAGGGAGAGGTGTGAGAATTGTGGGCTTCACTGGAAGGTAGAGACCCCT
TCCTATGCAACTTGTGTGGGTGGGTGAGCAGCTATTCATTGAGTTTGTCTGTGCTACTG

47549 AATTAGCTGGGCGTGGTGGTGCACGCCTGTAGTCCCAGCTACTCAGGAGGCCGAGGCAGG
AGAATAGCTTGAACCTGGGAGGCAGAAGTTGCAGTGAGCCAAGATCACACCACTGCATTC
CAGCCTGGGTGACAGAGTGAGACTTCATCTCAAAAAAAAAAAAAAGAGAGACTGATATG
GTTAGTACATTGGGGTGAATCGGGAGGGTCCAGGGAATGGAGCCCTGCATAGGGGGCTA
ATGAAACATTTAGATTTCTGAATTAAGGTAGTGGCTGTGGGGACAGGAGCCTGGGAGGC
[A,C]
GGGTGGAGTCAGAATGGAGAGACTGGTTGGCAATGAGGGAACAGGAGGAGGAGGAGGAGG
AGTTACGAGTGGCTTGAGGTGTCACTTACCAGACATTTGGGGGATGGGGGATAGCCGTGA
TTGTTGAGCAACTGGTTTGGGAAGAGCTAGCATTGATCCCTGCTGTTCTGTGCTAGCAGA
ACCTATCAGCATCTTCTGGGCAGGAACTGGCTCCATGAGACTGGCTTAGGGAGAGGCTG
CTAGTCACCTAATCTGCAGAGAAGGGGCAGCTGGAGCTGTGGGACAGAAGAGGCATCCAT

47908 GGAGTTACGAGTGGCTTGAGGTGTCACTTACCAGACATTTGGGGGATGGGGGATAGCCGT
GATTGTTGAGCAACTGGTTTGGGAAGAGCTAGCATTGATCCCTGCTGTTCTGTGCTAGCA
GAACCTATCAGCATCTTCTGGGCAGGAACTGGCTCCATGAGACTGGCTTAGGGAGAGGC
TGCTAGTCACCTAATCTGCAGAGAAGGGGCAGCTGGAGCTGTGGGACAGAAGAGGCATCC
ATGTAGCTGGTGGGGGTGTCTCAGCTTGTGAAGAGGAGATGGCTTTGAGCAGGGCTGACA
[C,A]
TGAAAAGGCTGGAAGAAAAAACAGACACACAAGAGTCTCAGGATCAGGTAGCATAGGAA
AGTTGTGGACAGTCTTTGAGGAGCACTCCCTCAGGCAGGCAGGCAGGCAGGTGATGAGCT
ATAGCGATTGAGGAAGAGCTCCCTGGGTGTGTGAGCAGCTCCAGGAGCCTAAGGGATGAA
AGTAGTATTGAGGGGGCTGGAGAGCAAGGAGTGGCTCCTTCTACATTTGCAAGGGAAGG
AGAAAGGAAGTTGCTCCTGAGAGTGGTAAGAGTCAAGTGGTGGAGGCCTGGAGAGGAGACA

52267 TTGTGAGGGGTAGAGGAGAGGAGAGACAAGGGATGGTTAGGATAATGAAGGAATGTTTTG
TTTTGTTTTGTTTTGAGATGGAGTTTCACTCTGTCACCCAGGCTGGAGTGCAGAGGT
GCAATCTTGGCTCACTGCAGCCTCCGCCTCCAGGTTCAAGCAATCCTCCTGCCCTCAGCC
TCCCAAGTAGCTGGGACTACAGGTGTGCGCCACCACGCCTGGCTAATTTTTGTATTTTCA
GTAGAGACAGGGTTTCGCCATATTGGCCAGGCTGGTCTCAAATGCCTGACCTCAGGTGAT
[C,A]
CACCCGCTTCAGCCTCCCAAAGTGCTGAGATTACAGGCATGAGCTACCGTGCTGGCCAT
GAAGGAAGATTTGTTTTAAAAAATTGTTTTCTTTAATATTAATTGAACACCTCTGTTTCA
AGCACTGGGCTGGTGCCAGAGGGTTTCAAGCATGAATCAGATCCAGCACCTCATAGAGCC
TTAATCTGGCACACACACAGCCACAAGGAGACACAGACAAGGCAGGGTAGGATGAGTG
GAAGCTAGGAGCAGATGCTGATTTGGAACACTTGGCTTCTGCAAGTGAAGCCCTTCTTAG

FIG.3-33

- 54654 GGCCCCGGCCCCGGCCCCAGGCCAGGCAGTGGCGGCCAAGGACCACGCATCTACTTTCA
GAGCCCCCCCCGGGGCCGAGGAGAGGGCCCCGGGTGGGCGGATGATGAGGGCCAGTGA
GGCGCCAAGGGAAGGTCACCATCAAGTATGACCCCAAGGAGCTACGGAAGCACCTCAACC
TAGAGGAGTGGATCCTGGAGCAGCTCACGCGCCTCTACGACTGCCAGGAAGAGGAGATCT
CAGAACTAGAGATTGACGTGGATGAGCTCCTGGACATGGAGAGTGACGATGCCTGGGCTT
[T,C]
CAGGGTCAAGGAGCTGCTGGTTGACTGTTACAAACCCACAGAGGCCCTTCATCTCTGGCCT
GCTGGACAAGATCCGGGCCATGCAGAAGCTGAGCACACCCAGAAAGTGAGGGTCCCC
GACCCAGGCGAACGGTGGCTCCCATAGGACAATCGCTACCCCCGACCTCGTAGCAACAG
CAATACCGGGGGACCTGCGGCCAGGCCTGGTTCCATGAGCAGGGCTCCTCGTGCCCTG
GCCAGGGGTCTCTTCCCCTGCCCCCTCAGTTTTCCACTTTTGGATTTTTTATTGTTAT
- 54679 GGCAGTGGCGGCCAAGGACCACGCATCTACTTTTCAGAGCCCCCCCCGGGGCCGAGGAGA
GGGCCCCGGGTGGGCGGATGATGAGGGCCAGTGAGGCGCCAAGGGAAGGTCACCATCAA
GTATGACCCCAAGGAGCTACGGAAGCACCTCAACCTAGAGGAGTGGATCCTGGAGCAGCT
CACGCGCCTCTACGACTGCCAGGAAGAGGAGATCTCAGAACTAGAGATTGACGTGGATGA
GCTCCTGGACATGGAGAGTGACGATGCCTGGGCTTCCAGGGTCAAGGAGCTGCTGGTTGA
[C,G]
TGTTACAAACCCACAGAGGCCCTTCATCTCTGGCCTGCTGGACAAGATCCGGGCCATGCAG
AAGCTGAGCACACCCAGAAAGTGAGGGTCCCCGACCCAGGCGAACGGTGGTCCCAT
AGGACAATCGCTACCCCCGACCTCGTAGCAACAGCAATACCGGGGGACCTGCGGCCAG
GCCTGGTTCCATGAGCAGGGCTCCTCGTGCCCTGGCCAGGGGTCTTCCCCCTGCCCC
CTCAGTTTTCCACTTTTGGATTTTTTATTGTTATTAACCTGATGGGACTTTGTGTTTTT
- 54693 AGGACCACGCATCTACTTTTCAGAGCCCCCCCCGGGGCCGAGGAGAGGGCCCCGGGCTGGG
CGGATGATGAGGGCCAGTGAGGCGCCAAGGGAAGGTCACCATCAAGTATGACCCCAAGG
AGCTACGGAAGCACCTCAACCTAGAGGAGTGGATCCTGGAGCAGCTCACGCGCCTTACG
ACTGCCAGGAAGAGGAGATCTCAGAACTAGAGATTGACGTGGATGAGCTCCTGGACATGG
AGAGTGACGATGCCTGGGCTTCCAGGGTCAAGGAGCTGCTGGTTGACTGTTACAAACCCA
[A,C]
AGAGGCCCTTCATCTCTGGCCTGCTGGACAAGATCCGGGCCATGCAGAAGCTGAGCACACC
CCAGAAGAAGTGAGGGTCCCCGACCCAGGCGAACGGTGGCTCCCATAGGACAATCGCTAC
CCCCGACCTCGTAGCAACAGCAATACCGGGGGACCTGCGGCCAGGCCTGGTTCCATGA
GCAGGGCTCCTCGTGCCCTGGCCAGGGGTCTTCCCCCTGCCCCCTCAGTTTTCCACT
TTTGGATTTTTTATTGTTATTAACCTGATGGGACTTTGTGTTTTTATATTGACTCTGCG
- 54706 TACTTTTCAGAGCCCCCCCCGGGGCCGAGGAGAGGGCCCCGGGTGGGCGGATGATGAGGG
CCCAGTGAGGCGCCAAGGGAAGGTCACCATCAAGTATGACCCCAAGGAGCTACGGAAGCA
CCTCAACCTAGAGGAGTGGATCCTGGAGCAGCTCACGCGCCTCTACGACTGCCAGGAAGA
GGAGATCTCAGAACTAGAGATTGACGTGGATGAGCTCCTGGACATGGAGAGTGACGATGC
CTGGGCTTCCAGGGTCAAGGAGCTGCTGGTTGACTGTTACAAACCCACAGAGGCCCTTCAT
[T,C]
TCTGGCCTGCTGGACAAGATCCGGGCCATGCAGAAGCTGAGCACACCCAGAAAGTGA
GGGTCCCCGACCCAGGCGAACGGTGGCTCCCATAGGACAATCGCTACCCCCGACCTCGT
AGCAACAGCAATACCGGGGGACCTGCGGCCAGGCCTGGTTCCATGAGCAGGGCTCCTCG
TGCCCTGGCCAGGGGTCTTCCCCCTGCCCCCTCAGTTTTCCACTTTTGGATTTTTT
ATTGTTATTAACCTGATGGGACTTTGTGTTTTTATATTGACTCTGCGGCACGGGCCCTT

FIG.3-34

- 54712 CAGAGCCCCCCCCGGGGCCGAGGAGAGGGCCCCGGGCTGGGCGGATGATGAGGGCCAGT
GAGGCGCCAAGGGAAGGTCACCATCAAGTATGACCCCAAGGAGCTACGGAAGCACCTCAA
CCTAGAGGAGTGGATCCTGGAGCAGCTCACGCGCCTCTACGACTGCCAGGAAGAGGAGAT
CTCAGAACTAGAGATTGACGTGGATGAGCTCCTGGACATGGAGAGTGACGATGCCTGGGC
TTCCAGGGTCAAGGAGCTGCTGGTTGACTGTTACAAACCCACAGAGGCCCTTCATCTCTGG
[T, C]
CTGCTGGACAAGATCCGGGCCATGCAGAAGCTGAGCACACCCAGAAGAAGTGAGGGTCC
CCGACCCAGGCGAACGGTGGCTCCCATAGGACAATCGCTACCCCCGACCTCGTAGCAAC
AGCAATACCGGGGGACCCTGCGGCCAGGCCTGGTTCCATGAGCAGGGCTCCTCGTGCCCC
TGGCCCAGGGGTCTCTTCCCTGCCCCCTCAGTTTTCCACTTTTGGATTTTTTATTGTT
ATTAACTGATGGGACTTTGTGTTTTATATTGACTCTGCGGCACGGGCCCTTAAATAAA
- 54799 GTATGACCCCAAGGAGCTACGGAAGCACCTCAACCTAGAGGAGTGGATCCTGGAGCAGCT
CACGCGCCTCTACGACTGCCAGGAAGAGGAGATCTCAGAACTAGAGATTGACGTGGATGA
GCTCCTGGACATGGAGAGTGACGATGCCTGGGCTTCCAGGGTCAAGGAGCTGCTGGTTGA
CTGTTACAAACCCACAGAGGCCCTTCATCTCTGGCCTGCTGGACAAGATCCGGGCCATGCA
GAAGCTGAGCACACCCCAAGAAGAAGTGAGGGTCCCCGACCCAGGCGAACGGTGGCTCCCA
[T, C]
AGGACAATCGCTACCCCCGACCTCGTAGCAACAGCAATACCGGGGGACCCTGCGGCCAG
GCCTGGTTCCATGAGCAGGGCTCCTCGTGCCCCCTGGCCAGGGGTCTCTTCCCTGCCCC
CTCAGTTTTCCACTTTTGGATTTTTTATTGTTATTAACTGATGGGACTTTGTGTTTTT
ATATTGACTCTGCGGCACGGGCCCTTAAATAAGCGAGGTAGGGTACGCCCTTGGTGACG
CTCAAAAAAAAAAAAAAAAAAATGATTTCCAGCGGTCCACATTAGAGTTGAAATTTCTGGT
- 54819 GGAAGCACCTCAACCTAGAGGAGTGGATCCTGGAGCAGCTCACGCGCCTCTACGACTGCC
AGGAAGAGGAGATCTCAGAACTAGAGATTGACGTGGATGAGCTCCTGGACATGGAGAGTG
ACGATGCCTGGGCTTCCAGGGTCAAGGAGCTGCTGGTTGACTGTTACAAACCCACAGAGG
CCTTCATCTCTGGCCTGCTGGACAAGATCCGGGCCATGCAGAAGCTGAGCACACCCAGA
AGAAGTGAGGGTCCCCGACCCAGGCGAACGGTGGCTCCCATAGGACAATCGCTACCCCCC
[G, A]
ACCTCGTAGCAACAGCAATACCGGGGGACCCTGCGGCCAGGCCTGGTTCCATGAGCAGGG
CTCCTCGTGCCCCCTGGCCAGGGGTCTCTTCCCTGCCCCCTCAGTTTTCCACTTTTGA
TTTTTTTATTGTTATTAACTGATGGGACTTTGTGTTTTTATATTGACTCTGCGGCACGG
GCCCTTTAATAAAGCGAGGTAGGGTACGCCCTTGGTGACGCTCAAAAAAAAAAAAAAAAAA
TGATTTCCAGCGGTCCACATTAGAGTTGAAATTTCTGGTGGGAGAATCTATACCTTGTT
- 55499 TTGTTTTCTAATACCTCTTGTCATTCTAAATATCTTTAATTTATTAATAAATATATATAT
ACAGTATTGAATGCCTACTGTGTGCTAGGTACAGTTCTAAACACTTGGGTTACAGCAGCG
AACAAAATAAAGGTGCTTACCCTCATAGAACATAGATTCTAGCATGGTATCTACTGTATC
ATACAGTAGATACAATAAGTAACTATATTGAATATTAGAATGTGGCAGATGCTATGGAA
AAAGAGTCAAGACAAGTAAAGACGATTGTTCAAGGTACCAGTTGCAATTTTAAATATGGT
[C, T]
GTCAGAGCAGGCCTCACTGAGGTGACATGACATTTAAGCATAAACATGGAGGAGGAGGAG
TAAGCCTGAGCTGTCTTAGGCTTCCGGGGCAGCCAAGCCATTTCCGTGGCACTAGGAGCC
TGGTGTTCGATTCCACCTTTGATACTGCATTTTCTCTAAGATATGGGAGGGAAGTTT
TTCTCCTATTGTTTTAAGTATTAAGTCCAGCTAGTCCAGCCTTGTTATAGTGTTACCTA
ATCTTTATAGCAAATATATGAGGTACCGGTAAACATTATGCCCATTTCTCACAGAGGCACT

FIG.3-35

56825 ACTGATGGCTCAAAGGGTGTGAAAAAGTCAGTGATGCTCCCCCTTTCTACTCCAGATCCT
GTCCTTCCTGGAGCAAGGTTGAGGGAGTAGGTTTTGAAGAGTCCCTTAATATGTGGTGGGA
ACAGGCCAGGAGTTAGAGAAAGGGCTGGCTTCTGTTTACCTGCTCACTGGCTCTAGCCAG
CCCAGGGACCACATCAATGTGAGAGGAAGCCTCCACCTCATGTTTTCAAACCTAATACTG
GAGACTGGCTGAGAACTTACGGACAACATCCTTTCTGTCTGAAACAAACAGTCACAAGCA
[C,A]
AGGAAGAGGCTGGGGGACTAGAAAGAGGCCCTGCCCTCTAGAAAGCTCAGATCTTGGCTT
CTGTTACTCATACTCGGGTGGGCTCCTTAGTCAGATGCCTAAACATTTTGCCTAAAGCT
CGATGGGTCTGGAGGACAGTGTGGCTTGTCACAGGCCTAGAGTCTGAGGGAGGGGAGTG
GGAGTCTCAGCAATCTCTTGGTCTTGGCTTCATGGCAACCACTGCTCACCCTTCAACATG
CCTGGTTTAGGCAGCAGCTTGGGCTGGGAAGAGGTGGTGGCAGAGTCTCAAAGCTGAGAT

58871 CGTCACCCACCACCCAACCCCTGCCGCACTCCAGCCTTTAACAAGGGCTGTCTAGATATT
CATTTTAACTACCTCCACCTTGGAACAATTGCTGAAGGGGAGAGGATTTGCAATGACCA
ACCACCTTGTTGGGACGCCTGCACACCTGTCTTCTGCTTCAACCTGAAAGATTCTCTGA
TGATGATAATCTGGACACAGAAGCCGGGCACGGTGGCTCTAGCCTGTAATCTCAGCACTT
TGGGAGGCCTCAGCAGGTGGATCACCTGAGATCAAGAGTTTGAGAACAGCCTGACCAACA
[T,A]
GGTGAAACCCCGTCTCTACTAAAAATACAAAAATTAGCCAGGTGTGGTGGCACATACCTG
TAATCCCAGCTACTCTGGAGGCTGAGGCAGGAGAATCGCTTGAACCCACAAGGCAGAGGT
TGCAGTGAGGCGAGATCATGCCATTGCACTCCAGCCTGTGCAACAAGAGCCAACTCCAT
CTCAAAAAAAAAA

FIG.3-36

1

ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN KINASE PROTEINS, AND USES THEREOF

FIELD OF THE INVENTION

The present invention is in the field of kinase proteins that are related to the serine/threonine kinase subfamily, recombinant DNA molecules, and protein production. The present invention specifically provides novel peptides and proteins that effect protein phosphorylation and nucleic acid molecules encoding such peptide and protein molecules, all of which are useful in the development of human therapeutics and diagnostic compositions and methods.

BACKGROUND OF THE INVENTION

Protein Kinases

Kinases regulate many different cell proliferation, differentiation, and signaling processes by adding phosphate groups to proteins. Uncontrolled signaling has been implicated in a variety of disease conditions including inflammation, cancer, arteriosclerosis, and psoriasis. Reversible protein phosphorylation is the main strategy for controlling activities of eukaryotic cells. It is estimated that more than 1000 of the 10,000 proteins active in a typical mammalian cell are phosphorylated. The high energy phosphate, which drives activation, is generally transferred from adenosine triphosphate molecules (ATP) to a particular protein by protein kinases and removed from that protein by protein phosphatases. Phosphorylation occurs in response to extracellular signals (hormones, neurotransmitters, growth and differentiation factors, etc), cell cycle checkpoints, and environmental or nutritional stresses and is roughly analogous to turning on a molecular switch. When the switch goes on, the appropriate protein kinase activates a metabolic enzyme, regulatory protein, receptor, cytoskeletal protein, ion channel or pump, or transcription factor.

The kinases comprise the largest known protein group, a superfamily of enzymes with widely varied functions and specificities. They are usually named after their substrate, their regulatory molecules, or some aspect of a mutant phenotype. With regard to substrates, the protein kinases may be roughly divided into two groups; those that phosphorylate tyrosine residues (protein tyrosine kinases, PTK) and those that phosphorylate serine or threonine residues (serine/threonine kinases, STK). A few protein kinases have dual specificity and phosphorylate threonine and tyrosine residues. Almost all kinases contain a similar 250-300 amino acid catalytic domain. The N-terminal domain, which contains subdomains I-IV, generally folds into a two-lobed structure, which binds and orients the ATP (or GTP) donor molecule. The larger C terminal lobe, which contains subdomains VI A-XI, binds the protein substrate and carries out the transfer of the gamma phosphate from ATP to the hydroxyl group of a serine, threonine, or tyrosine residue. Subdomain V spans the two lobes.

The kinases may be categorized into families by the different amino acid sequences (generally between 5 and 100 residues) located on either side of, or inserted into loops of, the kinase domain. These added amino acid sequences allow the regulation of each kinase as it recognizes and interacts with its target protein. The primary structure of the kinase domains is conserved and can be further subdivided into 11 subdomains. Each of the 11 subdomains contains specific residues and motifs or patterns of amino acids that

2

are characteristic of that subdomain and are highly conserved (Hardie, G. and Hanks, S. (1995) *The Protein Kinase Facts Books*, Vol I:7-20 Academic Press, San Diego, Calif.).

The second messenger dependent protein kinases primarily mediate the effects of second messengers such as cyclic AMP (cAMP), cyclic GMP, inositol triphosphate, phosphatidylinositol, 3,4,5-triphosphate, cyclic-ADP-ribose, arachidonic acid, diacylglycerol and calcium-calmodulin. The cyclic-AMP dependent protein kinases (PKA) are important members of the STK family. Cyclic-AMP is an intracellular mediator of hormone action in all prokaryotic and animal cells that have been studied. Such hormone-induced cellular responses include thyroid hormone secretion, cortisol secretion, progesterone secretion, glycogen breakdown, bone resorption, and regulation of heart rate and force of heart muscle contraction. PKA is found in all animal cells and is thought to account for the effects of cyclic-AMP in most of these cells. Altered PKA expression is implicated in a variety of disorders and diseases including cancer, thyroid disorders, diabetes, atherosclerosis, and cardiovascular disease (Isselbacher, K. J. et al. (1994) *Harrison's Principles of Internal Medicine*, McGraw-Hill, New York, N.Y., pp. 416-431, 1887).

Calcium-calmodulin (CaM) dependent protein kinases are also members of STK family. Calmodulin is a calcium receptor that mediates many calcium regulated processes by binding to target proteins in response to the binding of calcium. The principle target protein in these processes is CaM dependent protein kinases. CaM-kinases are involved in regulation of smooth muscle contraction (MLC kinase), glycogen breakdown (phosphorylase kinase), and neurotransmission (CaM kinase I and CaM kinase II). CaM kinase I phosphorylates a variety of substrates including the neurotransmitter related proteins synapsin I and II, the gene transcription regulator, CREB, and the cystic fibrosis conductance regulator protein, CFTR (Haribabu, B. et al. (1995) *EMBO Journal* 14:3679-86). CaM II kinase also phosphorylates synapsin at different sites, and controls the synthesis of catecholamines in the brain through phosphorylation and activation of tyrosine hydroxylase. Many of the CaM kinases are activated by phosphorylation in addition to binding to CaM. The kinase may autophosphorylate itself, or be phosphorylated by another kinase as part of a "kinase cascade".

Another ligand-activated protein kinase is 5'-AMP-activated protein kinase (AMPK) (Gao, G. et al. (1996) *J. Biol. Chem.* 15:8675-81). Mammalian AMPK is a regulator of fatty acid and sterol synthesis through phosphorylation of the enzymes acetyl-CoA carboxylase and hydroxymethylglutaryl-CoA reductase and mediates responses of these pathways to cellular stresses such as heat shock and depletion of glucose and ATP. AMPK is a heterotimeric complex comprised of a catalytic alpha subunit and two non-catalytic beta and gamma subunits that are believed to regulate the activity of the alpha subunit. Subunits of AMPK have a much wider distribution in non-lipogenic tissues such as brain, heart, spleen, and lung than expected. This distribution suggests that its role may extend beyond regulation of lipid metabolism alone.

The mitogen-activated protein kinases (MAP) are also members of the STK family. MAP kinases also regulate intracellular signaling pathways. They mediate signal transduction from the cell surface to the nucleus via phosphorylation cascades. Several subgroups have been identified, and each manifests different substrate specificities and responds to distinct extracellular stimuli (Egan, S. E. and Weinberg, R. A. (1993) *Nature* 365:781-783). MAP kinase signaling

pathways are present in mammalian cells as well as in yeast. The extracellular stimuli that activate mammalian pathways include epidermal growth factor (EGF), ultraviolet light, hyperosmolar medium, heat shock, endotoxic lipopolysaccharide (LPS), and pro-inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1).

PRK (proliferation-related kinase) is a serum/cytokine inducible STK that is involved in regulation of the cell cycle and cell proliferation in human megakaryotic cells (Li, B. et al. (1996) *J. Biol. Chem.* 271:19402-8). PRK is related to the polo (derived from humans polo gene) family of STKs implicated in cell division. PRK is downregulated in lung tumor tissue and may be a proto-oncogene whose deregulated expression in normal tissue leads to oncogenic transformation. Altered MAP kinase expression is implicated in a variety of disease conditions including cancer, inflammation, immune disorders, and disorders affecting growth and development.

The cyclin-dependent protein kinases (CDKs) are another group of STKs that control the progression of cells through the cell cycle. Cyclins are small regulatory proteins that act by binding to and activating CDKs that then trigger various phases of the cell cycle by phosphorylating and activating selected proteins involved in the mitotic process. CDKs are unique in that they require multiple inputs to become activated. In addition to the binding of cyclin, CDK activation requires the phosphorylation of a specific threonine residue and the dephosphorylation of a specific tyrosine residue.

Protein tyrosine kinases, PTKs, specifically phosphorylate tyrosine residues on their target proteins and may be divided into transmembrane, receptor PTKs and nontransmembrane, non-receptor PTKs. Transmembrane protein-tyrosine kinases are receptors for most growth factors. Binding of growth factor to the receptor activates the transfer of a phosphate group from ATP to selected tyrosine side chains of the receptor and other specific proteins. Growth factors (GF) associated with receptor PTKs include; epidermal GF, platelet-derived GF, fibroblast GF, hepatocyte GF, insulin and insulin-like GFs, nerve GF, vascular endothelial GF, and macrophage colony stimulating factor.

Non-receptor PTKs lack transmembrane regions and, instead, form complexes with the intracellular regions of cell surface receptors. Such receptors that function through non-receptor PTKs include those for cytokines, hormones (growth hormone and prolactin) and antigen-specific receptors on T and B lymphocytes.

Many of these PTKs were first identified as the products of mutant oncogenes in cancer cells where their activation was no longer subject to normal cellular controls. In fact, about one third of the known oncogenes encode PTKs, and it is well known that cellular transformation (oncogenesis) is often accompanied by increased tyrosine phosphorylation activity (Carbonneau H and Tonks NK (1992) *Annu. Rev. Cell. Biol.* 8:463-93). Regulation of PTK activity may therefore be an important strategy in controlling some types of cancer.

LIM Domain Kinases

The novel human protein, and encoding gene, provided by the present invention is related to the family of serine/threonine kinases in general, particularly LIM domain kinases (LIMK), and shows the highest degree of similarity to LIMK2, and the LIMK2b isoform (Genbank gi8051618) in particular (see the amino acid sequence alignment of the protein of the present invention against LIMK2b provided in

FIG. 2). LIMK proteins generally have serine/threonine kinase activity. The protein of the present invention may be a novel alternative splice form of the art-known protein provided in Genbank gi805161; however, the structure of the gene provided by the present invention is different from the art-known gene of gi8051618 and the first exon of the gene of the present invention is novel, suggesting a novel gene rather than an alternative splice form. Furthermore, the protein of the present invention lacks an LIM domain relative to gi8051618. The protein of the present invention does contain the kinase catalytic domain.

Approximately 40 LIM proteins, named for the LIM domains they contain, are known to exist in eukaryotes. LIM domains are conserved, cysteine-rich structures that contain 2 zinc fingers that are thought to modulate protein-protein interactions. LIMK1 and LIMK2 are members of a LIM subfamily characterized by 2 N-terminal LIM domains and a C-terminal protein kinase domain. LIMK1 and LIMK2 mRNA expression varies greatly between different tissues. The protein kinase domains of LIMK1 and LIMK2 contain a unique sequence motif comprising Asp-Leu-Asn-Ser-His-Asn in subdomain VIB and a strongly basic insert between subdomains VII and VIII (Okano et al., *J. Biol. Chem.* 270 (52), 31321-31330 (1995)). The protein kinase domain present in LIMKs is significantly different than other kinase domains, sharing about 32% identity.

LIMK is activated by ROCK (a downstream effector of Rho) via phosphorylation. LIMK then phosphorylates cofilin, which inhibits its actin-depolymerizing activity, thereby leading to Rho-induced reorganization of the actin cytoskeleton (Maekawa et al., *Science* 285: 895-898, 1999).

The LIMK2a and LIMK2b alternative transcript forms are differentially expressed in a tissue-specific manner and are generated by variation in transcriptional initiation utilizing alternative promoters. LIMK2a contains 2 LIM domains, a PDZ domain (a domain that functions in protein-protein interactions targeting the protein to the submembranous compartment), and a kinase domain; whereas LIMK2b just has 1.5 LIM domains. Alteration of LIMK2a and LIMK2b regulation has been observed in some cancer cell lines (Osada et al., *Biochem. Biophys. Res. Commun.* 229: 582-589, 1996).

For a further review of LIMK proteins, see Nomoto et al, *Gene* 236 (2), 259-271 (1999).

Kinase proteins, particularly members of the serine/threonine kinase subfamily, are a major target for drug action and development. Accordingly, it is valuable to the field of pharmaceutical development to identify and characterize previously unknown members of this subfamily of kinase proteins. The present invention advances the state of the art by providing previously unidentified human kinase proteins that have homology to members of the serine/threonine kinase subfamily.

SUMMARY OF THE INVENTION

The present invention is based in part on the identification of amino acid sequences of human kinase peptides and proteins that are related to the serine/threonine kinase subfamily, as well as allelic variants and other mammalian orthologs thereof. These unique peptide sequences, and nucleic acid sequences that encode these peptides, can be used as models for the development of human therapeutic targets, aid in the identification of therapeutic proteins, and serve as targets for the development of human therapeutic agents that modulate kinase activity in cells and tissues that express the kinase. Experimental data as provided in FIG. 1

5

indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland.

DESCRIPTION OF THE FIGURE SHEETS

FIG. 1 provides the nucleotide sequence of a cDNA molecule that encodes the kinase protein of the present invention. (SEQ ID NO:1) In addition, structure and functional information is provided, such as ATG start, stop and tissue distribution, where available, that allows one to readily determine specific uses of inventions based on this molecular sequence. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland.

FIG. 2 provides the predicted amino acid sequence of the kinase of the present invention. (SEQ ID NO:2) In addition structure and functional information such as protein family, function, and modification sites is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence.

FIG. 3 provides genomic sequences that span the gene encoding the kinase protein of the present invention. (SEQ ID NO:3) In addition structure and functional information, such as intron/exon structure, promoter location, etc., is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence. As illustrated in FIG. 3, SNPs were identified at 42 different nucleotide positions.

DETAILED DESCRIPTION OF THE INVENTION

General Description

The present invention is based on the sequencing of the human genome. During the sequencing and assembly of the human genome, analysis of the sequence information revealed previously unidentified fragments of the human genome that encode peptides that share structural and/or sequence homology to protein/peptide/domains identified and characterized within the art as being a kinase protein or part of a kinase protein and are related to the serine/threonine kinase subfamily. Utilizing these sequences, additional genomic sequences were assembled and transcript and/or cDNA sequences were isolated and characterized. Based on this analysis, the present invention provides amino acid sequences of human kinase peptides and proteins that are related to the serine/threonine kinase subfamily, nucleic acid sequences in the form of transcript sequences, cDNA sequences and/or genomic sequences that encode these kinase peptides and proteins, nucleic acid variation (allelic information), tissue distribution of expression, and information about the closest art known protein/peptide/domain that has structural or sequence homology to the kinase of the present invention.

In addition to being previously unknown, the peptides that are provided in the present invention are selected based on their ability to be used for the development of commercially important products and services. Specifically, the present peptides are selected based on homology and/or structural relatedness to known kinase proteins of the serine/threonine kinase subfamily and the expression pattern observed. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. The art has clearly established the commercial importance of

6

members of this family of proteins and proteins that have expression patterns similar to that of the present gene. Some of the more specific features of the peptides of the present invention, and the uses thereof, are described herein, particularly in the Background of the Invention and in the annotation provided in the Figures, and/or are known within the art for each of the known serine/threonine kinase family or subfamily of kinase proteins.

Specific Embodiments

Peptide Molecules

The present invention provides nucleic acid sequences that encode protein molecules that have been identified as being members of the kinase family of proteins and are related to the serine/threonine kinase subfamily (protein sequences are provided in FIG. 2, transcript/cDNA sequences are provided in FIG. 1 and genomic sequences are provided in FIG. 3). The peptide sequences provided in FIG. 2, as well as the obvious variants described herein, particularly allelic variants as identified herein and using the information in FIG. 3, will be referred herein as the kinase peptides of the present invention, kinase peptides, or peptides/proteins of the present invention.

The present invention provides isolated peptide and protein molecules that consist of, consist essentially of, or comprise the amino acid sequences of the kinase peptides disclosed in the FIG. 2, (encoded by the nucleic acid molecule shown in FIG. 1, transcript/cDNA or FIG. 3, genomic sequence), as well as all obvious variants of these peptides that are within the art to make and use. Some of these variants are described in detail below.

As used herein, a peptide is said to be "isolated" or "purified" when it is substantially free of cellular material or free of chemical precursors or other chemicals. The peptides of the present invention can be purified to homogeneity or other degrees of purity. The level of purification will be based on the intended use. The critical feature is that the preparation allows for the desired function of the peptide, even if in the presence of considerable amounts of other components (the features of an isolated nucleic acid molecule is discussed below).

In some uses, "substantially free of cellular material" includes preparations of the peptide having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins. When the peptide is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of the peptide in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of the kinase peptide having less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.

The isolated kinase peptide can be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods. Experimental data as

provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. For example, a nucleic acid molecule encoding the kinase peptide is cloned into an expression vector, the expression vector introduced into a host cell and the protein expressed in the host cell. The protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Many of these techniques are described in detail below.

Accordingly, the present invention provides proteins that consist of the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). The amino acid sequence of such a protein is provided in FIG. 2. A protein consists of an amino acid sequence when the amino acid sequence is the final amino acid sequence of the protein.

The present invention further provides proteins that consist essentially of the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). A protein consists essentially of an amino acid sequence when such an amino acid sequence is present with only a few additional amino acid residues, for example from about 1 to about 100 or so additional residues, typically from 1 to about 20 additional residues in the final protein.

The present invention further provides proteins that comprise the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). A protein comprises an amino acid sequence when the amino acid sequence is at least part of the final amino acid sequence of the protein. In such a fashion, the protein can be only the peptide or have additional amino acid molecules, such as amino acid residues (contiguous encoded sequence) that are naturally associated with it or heterologous amino acid residues/peptide sequences. Such a protein can have a few additional amino acid residues or can comprise several hundred or more additional amino acids. The preferred classes of proteins that are comprised of the kinase peptides of the present invention are the naturally occurring mature proteins. A brief description of how various types of these proteins can be made/isolated is provided below.

The kinase peptides of the present invention can be attached to heterologous sequences to form chimeric or fusion proteins. Such chimeric and fusion proteins comprise a kinase peptide operatively linked to a heterologous protein having an amino acid sequence not substantially homologous to the kinase peptide. "Operatively linked" indicates that the kinase peptide and the heterologous protein are fused in-frame. The heterologous protein can be fused to the N-terminus or C-terminus of the kinase peptide.

In some uses, the fusion protein does not affect the activity of the kinase peptide per se. For example, the fusion protein can include, but is not limited to, enzymatic fusion proteins, for example beta-galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions, MYC-tagged, HI-tagged and Ig fusions. Such fusion proteins, particularly poly-His fusions, can facilitate the purification of recombinant kinase peptide. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a protein can be increased by using a heterologous signal sequence.

A chimeric or fusion protein can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different protein sequences are ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (see Ausubel et al., *Current Protocols in Molecular Biology*, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST protein). A kinase peptide-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the kinase peptide.

As mentioned above, the present invention also provides and enables obvious variants of the amino acid sequence of the proteins of the present invention, such as naturally occurring mature forms of the peptide, allelic/sequence variants of the peptides, non-naturally occurring recombinantly derived variants of the peptides, and orthologs and paralogs of the peptides. Such variants can readily be generated using art-known techniques in the fields of recombinant nucleic acid technology and protein biochemistry. It is understood, however, that variants exclude any amino acid sequences disclosed prior to the invention.

Such variants can readily be identified/made using molecular techniques and the sequence information disclosed herein. Further, such variants can readily be distinguished from other peptides based on sequence and/or structural homology to the kinase peptides of the present invention. The degree of homology/identity present will be based primarily on whether the peptide is a functional variant or non-functional variant, the amount of divergence present in the paralog family and the evolutionary distance between the orthologs.

To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the length of a reference sequence is aligned for comparison purposes. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity and similarity between two sequences can be accomplished using a mathematical algorithm. (*Computational Molecular Biology*, Lesk, A. M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D. W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part 1, Griffin, A. M., and Griffin, H. G.,

eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (*J. Mol. Biol.* (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (Devereux, J., et al., *Nucleic Acids Res.* 12(1):387 (1984)) (available at <http://www.gcg.com>), using a NWS-gapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Myers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against sequence databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (*J. Mol. Biol.* 215:403-10 (1990)). BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to the proteins of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (*Nucleic Acids Res.* 25(17):3389-3402 (1997)). When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

Full-length pre-processed forms, as well as mature processed forms, of proteins that comprise one of the peptides of the present invention can readily be identified as having complete sequence identity to one of the kinase peptides of the present invention as well as being encoded by the same genetic locus as the kinase peptide provided herein. The gene encoding the novel kinase protein of the present invention is located on a genome component that has been mapped to human chromosome 22 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

Allelic variants of a kinase peptide can readily be identified as being a human protein having a high degree (significant) of sequence homology/identity to at least a portion of the kinase peptide as well as being encoded by the same genetic locus as the kinase peptide provided herein. Genetic locus can readily be determined based on the genomic information provided in FIG. 3, such as the genomic sequence mapped to the reference human. The gene encoding the novel kinase protein of the present invention is located on a genome component that has been mapped to human chromosome 22 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data. As used herein, two proteins (or a region of

the proteins) have significant homology when the amino acid sequences are typically at least about 70-80%, 80-90%, and more typically at least about 90-95% or more homologous. A significantly homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence that will hybridize to a kinase peptide encoding nucleic acid molecule under stringent conditions as more fully described below.

FIG. 3 provides information on SNPs that have been found in the gene encoding the kinase protein of the present invention. SNPs were identified at 42 different nucleotide positions. Some of these SNPs, which are located outside the ORF and in introns, may affect gene transcription.

Paralogs of a kinase peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the kinase peptide, as being encoded by a gene from humans, and as having similar activity or function. Two proteins will typically be considered paralogs when the amino acid sequences are typically at least about 60% or greater, and more typically at least about 70% or greater homology through a given region or domain. Such paralogs will be encoded by a nucleic acid sequence that will hybridize to a kinase peptide encoding nucleic acid molecule under moderate to stringent conditions as more fully described below.

Orthologs of a kinase peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the kinase peptide as well as being encoded by a gene from another organism. Preferred orthologs will be isolated from mammals, preferably primates, for the development of human therapeutic targets and agents. Such orthologs will be encoded by a nucleic acid sequence that will hybridize to a kinase peptide encoding nucleic acid molecule under moderate to stringent conditions, as more fully described below, depending on the degree of relatedness of the two organisms yielding the proteins.

Non-naturally occurring variants of the kinase peptides of the present invention can readily be generated using recombinant techniques. Such variants include, but are not limited to deletions, additions and substitutions in the amino acid sequence of the kinase peptide. For example, one class of substitutions are conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a kinase peptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between the amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among the aromatic residues Phe and Tyr. Guidance concerning which amino acid changes are likely to be phenotypically silent are found in Bowie et al., *Science* 247:1306-1310 (1990).

Variant kinase peptides can be fully functional or can lack function in one or more activities, e.g. ability to bind substrate, ability to phosphorylate substrate, ability to mediate signaling, etc. Fully functional variants typically contain only conservative variation or variation in non-critical residues or in non-critical regions. FIG. 2 provides the result of protein analysis and can be used to identify critical domains/regions. Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree.

Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion, inversion, or deletion in a critical residue or critical region.

Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham et al., *Science* 244:1081-1085 (1989)), particularly using the results provided in FIG. 2. The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as kinase activity or in assays such as an in vitro proliferative activity. Sites that are critical for binding partner/substrate binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith et al., *J. Mol. Biol.* 224:899-904 (1992); de Vos et al. *Science* 255:306-312 (1992)).

The present invention further provides fragments of the kinase peptides, in addition to proteins and peptides that comprise and consist of such fragments, particularly those comprising the residues identified in FIG. 2. The fragments to which the invention pertains, however, are not to be construed as encompassing fragments that may be disclosed publicly prior to the present invention.

As used herein, a fragment comprises at least 8, 10, 12, 14, 16, or more contiguous amino acid residues from a kinase peptide. Such fragments can be chosen based on the ability to retain one or more of the biological activities of the kinase peptide or could be chosen for the ability to perform a function, e.g. bind a substrate or act as an immunogen. Particularly important fragments are biologically active fragments, peptides that are, for example, about 8 or more amino acids in length. Such fragments will typically comprise a domain or motif of the kinase peptide, e.g., active site, a transmembrane domain or a substrate-binding domain. Further, possible fragments include, but are not limited to, domain or motif containing fragments, soluble peptide fragments, and fragments containing immunogenic structures. Predicted domains and functional sites are readily identifiable by computer programs well known and readily available to those of skill in the art (e.g., PROSITE analysis). The results of one such analysis are provided in FIG. 2.

Polypeptides often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids. Further, many amino acids, including the terminal amino acids, may be modified by natural processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art. Common modifications that occur naturally in kinase peptides are described in basic texts, detailed monographs, and the research literature, and they are well known to those of skill in the art (some of these features are identified in FIG. 2).

Known modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pro-

teolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Such modifications are well known to those of skill in the art and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as *Proteins—Structure and Molecular Properties*, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993). Many detailed reviews are available on this subject, such as by Wold, F., *Posttranslational Covalent Modification of Proteins*, B. C. Johnson, Ed., Academic Press, New York 1-12 (1983); Seifter et al. (*Meth. Enzymol.* 182: 626-646 (1990)) and Rattan et al. (*Ann. N.Y. Acad. Sci.* 663:48-62 (1992)).

Accordingly, the kinase peptides of the present invention also encompass derivatives or analogs in which a substituted amino acid residue is not one encoded by the genetic code, in which a substituent group is included, in which the mature kinase peptide is fused with another compound, such as a compound to increase the half-life of the kinase peptide (for example, polyethylene glycol), or in which the additional amino acids are fused to the mature kinase peptide, such as a leader or secretory sequence or a sequence for purification of the mature kinase peptide or a pro-protein sequence.

Protein/Peptide Uses

The proteins of the present invention can be used in substantial and specific assays related to the functional information provided in the Figures; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its binding partner or ligand) in biological fluids; and as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state). Where the protein binds or potentially binds to another protein or ligand (such as, for example, in a kinase-effector protein interaction or kinase-ligand interaction), the protein can be used to identify the binding partner/ligand so as to develop a system to identify inhibitors of the binding interaction. Any or all of these uses are capable of being developed into reagent grade or kit format for commercialization as commercial products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

The potential uses of the peptides of the present invention are based primarily on the source of the protein as well as the class/action of the protein. For example, kinases isolated from humans and their human/mammalian orthologs serve as targets for identifying agents for use in mammalian therapeutic applications, e.g. a human drug, particularly in modulating a biological or pathological response in a cell or tissue that expresses the kinase. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant

brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain. A large percentage of pharmaceutical agents are being developed that modulate the activity of kinase proteins, particularly members of the serine/threonine kinase subfamily (see Background of the Invention). The structural and functional information provided in the Background and Figures provide specific and substantial uses for the molecules of the present invention, particularly in combination with the expression information provided in FIG. 1. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. Such uses can readily be determined using the information provided herein, that which is known in the art, and routine experimentation.

The proteins of the present invention (including variants and fragments that may have been disclosed prior to the present invention) are useful for biological assays related to kinases that are related to members of the serine/threonine kinase subfamily. Such assays involve any of the known kinase functions or activities or properties useful for diagnosis and treatment of kinase-related conditions that are specific for the subfamily of kinases that the one of the present invention belongs to, particularly in cells and tissues that express the kinase. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain.

The proteins of the present invention are also useful in drug screening assays, in cell-based or cell-free systems. Cell-based systems can be native, i.e., cells that normally express the kinase, as a biopsy or expanded in cell culture. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. In an alternate embodiment, cell-based assays involve recombinant host cells expressing the kinase protein.

The polypeptides can be used to identify compounds that modulate kinase activity of the protein in its natural state or an altered form that causes a specific disease or pathology associated with the kinase. Both the kinases of the present invention and appropriate variants and fragments can be used in high-throughput screens to assay candidate compounds for the ability to bind to the kinase. These compounds can be further screened against a functional kinase to determine the effect of the compound on the kinase activity. Further, these compounds can be tested in animal or invertebrate systems to determine activity/effectiveness. Compounds can be identified that activate (agonist) or inactivate (antagonist) the kinase to a desired degree.

Further, the proteins of the present invention can be used to screen a compound for the ability to stimulate or inhibit interaction between the kinase protein and a molecule that normally interacts with the kinase protein, e.g. a substrate or a component of the signal pathway that the kinase protein normally interacts (for example, another kinase). Such assays typically include the steps of combining the kinase protein with a candidate compound under conditions that allow the kinase protein, or fragment, to interact with the target molecule, and to detect the formation of a complex between the protein and the target or to detect the biochemical consequence of the interaction with the kinase protein and the target, such as any of the associated effects of signal

transduction such as protein phosphorylation, cAMP turnover, and adenylate cyclase activation, etc.

Candidate compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam et al., *Nature* 354:82-84 (1991); Houghten et al., *Nature* 354:84-86 (1991)) and combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids; 2) phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang et al., *Cell* 72:767-778 (1993)); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab')₂, Fab expression library fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural product libraries).

One candidate compound is a soluble fragment of the receptor that competes for substrate binding. Other candidate compounds include mutant kinases or appropriate fragments containing mutations that affect kinase function and thus compete for substrate. Accordingly, a fragment that competes for substrate, for example with a higher affinity, or a fragment that binds substrate but does not allow release, is encompassed by the invention.

The invention further includes other end point assays to identify compounds that modulate (stimulate or inhibit) kinase activity. The assays typically involve an assay of events in the signal transduction pathway that indicate kinase activity. Thus, the phosphorylation of a substrate, activation of a protein, a change in the expression of genes that are up- or down-regulated in response to the kinase protein dependent signal cascade can be assayed.

Any of the biological or biochemical functions mediated by the kinase can be used as an endpoint assay. These include all of the biochemical or biochemical/biological events described herein, in the references cited herein, incorporated by reference for these endpoint assay targets, and other functions known to those of ordinary skill in the art or that can be readily identified using the information provided in the Figures, particularly FIG. 2. Specifically, a biological function of a cell or tissues that expresses the kinase can be assayed. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain.

Binding and/or activating compounds can also be screened by using chimeric kinase proteins in which the amino terminal extracellular domain, or parts thereof, the entire transmembrane domain or subregions, such as any of the seven transmembrane segments or any of the intracellular or extracellular loops and the carboxy terminal intracellular domain, or parts thereof, can be replaced by heterologous domains or subregions. For example, a substrate-binding region can be used that interacts with a different substrate than that which is recognized by the native kinase. Accordingly, a different set of signal transduction components is available as an end-point assay for activation. This allows for assays to be performed in other than the specific host cell from which the kinase is derived.

The proteins of the present invention are also useful in competition binding assays in methods designed to discover compounds that interact with the kinase (e.g. binding part-

ners and/or ligands). Thus, a compound is exposed to a kinase polypeptide under conditions that allow the compound to bind or to otherwise interact with the polypeptide. Soluble kinase polypeptide is also added to the mixture. If the test compound interacts with the soluble kinase polypeptide, it decreases the amount of complex formed or activity from the kinase target. This type of assay is particularly useful in cases in which compounds are sought that interact with specific regions of the kinase. Thus, the soluble polypeptide that competes with the target kinase region is designed to contain peptide sequences corresponding to the region of interest.

To perform cell free drug screening assays, it is sometimes desirable to immobilize either the kinase protein, or fragment, or its target molecule to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay.

Techniques for immobilizing proteins on matrices can be used in the drug screening assays. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtitre plates, which are then combined with the cell lysates (e.g., ^{35}S -labeled) and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of kinase-binding protein found in the bead fraction quantitated from the gel using standard electrophoretic techniques. For example, either the polypeptide or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin using techniques well known in the art. Alternatively, antibodies reactive with the protein but which do not interfere with binding of the protein to its target molecule can be derivatized to the wells of the plate, and the protein trapped in the wells by antibody conjugation. Preparations of a kinase-binding protein and a candidate compound are incubated in the kinase protein-presenting wells and the amount of complex trapped in the well can be quantitated. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the kinase protein target molecule, or which are reactive with kinase protein and compete with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

Agents that modulate one of the kinases of the present invention can be identified using one or more of the above assays, alone or in combination. It is generally preferable to use a cell-based or cell free system first and then confirm activity in an animal or other model system. Such model systems are well known in the art and can readily be employed in this context.

Modulators of kinase protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the kinase pathway, by treating cells or tissues that express the kinase. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. These methods of treatment include the steps of administering a modulator of

kinase activity in a pharmaceutical composition to a subject in need of such treatment, the modulator being identified as described herein.

In yet another aspect of the invention, the kinase proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos et al. (1993) *Cell* 72:223-232; Madura et al. (1993) *J. Biol. Chem.* 268:12046-12054; Bartel et al. (1993) *Biotechniques* 14:920-924; Iwabuchi et al. (1993) *Oncogene* 8:1693/1696; and Brent WO94110300), to identify other proteins, which bind to or interact with the kinase and are involved in kinase activity. Such kinase-binding proteins are also likely to be involved in the propagation of signals by the kinase proteins or kinase targets as, for example, downstream elements of a kinase-mediated signaling pathway. Alternatively, such kinase-binding proteins are likely to be kinase inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a kinase protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, in vivo, forming a kinase-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the kinase protein.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., a kinase-modulating agent, an antisense kinase nucleic acid molecule, a kinase-specific antibody, or a kinase-binding partner) can be used in an animal or other model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal or other model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

The kinase proteins of the present invention are also useful to provide a target for diagnosing a disease or predisposition to disease mediated by the peptide. Accordingly, the invention provides methods for detecting the presence, or levels of, the protein (or encoding mRNA) in a cell, tissue, or organism. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. The method involves contacting a biological sample with a compound capable of interacting with the kinase protein such that the interaction can be detected. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

One agent for detecting a protein in a sample is an antibody capable of selectively binding to protein. A bio-

logical sample includes tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.

The peptides of the present invention also provide targets for diagnosing active protein activity, disease, or predisposition to disease, in a patient having a variant peptide, particularly activities and conditions that are known for other members of the family of proteins to which the present one belongs. Thus, the peptide can be isolated from a biological sample and assayed for the presence of a genetic mutation that results in aberrant peptide. This includes amino acid substitution, deletion, insertion, rearrangement, (as the result of aberrant splicing events), and inappropriate post-translational modification. Analytic methods include altered electrophoretic mobility, altered tryptic peptide digest, altered kinase activity in cell-based or cell-free assay, alteration in substrate or antibody-binding pattern, altered isoelectric point, direct amino acid sequencing, and any other of the known assay techniques useful for detecting mutations in a protein. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

In vitro techniques for detection of peptide include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence using a detection reagent, such as an antibody or protein binding agent. Alternatively, the peptide can be detected in vivo in a subject by introducing into the subject a labeled anti-peptide antibody or other types of detection agent. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Particularly useful are methods that detect the allelic variant of a peptide expressed in a subject and methods which detect fragments of a peptide in a sample.

The peptides are also useful in pharmacogenomic analysis. Pharmacogenomics deal with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Eichelbaum, M. (*Clin. Exp. Pharmacol. Physiol.* 23(10-11):983-985 (1996)), and Linder, M. W. (*Clin. Chem.* 43(2):254-266 (1997)). The clinical outcomes of these variations result in severe toxicity of therapeutic drugs in certain individuals or therapeutic failure of drugs in certain individuals as a result of individual variation in metabolism. Thus, the genotype of the individual can determine the way a therapeutic compound acts on the body or the way the body metabolizes the compound. Further, the activity of drug metabolizing enzymes effects both the intensity and duration of drug action. Thus, the pharmacogenomics of the individual permit the selection of effective compounds and effective dosages of such compounds for prophylactic or therapeutic treatment based on the individual's genotype. The discovery of genetic polymorphisms in some drug metabolizing enzymes has explained why some patients do not obtain the expected drug effects, show an exaggerated drug effect, or experience serious toxicity from standard drug dosages. Polymorphisms can be expressed in the phenotype of the extensive metabolizer and the phenotype of the poor metabolizer. Accordingly, genetic polymorphism may lead to allelic protein variants of the kinase protein in which one or more of the kinase functions in one population is different from those in another population. The peptides thus allow a target to ascertain a genetic predisposition that can affect treatment modality. Thus, in a ligand-based treatment, polymorphism may give rise to amino terminal extracellular domains and/or other substrate-binding regions that are

more or less active in substrate binding, and kinase activation. Accordingly, substrate dosage would necessarily be modified to maximize the therapeutic effect within a given population containing a polymorphism. As an alternative to genotyping, specific polymorphic peptides could be identified.

The peptides are also useful for treating a disorder characterized by an absence of, inappropriate, or unwanted expression of the protein. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. Accordingly, methods for treatment include the use of the kinase protein or fragments.

Antibodies

The invention also provides antibodies that selectively bind to one of the peptides of the present invention, a protein comprising such a peptide, as well as variants and fragments thereof. As used herein, an antibody selectively binds a target peptide when it binds the target peptide and does not significantly bind to unrelated proteins. An antibody is still considered to selectively bind a peptide even if it also binds to other proteins that are not substantially homologous with the target peptide so long as such proteins share homology with a fragment or domain of the peptide target of the antibody. In this case, it would be understood that antibody binding to the peptide is still selective despite some degree of cross-reactivity.

As used herein, an antibody is defined in terms consistent with that recognized within the art: they are multi-subunit proteins produced by a mammalian organism in response to an antigen challenge. The antibodies of the present invention include polyclonal antibodies and monoclonal antibodies, as well as fragments of such antibodies, including, but not limited to, Fab or F(ab')₂, and Fv fragments.

Many methods are known for generating and/or identifying antibodies to a given target peptide. Several such methods are described by Harlow, *Antibodies*, Cold Spring Harbor Press, (1989).

In general, to generate antibodies, an isolated peptide is used as an immunogen and is administered to a mammalian organism, such as a rat, rabbit or mouse. The full-length protein, an antigenic peptide fragment or a fusion protein can be used. Particularly important fragments are those covering functional domains, such as the domains identified in FIG. 2, and domain of sequence homology or divergence amongst the family, such as those that can readily be identified using protein alignment methods and as presented in the Figures.

Antibodies are preferably prepared from regions or discrete fragments of the kinase proteins. Antibodies can be prepared from any region of the peptide as described herein. However, preferred regions will include those involved in function/activity and/or kinase/binding partner interaction. FIG. 2 can be used to identify particularly important regions while sequence alignment can be used to identify conserved and unique sequence fragments.

An antigenic fragment will typically comprise at least 8 contiguous amino acid residues. The antigenic peptide can comprise, however, at least 10, 12, 14, 16 or more amino acid residues. Such fragments can be selected on a physical property, such as fragments correspond to regions that are located on the surface of the protein, e.g., hydrophilic regions or can be selected based on sequence uniqueness (see FIG. 2).

Detection on an antibody of the present invention can be facilitated by coupling (i.e., physically linking) the antibody

to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

Antibody Uses

The antibodies can be used to isolate one of the proteins of the present invention by standard techniques, such as affinity chromatography or immunoprecipitation. The antibodies can facilitate the purification of the natural protein from cells and recombinantly produced protein expressed in host cells. In addition, such antibodies are useful to detect the presence of one of the proteins of the present invention in cells or tissues to determine the pattern of expression of the protein among various tissues in an organism and over the course of normal development. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain. Further, such antibodies can be used to detect protein *in situ*, *in vitro*, or in a cell lysate or supernatant in order to evaluate the abundance and pattern of expression. Also, such antibodies can be used to assess abnormal tissue distribution or abnormal expression during development or progression of a biological condition. Antibody detection of circulating fragments of the full length protein can be used to identify turnover.

Further, the antibodies can be used to assess expression in disease states such as in active stages of the disease or in an individual with a predisposition toward disease related to the protein's function. When a disorder is caused by an inappropriate tissue distribution, developmental expression, level of expression of the protein, or expressed/processed form, the antibody can be prepared against the normal protein. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. If a disorder is characterized by a specific mutation in the protein, antibodies specific for this mutant protein can be used to assay for the presence of the specific mutant protein.

The antibodies can also be used to assess normal and aberrant subcellular localization of cells in the various tissues in an organism. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. The diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at correcting expression level or the presence of aberrant sequence and aberrant tissue distribution or developmental expression, antibodies directed against the protein or relevant fragments can be used to monitor therapeutic efficacy.

Additionally, antibodies are useful in pharmacogenomic analysis. Thus, antibodies prepared against polymorphic

proteins can be used to identify individuals that require modified treatment modalities. The antibodies are also useful as diagnostic tools as an immunological marker for aberrant protein analyzed by electrophoretic mobility, isoelectric point, tryptic peptide digest, and other physical assays known to those in the art.

The antibodies are also useful for tissue typing. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. Thus, where a specific protein has been correlated with expression in a specific tissue, antibodies that are specific for this protein can be used to identify a tissue type.

The antibodies are also useful for inhibiting protein function, for example, blocking the binding of the kinase peptide to a binding partner such as a substrate. These uses can also be applied in a therapeutic context in which treatment involves inhibiting the protein's function. An antibody can be used, for example, to block binding, thus modulating (agonizing or antagonizing) the peptides activity. Antibodies can be prepared against specific fragments containing sites required for function or against intact protein that is associated with a cell or cell membrane. See FIG. 2 for structural information relating to the proteins of the present invention.

The invention also encompasses kits for using antibodies to detect the presence of a protein in a biological sample. The kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting protein in a biological sample; means for determining the amount of protein in the sample; means for comparing the amount of protein in the sample with a standard; and instructions for use. Such a kit can be supplied to detect a single protein or epitope or can be configured to detect one of a multitude of epitopes, such as in an antibody detection array. Arrays are described in detail below for nucleic acid arrays and similar methods have been developed for antibody arrays.

Nucleic Acid Molecules

The present invention further provides isolated nucleic acid molecules that encode a kinase peptide or protein of the present invention (cDNA, transcript and genomic sequence). Such nucleic acid molecules will consist of, consist essentially of, or comprise a nucleotide sequence that encodes one of the kinase peptides of the present invention, an allelic variant thereof, or an ortholog or paralog thereof.

As used herein, an "isolated" nucleic acid molecule is one that is separated from other nucleic acid present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. However, there can be some flanking nucleotide sequences, for example up to about 5KB, 4KB, 3KB, 2KB, or 1KB or less, particularly contiguous peptide encoding sequences and peptide encoding sequences within the same gene but separated by introns in the genomic sequence. The important point is that the nucleic acid is isolated from remote and unimportant flanking sequences such that it can be subjected to the specific manipulations described herein such as recombinant expression, preparation of probes and primers, and other uses specific to the nucleic acid sequences.

Moreover, an "isolated" nucleic acid molecule, such as a transcript/cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by

recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. However, the nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated.

For example, recombinant DNA molecules contained in a vector are considered isolated. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the isolated DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.

Accordingly, the present invention provides nucleic acid molecules that consist of the nucleotide sequence shown in FIG. 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule consists of a nucleotide sequence when the nucleotide sequence is the complete nucleotide sequence of the nucleic acid molecule.

The present invention further provides nucleic acid molecules that consist essentially of the nucleotide sequence shown in FIG. 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule consists essentially of a nucleotide sequence when such a nucleotide sequence is present with only a few additional nucleic acid residues in the final nucleic acid molecule.

The present invention further provides nucleic acid molecules that comprise the nucleotide sequences shown in FIG. 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule comprises a nucleotide sequence when the nucleotide sequence is at least part of the final nucleotide sequence of the nucleic acid molecule. In such a fashion, the nucleic acid molecule can be only the nucleotide sequence or have additional nucleic acid residues, such as nucleic acid residues that are naturally associated with it or heterologous nucleotide sequences. Such a nucleic acid molecule can have a few additional nucleotides or can comprise several hundred or more additional nucleotides. A brief description of how various types of these nucleic acid molecules can be readily made/isolated is provided below.

In FIGS. 1 and 3, both coding and non-coding sequences are provided. Because of the source of the present invention, humans genomic sequence (FIG. 3) and cDNA/transcript sequences (FIG. 1), the nucleic acid molecules in the Figures will contain genomic intronic sequences, 5' and 3' non-coding sequences, gene regulatory regions and non-coding intergenic sequences. In general such sequence features are either noted in FIGS. 1 and 3 or can readily be identified using computational tools known in the art. As discussed below, some of the non-coding regions, particularly gene regulatory elements such as promoters, are useful for a variety of purposes, e.g. control of heterologous gene expression, target for identifying gene activity modulating compounds, and are particularly claimed as fragments of the genomic sequence provided herein.

The isolated nucleic acid molecules can encode the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature peptide (when the mature form has more than one peptide chain, for instance). Such sequences may play a role in processing of

a protein from precursor to a mature form, facilitate protein trafficking, prolong or shorten protein half-life or facilitate manipulation of a protein for assay or production, among other things. As generally is the case in situ, the additional amino acids may be processed away from the mature protein by cellular enzymes.

As mentioned above, the isolated nucleic acid molecules include, but are not limited to, the sequence encoding the kinase peptide alone, the sequence encoding the mature peptide and additional coding sequences, such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), the sequence encoding the mature peptide, with or without the additional coding sequences, plus additional non-coding sequences, for example introns and non-coding 5' and 3' sequences such as transcribed but non-translated sequences that play a role in transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding and stability of mRNA. In addition, the nucleic acid molecule may be fused to a marker sequence encoding, for example, a peptide that facilitates purification.

Isolated nucleic acid molecules can be in the form of RNA, such as mRNA, or in the form DNA, including cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The nucleic acid, especially DNA, can be double-stranded or single-stranded. Single-stranded nucleic acid can be the coding strand (sense strand) or the non-coding strand (anti-sense strand).

The invention further provides nucleic acid molecules that encode fragments of the peptides of the present invention as well as nucleic acid molecules that encode obvious variants of the kinase proteins of the present invention that are described above. Such nucleic acid molecules may be naturally occurring, such as allelic variants (same locus), paralogs (different locus), and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Such non-naturally occurring variants may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells, or organisms. Accordingly, as discussed above, the variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions.

The present invention further provides non-coding fragments of the nucleic acid molecules provided in FIGS. 1 and 3. Preferred non-coding fragments include, but are not limited to, promoter sequences, enhancer sequences, gene modulating sequences and gene termination sequences. Such fragments are useful in controlling heterologous gene expression and in developing screens to identify gene-modulating agents. A promoter can readily be identified as being 5' to the ATG start site in the genomic sequence provided in FIG. 3.

A fragment comprises a contiguous nucleotide sequence greater than 12 or more nucleotides. Further, a fragment could at least 30, 40, 50, 100, 250 or 500 nucleotides in length. The length of the fragment will be based on its intended use. For example, the fragment can encode epitope bearing regions of the peptide, or can be useful as DNA probes and primers. Such fragments can be isolated using the known nucleotide sequence to synthesize an oligonucleotide probe. A labeled probe can then be used to screen a cDNA library, genomic DNA library, or mRNA to isolate nucleic acid corresponding to the coding region. Further, primers can be used in PCR reactions to clone specific regions of gene.

A probe/primer typically comprises substantially a purified oligonucleotide or oligonucleotide pair. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 20, 25, 40, 50 or more consecutive nucleotides.

Orthologs, homologs, and allelic variants can be identified using methods well known in the art. As described in the Peptide Section, these variants comprise a nucleotide sequence encoding a peptide that is typically 60–70%, 70–80%, 80–90%, and more typically at least about 90–95% or more homologous to the nucleotide sequence shown in the Figure sheets or a fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under moderate to stringent conditions, to the nucleotide sequence shown in the Figure sheets or a fragment of the sequence. Allelic variants can readily be determined by genetic locus of the encoding gene. The gene encoding the novel kinase protein of the present invention is located on a genome component that has been mapped to human chromosome 22 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

FIG. 3 provides information on SNPs that have been found in the gene encoding the kinase protein of the present invention. SNPs were identified at 42 different nucleotide positions. Some of these SNPs, which are located outside the ORF and in introns, may affect gene transcription.

As used herein, the term “hybridizes under stringent conditions” is intended to describe conditions for hybridization and washing under which nucleotide sequences encoding a peptide at least 60–70% homologous to each other typically remain hybridized to each other. The conditions can be such that sequences at least about 60%, at least about 70%, or at least about 80% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1–6.3.6. One example of stringent hybridization conditions are hybridization in 6× sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2×SSC, 0.1% SDS at 50–65°C. Examples of moderate to low stringency hybridization conditions are well known in the art.

Nucleic Acid Molecule Uses

The nucleic acid molecules of the present invention are useful for probes, primers, chemical intermediates, and in biological assays. The nucleic acid molecules are useful as a hybridization probe for messenger RNA, transcript/cDNA and genomic DNA to isolate full-length cDNA and genomic clones encoding the peptide described in FIG. 2 and to isolate cDNA and genomic clones that correspond to variants (alleles, orthologs, etc.) producing the same or related peptides shown in FIG. 2. As illustrated in FIG. 3, SNPs were identified at 42 different nucleotide positions.

The probe can correspond to any sequence along the entire length of the nucleic acid molecules provided in the Figures. Accordingly, it could be derived from 5' noncoding regions, the coding region, and 3' noncoding regions. However, as discussed, fragments are not to be construed as encompassing fragments disclosed prior to the present invention.

The nucleic acid molecules are also useful as primers for PCR to amplify any given region of a nucleic acid molecule and are useful to synthesize antisense molecules of desired length and sequence.

The nucleic acid molecules are also useful for constructing recombinant vectors. Such vectors include expression vectors that express a portion of, or all of, the peptide sequences. Vectors also include insertion vectors, used to integrate into another nucleic acid molecule sequence, such as into the cellular genome, to alter in situ expression of a gene and/or gene product. For example, an endogenous coding sequence can be replaced via homologous recombination with all or part of the coding region containing one or more specifically introduced mutations.

The nucleic acid molecules are also useful for expressing antigenic portions of the proteins.

The nucleic acid molecules are also useful as probes for determining the chromosomal positions of the nucleic acid molecules by means of in situ hybridization methods. The gene encoding the novel kinase protein of the present invention is located on a genome component that has been mapped to human chromosome 22 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

The nucleic acid molecules are also useful in making vectors containing the gene regulatory regions of the nucleic acid molecules of the present invention.

The nucleic acid molecules are also useful for designing ribozymes corresponding to all, or a part, of the mRNA produced from the nucleic acid molecules described herein.

The nucleic acid molecules are also useful for making vectors that express part, or all, of the peptides.

The nucleic acid molecules are also useful for constructing host cells expressing a part, or all, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful for constructing transgenic animals expressing all, or a part, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful as hybridization probes for determining the presence, level, form and distribution of nucleic acid expression. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain. Accordingly, the probes can be used to detect the presence of, or to determine levels of, a specific nucleic acid molecule in cells, tissues, and in organisms. The nucleic acid whose level is determined can be DNA or RNA. Accordingly, probes corresponding to the peptides described herein can be used to assess expression and/or gene copy number in a given cell, tissue, or organism. These uses are relevant for diagnosis of disorders involving an increase or decrease in kinase protein expression relative to normal results.

In vitro techniques for detection of mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detecting DNA includes Southern hybridizations and in situ hybridization.

Probes can be used as a part of a diagnostic test kit for identifying cells or tissues that express a kinase protein, such as by measuring a level of a kinase-encoding nucleic acid in a sample of cells from a subject e.g., mRNA or genomic DNA, or determining if a kinase gene has been mutated. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by

virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain.

Nucleic acid expression assays are useful for drug screening to identify compounds that modulate kinase nucleic acid expression.

The invention thus provides a method for identifying a compound that can be used to treat a disorder associated with nucleic acid expression of the kinase gene, particularly biological and pathological processes that are mediated by the kinase in cells and tissues that express it. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland. The method typically includes assaying the ability of the compound to modulate the expression of the kinase nucleic acid and thus identifying a compound that can be used to treat a disorder characterized by undesired kinase nucleic acid expression. The assays can be performed in cell-based and cell-free systems. Cell-based assays include cells naturally expressing the kinase nucleic acid or recombinant cells genetically engineered to express specific nucleic acid sequences.

The assay for kinase nucleic acid expression can involve direct assay of nucleic acid levels, such as mRNA levels, or on collateral compounds involved in the signal pathway. Further, the expression of genes that are up- or down-regulated in response to the kinase protein signal pathway can also be assayed. In this embodiment the regulatory regions of these genes can be operably linked to a reporter gene such as luciferase.

Thus, modulators of kinase gene expression can be identified in a method wherein a cell is contacted with a candidate compound and the expression of mRNA determined. The level of expression of kinase mRNA in the presence of the candidate compound is compared to the level of expression of kinase mRNA in the absence of the candidate compound. The candidate compound can then be identified as a modulator of nucleic acid expression based on this comparison and be used, for example to treat a disorder characterized by aberrant nucleic acid expression. When expression of mRNA is statistically significantly greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of nucleic acid expression.

The invention further provides methods of treatment, with the nucleic acid as a target, using a compound identified through drug screening as a gene modulator to modulate kinase nucleic acid expression in cells and tissues that express the kinase. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain. Modulation includes both up-regulation (i.e. activation or agonization) or down-regulation (suppression or antagonization) or nucleic acid expression.

Alternatively, a modulator for kinase nucleic acid expression can be a small molecule or drug identified using the screening assays described herein as long as the drug or small molecule inhibits the kinase nucleic acid expression in the cells and tissues that express the protein. Experimental data as provided in FIG. 1 indicates expression in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant and fetal brain, and thyroid gland.

The nucleic acid molecules are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of the kinase gene in clinical trials or in a treatment regimen. Thus, the gene expression pattern can serve as a barometer for the continuing effectiveness of treatment with the compound, particularly with compounds to which a patient can develop resistance. The gene expression pattern can also serve as a marker indicative of a physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has not become resistant. Similarly, if the level of nucleic acid expression falls below a desirable level, administration of the compound could be commensurately decreased.

The nucleic acid molecules are also useful in diagnostic assays for qualitative changes in kinase nucleic acid expression, and particularly in qualitative changes that lead to pathology. The nucleic acid molecules can be used to detect mutations in kinase genes and gene expression products such as mRNA. The nucleic acid molecules can be used as hybridization probes to detect naturally occurring genetic mutations in the kinase gene and thereby to determine whether a subject with the mutation is at risk for a disorder caused by the mutation. Mutations include deletion, addition, or substitution of one or more nucleotides in the gene, chromosomal rearrangement, such as inversion or transposition, modification of genomic DNA, such as aberrant methylation patterns or changes in gene copy number, such as amplification. Detection of a mutated form of the kinase gene associated with a dysfunction provides a diagnostic tool for an active disease or susceptibility to disease when the disease results from overexpression, underexpression, or altered expression of a kinase protein.

Individuals carrying mutations in the kinase gene can be detected at the nucleic acid level by a variety of techniques. FIG. 3 provides information on SNPs that have been found in the gene encoding the kinase protein of the present invention. SNPs were identified at 42 different nucleotide positions. Some of these SNPs, which are located outside the ORF and in introns, may affect gene transcription. The gene encoding the novel kinase protein of the present invention is located on a genome component that has been mapped to human chromosome 22 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data. Genomic DNA can be analyzed directly or can be amplified by using PCR prior to analysis. RNA or cDNA can be used in the same way. In some uses, detection of the mutation involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al., *Science* 241:1077-1080 (1988); and Nakazawa et al., *PNAS* 91:360-364 (1994)), the latter of which can be particularly useful for detecting point mutations in the gene (see Abravaya et al., *Nucleic Acids Res.* 23:675-682 (1995)). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. Deletions and insertions can be detected by a change in size of the amplified product compared to the normal

genotype. Point mutations can be identified by hybridizing amplified DNA to normal RNA or antisense DNA sequences.

Alternatively, mutations in a kinase gene can be directly identified, for example, by alterations in restriction enzyme digestion patterns determined by gel electrophoresis.

Further, sequence-specific ribozymes (U.S. Pat. No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature.

Sequence changes at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or the chemical cleavage method. Furthermore, sequence differences between a mutant kinase gene and a wild-type gene can be determined by direct DNA sequencing. A variety of automated sequencing procedures can be utilized when performing the diagnostic assays (Naeve, C. W., (1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen et al., *Adv. Chromatogr.* 36:127-162 (1996); and Griffin et al., *Appl. Biochem. Biotechnol.* 38:147-159 (1993)).

Other methods for detecting mutations in the gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers et al., *Science* 230:1242 (1985)); Cotton et al., *PNAS* 85:4397 (1988); Saleeba et al., *Meth. Enzymol.* 217:286-295 (1992)), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita et al., *PNAS* 86:2766 (1989); Cotton et al., *Mutat. Res.* 285:125-144 (1993); and Hayashi et al., *Genet. Anal. Tech. Appl.* 9:73-79 (1992)), and movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (Myers et al., *Nature* 313:495 (1985)). Examples of other techniques for detecting point mutations include selective oligonucleotide hybridization, selective amplification, and selective primer extension.

The nucleic acid molecules are also useful for testing an individual for a genotype that while not necessarily causing the disease, nevertheless affects the treatment modality. Thus, the nucleic acid molecules can be used to study the relationship between an individual's genotype and the individual's response to a compound used for treatment (pharmacogenomic relationship). Accordingly, the nucleic acid molecules described herein can be used to assess the mutation content of the kinase gene in an individual in order to select an appropriate compound or dosage regimen for treatment. FIG. 3 provides information on SNPs that have been found in the gene encoding the kinase protein of the present invention. SNPs were identified at 42 different nucleotide positions. Some of these SNPs, which are located outside the ORF and in introns, may affect gene transcription.

Thus nucleic acid molecules displaying genetic variations that affect treatment provide a diagnostic target that can be used to tailor treatment in an individual. Accordingly, the production of recombinant cells and animals containing these polymorphisms allow effective clinical design of treatment compounds and dosage regimens.

The nucleic acid molecules are thus useful as antisense constructs to control kinase gene expression in cells, tissues, and organisms. A DNA antisense nucleic acid molecule is designed to be complementary to a region of the gene

involved in transcription, preventing transcription and hence production of kinase protein. An antisense RNA or DNA nucleic acid molecule would hybridize to the mRNA and thus block translation of mRNA into kinase protein.

Alternatively, a class of antisense molecules can be used to inactivate mRNA in order to decrease expression of kinase nucleic acid. Accordingly, these molecules can treat a disorder characterized by abnormal or undesired kinase nucleic acid expression. This technique involves cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated. Possible regions include coding regions and particularly coding regions corresponding to the catalytic and other functional activities of the kinase protein, such as substrate binding.

The nucleic acid molecules also provide vectors for gene therapy in patients containing cells that are aberrant in kinase gene expression. Thus, recombinant cells, which include the patient's cells that have been engineered ex vivo and returned to the patient, are introduced into an individual where the cells produce the desired kinase protein to treat the individual.

The invention also encompasses kits for detecting the presence of a kinase nucleic acid in a biological sample. Experimental data as provided in FIG. 1 indicates that the kinase proteins of the present invention are expressed in humans in teratocarcinoma, ovary, testis, nervous tissue, bladder, infant brain, and thyroid gland, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in fetal brain. For example, the kit can comprise reagents such as a labeled or labelable nucleic acid or agent capable of detecting kinase nucleic acid in a biological sample; means for determining the amount of kinase nucleic acid in the sample; and means for comparing the amount of kinase nucleic acid in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect kinase protein mRNA or DNA.

Nucleic Acid Arrays

The present invention further provides nucleic acid detection kits, such as arrays or microarrays of nucleic acid molecules that are based on the sequence information provided in FIGS. 1 and 3 (SEQ ID NOS:1 and 3).

As used herein "Arrays" or "Microarrays" refers to an array of distinct polynucleotides or oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support. In one embodiment, the microarray is prepared and used according to the methods described in U.S. Pat. No. 5,837,832, Chee et al., PCT application W095/11995 (Chee et al.), Lockhart, D. J. et al. (1996; *Nat. Biotech.* 14: 1675-1680) and Schena, M. et al. (1996; *Proc. Natl. Acad. Sci.* 93: 10614-10619), all of which are incorporated herein in their entirety by reference. In other embodiments, such arrays are produced by the methods described by Brown et al., U.S. Pat. No. 5,807,522.

The microarray or detection kit is preferably composed of a large number of unique, single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides in length, more preferably 15-30 nucleotides in length, and most preferably about 20-25 nucleotides in length. For a certain type of microarray or detection kit, it may be

preferable to use oligonucleotides that are only 7–20 nucleotides in length. The microarray or detection kit may contain oligonucleotides that cover the known 5', or 3', sequence, sequential oligonucleotides which cover the full length sequence; or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray or detection kit may be oligonucleotides that are specific to a gene or genes of interest.

In order to produce oligonucleotides to a known sequence for a microarray or detection kit, the gene(s) of interest (or an ORF identified from the contigs of the present invention) is typically examined using a computer algorithm which starts at the 5' or at the 3' end of the nucleotide sequence. Typical algorithms will then identify oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray or detection kit. The "pairs" will be identical, except for one nucleotide that preferably is located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support.

In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/251116 (Baldeschweiler et al.) which is incorporated herein in its entirety by reference. In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536, 6144 or more oligonucleotides, or any other number between two and one million which lends itself to the efficient use of commercially available instrumentation.

In order to conduct sample analysis using a microarray or detection kit, the RNA or DNA from a biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray or detection kit so that the probe sequences hybridize to complementary oligonucleotides of the microarray or detection kit. Incubation conditions are adjusted so that hybridization occurs with precise complementarity matches or with various degrees of less complementarity. After removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray or detection kit. The biological samples may be obtained from any bodily fluids (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large-scale correlation studies on the sequences, expression patterns, mutations, variants, or polymorphisms among samples.

Using such arrays, the present invention provides methods to identify the expression of the kinase proteins/peptides of the present invention. In detail, such methods comprise incubating a test sample with one or more nucleic acid molecules and assaying for binding of the nucleic acid molecule with components within the test sample. Such assays will typically involve arrays comprising many genes, at least one of which is a gene of the present invention and or alleles of the kinase gene of the present invention. FIG. 3 provides information on SNPs that have been found in the gene encoding the kinase protein of the present invention. SNPs were identified at 42 different nucleotide positions. Some of these SNPs, which are located outside the ORF and in introns, may affect gene transcription.

Conditions for incubating a nucleic acid molecule with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid molecule used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or array assay formats can readily be adapted to employ the novel fragments of the Human genome disclosed herein. Examples of such assays can be found in Chard, T, *An Introduction to Radioimmunoassay and Related Techniques*, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G. R. et al., *Techniques in Immunocytochemistry*, Academic Press, Orlando, Fla. Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., *Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology*, Elsevier Science Publishers, Amsterdam, The Netherlands (1985).

The test samples of the present invention include cells, protein or membrane extracts of cells. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing nucleic acid extracts or of cells are well known in the art and can be readily be adapted in order to obtain a sample that is compatible with the system utilized.

In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention.

Specifically, the invention provides a compartmentalized kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the nucleic acid molecules that can bind to a fragment of the Human genome disclosed herein; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound nucleic acid.

In detail, a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the nucleic acid probe, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound probe. One skilled in the art will readily recognize that the previously unidentified kinase gene of the present invention can be routinely identified using the sequence information disclosed herein can be readily incorporated into one of the established kit formats which are well known in the art, particularly expression arrays.

The invention also provides vectors containing the nucleic acid molecules described herein. The term "vector" refers to a vehicle, preferably a nucleic acid molecule, which can transport the nucleic acid molecules. When the vector is a nucleic acid molecule, the nucleic acid molecules are covalently linked to the vector nucleic acid. With this aspect of the invention, the vector includes a plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, OR MAC.

A vector can be maintained in the host cell as an extra-chromosomal element where it replicates and produces additional copies of the nucleic acid molecules. Alternatively, the vector may integrate into the host cell genome and produce additional copies of the nucleic acid molecules when the host cell replicates.

The invention provides vectors for the maintenance (cloning vectors) or vectors for expression (expression vectors) of the nucleic acid molecules. The vectors can function in prokaryotic or eukaryotic cells or in both (shuttle vectors).

Expression vectors contain cis-acting regulatory regions that are operably linked in the vector to the nucleic acid molecules such that transcription of the nucleic acid molecules is allowed in a host cell. The nucleic acid molecules can be introduced into the host cell with a separate nucleic acid molecule capable of affecting transcription. Thus, the second nucleic acid molecule may provide a trans-acting factor interacting with the cis-regulatory control region to allow transcription of the nucleic acid molecules from the vector. Alternatively, a trans-acting factor may be supplied by the host cell. Finally, a trans-acting factor can be produced from the vector itself. It is understood, however, that in some embodiments, transcription and/or translation of the nucleic acid molecules can occur in a cell-free system.

The regulatory sequence to which the nucleic acid molecules described herein can be operably linked include promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage λ , the lac, TRP, and TAC promoters from *E. coli*, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.

In addition to control regions that promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.

In addition to containing sites for transcription initiation and control, expression vectors can also contain sequences necessary for transcription termination and, in the transcribed region a ribosome binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. The person of ordinary skill in the art would be aware of the numerous regulatory sequences that are useful in expression vectors. Such regulatory sequences are described, for example, in Sambrook et al., *Molecular Cloning: A Laboratory Manual*. 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1989).

A variety of expression vectors can be used to express a nucleic acid molecule. Such vectors include chromosomal, episomal, and virus-derived vectors, for example vectors derived from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40, Vaccinia

viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses. Vectors may also be derived from combinations of these sources such as those derived from plasmid and bacteriophage genetic elements, e.g. cosmids and phagemids. Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook et al., *Molecular Cloning: A Laboratory Manual*. 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1989).

The regulatory sequence may provide constitutive expression in one or more host cells (i.e. tissue specific) or may provide for inducible expression in one or more cell types such as by temperature, nutrient additive, or exogenous factor such as a hormone or other ligand. A variety of vectors providing for constitutive and inducible expression in prokaryotic and eukaryotic hosts are well known to those of ordinary skill in the art.

The nucleic acid molecules can be inserted into the vector nucleic acid by well-known methodology. Generally, the DNA sequence that will ultimately be expressed is joined to an expression vector by cleaving the DNA sequence and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for restriction enzyme digestion and ligation are well known to those of ordinary skill in the art.

The vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using well-known techniques. Bacterial cells include, but are not limited to, *E. coli*, *Streptomyces*, and *Salmonella typhimurium*. Eukaryotic cells include, but are not limited to, yeast, insect cells such as *Drosophila*, animal cells such as COS and CHO cells, and plant cells.

As described herein, it may be desirable to express the peptide as a fusion protein. Accordingly, the invention provides fusion vectors that allow for the production of the peptides. Fusion vectors can increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting for example as a ligand for affinity purification. A proteolytic cleavage site may be introduced at the junction of the fusion moiety so that the desired peptide can ultimately be separated from the fusion moiety. Proteolytic enzymes include, but are not limited to, factor Xa, thrombin, and enterokinase. Typical fusion expression vectors include pGEX (Smith et al., *Gene* 67:31-40 (1988)), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann et al., *Gene* 69:301-315 (1988)) and pET 11 d (Studier et al., *Gene Expression Technology: Methods in Enzymology* 185:60-89 (1990)).

Recombinant protein expression can be maximized in host bacteria by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant protein. (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, Calif. (1990) 119-128). Alternatively, the sequence of the nucleic acid molecule of interest can be altered to provide preferential codon usage for a specific host cell, for example *E. coli*. (Wada et al., *Nucleic Acids Res.* 20:2111-2118 (1992)).

The nucleic acid molecules can also be expressed by expression vectors that are operative in yeast. Examples of vectors for expression in yeast e.g., *S. cerevisiae* include pYpSec1 (Baldari, et al., *EMBO J.* 6:229-234 (1987)), pMFa (Kurjan et al., *Cell* 30:933-943(1982)), pJRY88 (Schultz et al., *Gene* 54:113-123 (1987)), and pYES2 (Invitrogen Corporation, San Diego, Calif.).

The nucleic acid molecules can also be expressed in insect cells using, for example, baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al., *Mol. Cell Biol.* 3:2156-2165 (1983)) and the pVL series (Lucklow et al., *Virology* 170:31-39 (1989)).

In certain embodiments of the invention, the nucleic acid molecules described herein are expressed in mammalian cells using mammalian expression vectors. Examples of mammalian expression vectors include pCDM8 (Seed, B. *Nature* 329:840(1987)) and pMT2PC (Kaufman et al., *EMBO J.* 6:187-195 (1987)).

The expression vectors listed herein are provided by way of example only of the well-known vectors available to those of ordinary skill in the art that would be useful to express the nucleic acid molecules. The person of ordinary skill in the art would be aware of other vectors suitable for maintenance propagation or expression of the nucleic acid molecules described herein. These are found for example in Sambrook, J., Fritsch, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

The invention also encompasses vectors in which the nucleic acid sequences described herein are cloned into the vector in reverse orientation, but operably linked to a regulatory sequence that permits transcription of antisense RNA. Thus, an antisense transcript can be produced to all, or to a portion, of the nucleic acid molecule sequences described herein, including both coding and non-coding regions. Expression of this antisense RNA is subject to each of the parameters described above in relation to expression of the sense RNA (regulatory sequences, constitutive or inducible expression, tissue-specific expression).

The invention also relates to recombinant host cells containing the vectors described herein. Host cells therefore include prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.

The recombinant host cells are prepared by introducing the vector constructs described herein into the cells by techniques readily available to the person of ordinary skill in the art. These include, but are not limited to, calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, lipofection, and other techniques such as those found in Sambrook, et al. (*Molecular Cloning: A Laboratory Manual*. 2nd, ed, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).

Host cells can contain more than one vector. Thus, different nucleotide sequences can be introduced on different vectors of the same cell. Similarly, the nucleic acid molecules can be introduced either alone or with other nucleic acid molecules that are not related to the nucleic acid molecules such as those providing trans-acting factors for expression vectors. When more than one vector is introduced into a cell, the vectors can be introduced independently, co-introduced or joined to the nucleic acid molecule vector.

In the case of bacteriophage and viral vectors, these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction. Viral vectors can be replication-competent or replication-defective. In the case in which viral replication is defective, replication will occur in host cells providing functions that complement the defects.

Vectors generally include selectable markers that enable the selection of the subpopulation of cells that contain the

recombinant vector constructs. The marker can be contained in the same vector that contains the nucleic acid molecules described herein or may be on a separate vector. Markers include tetracycline or ampicillin-resistance genes for prokaryotic host cells and dihydrofolate reductase or neomycin resistance for eukaryotic host cells. However, any marker that provides selection for a phenotypic trait will be effective.

While the mature proteins can be produced in bacteria, yeast, mammalian cells, and other cells under the control of the appropriate regulatory sequences, cell-free transcription and translation systems can also be used to produce these proteins using RNA derived from the DNA constructs described herein.

Where secretion of the peptide is desired, which is difficult to achieve with multi-transmembrane domain containing proteins such as kinases, appropriate secretion signals are incorporated into the vector. The signal sequence can be endogenous to the peptides or heterologous to these peptides.

Where the peptide is not secreted into the medium, which is typically the case with kinases, the protein can be isolated from the host cell by standard disruption procedures, including freeze thaw, sonication, mechanical disruption, use of lysing agents and the like. The peptide can then be recovered and purified by well-known purification methods including ammonium sulfate precipitation, acid extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, or high performance liquid chromatography.

It is also understood that depending upon the host cell in recombinant production of the peptides described herein, the peptides can have various glycosylation patterns, depending upon the cell, or maybe non-glycosylated as when produced in bacteria. In addition, the peptides may include an initial modified methionine in some cases as a result of a host-mediated process.

Uses of Vectors and Host Cells

The recombinant host cells expressing the peptides described herein have a variety of uses. First, the cells are useful for producing a kinase protein or peptide that can be further purified to produce desired amounts of kinase protein or fragments. Thus, host cells containing expression vectors are useful for peptide production.

Host cells are also useful for conducting cell-based assays involving the kinase protein or kinase protein fragments, such as those described above as well as other formats known in the art. Thus, a recombinant host cell expressing a native kinase protein is useful for assaying compounds that stimulate or inhibit kinase protein function.

Host cells are also useful for identifying kinase protein mutants in which these functions are affected. If the mutants naturally occur and give rise to a pathology, host cells containing the mutations are useful to assay compounds that have a desired effect on the mutant kinase protein (for example, stimulating or inhibiting function) which may not be indicated by their effect on the native kinase protein.

Genetically engineered host cells can be further used to produce non-human transgenic animals. A transgenic animal is preferably a mammal, for example a rodent, such as a rat or mouse, in which one or more of the cells of the animal include a transgene. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more cell types or tissues of the transgenic animal. These animals are useful for

studying the function of a kinase protein and identifying and evaluating modulators of kinase protein activity. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, and amphibians.

A transgenic animal can be produced by introducing nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Any of the kinase protein nucleotide sequences can be introduced as a transgene into the genome of a non-human animal, such as a mouse.

Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included. A tissue-specific regulatory sequence (s) can be operably linked to the transgene to direct expression of the kinase protein to particular cells.

Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al, U.S. Pat. No. 4,873,191 by Wagner et al. and in Hogan, B., *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene can further be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes animals in which the entire animal or tissues in the animal have been produced using the homologously recombinant host cells described herein.

In another embodiment, transgenic non-human animals can be produced which contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, see, e.g., Lakso et al. *PNAS* 89:6232-6236 (1992). Another example of a recombinase system is the FLP recombinase system of *S. cerevisiae* (O'Gorman et al. *Science* 251:1351-1355 (1991)). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recom-

binase and a selected protein is required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. et al. *Nature* 385:810-813 (1997) and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring born of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

Transgenic animals containing recombinant cells that express the peptides described herein are useful to conduct the assays described herein in an in vivo context. Accordingly, the various physiological factors that are present in vivo and that could effect substrate binding, kinase protein activation, and signal transduction, may not be evident from in vitro cell-free or cell-based assays. Accordingly, it is useful to provide non-human transgenic animals to assay in vivo kinase protein function, including substrate interaction, the effect of specific mutant kinase proteins on kinase protein function and substrate interaction, and the effect of chimeric kinase proteins. It is also possible to assess the effect of null mutations, that is, mutations that substantially or completely eliminate one or more kinase protein functions.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 4

<210> SEQ ID NO 1

<211> LENGTH: 2320

<212> TYPE: DNA

<213> ORGANISM: Human

<400> SEQUENCE: 1

```

cccagggcgc cgtaggcggg gcatccggtt cgcgcctggg gctgtggtct tcccgcgcct    60
gaggcgccgg cggcaggagc tgaggggagt ttaggggaac tgaggggagc tgctgtgtcc    120
cccgcctcct cctccccatt tccgcgtccc cgggaccatg tccgcgtgg cgggtgaaga    180
tgtctggagg tgtccaggct gtggggacca cattgtccca agccagatat ggtacaggac    240

```

-continued

tgtcaacgaa acctggcagc gctcttgctt ccggtgaaag tgatgcgcag cctggaccac	300
cccaatgtgc tcaagttcat tgggtgtgtg tacaaggata agaagctgaa cctgctgaca	360
gagtacattg agggggggcac actgaaggac tttctgcgca gtatggatcc gttccctgg	420
cagcagaagg tcaggtttgc caaaggaatc gcctccggaa tggacaagac tgtgtgtgtg	480
gcagactttg ggctgtcacg gctcatagtg gaagagagga aaagggcccc catggagaag	540
gccaccacca agaaacgcac cttgcgcaag aacgaccgca agaagcgcta cagggtgtgtg	600
ggaaaccctt actggatggc ccctgagatg ctgaacggaa agagctatga tgagacggtg	660
gatatcttct cctttgggat cgttctctgt gagatcattg ggcagggtga tgcagatcct	720
gactgccttc cccgaacact ggactttggc ctcaacgtga agcttttctg ggagaagttt	780
gttcccacag attgtccccc ggcccttctc ccgctggccg ccatctgtg cagactggag	840
cctgagagca gaccagcatt ctcgaaattg gaggactcct ttgaggccct ctccctgtac	900
ctgggggagc tgggcatccc gctgcctgca gagctggagg agttggacca cactgtgagc	960
atgcagtacg gctgacccg ggactcacct ccctagccct ggcccagccc cctgcagggg	1020
ggtgttctac agccagcatt gcccctctgt gcccattcc tgctgtgagc agggccgtcc	1080
gggcttctg tggattggcg gaatgttag aagcagaaca aaccattcct attacctccc	1140
caggaggcaa gtgggcgcag caccaggga atgtatctcc acaggttctg gggcctagtt	1200
actgtctgta aatccaatac ttgcctgaaa gctgtgaaga agaaaaaac ccctggcctt	1260
tgggccagga ggaatctgtt actcgaatcc acccaggaac tccctggcag tggattgtgg	1320
gaggctcttg cttacactaa tcagcgtgac ctggacctgc tgggcaggat ccaggggtga	1380
acctgcctgt gaactctgaa gtcactagtc cagctgggtg caggaggact tcaagtgtgt	1440
ggacgaaaga aagactgatg gctcaaaagg tgtgaaaaag tcagtgatgc tcccccttc	1500
tactccagat cctgtccttc ctggagcaag gttgaggag taggttttga agagtccctt	1560
aatatgtggt ggaacaggcc aggagttaga gaaagggtg gcttctgttt acctgtcac	1620
tggctctagc cagcccaggg accacatcaa tgtgagagga agcctccacc tcatgttttc	1680
aaacttaata ctggagactg gctgagaact tacggacaac atcctttctg tctgaaacaa	1740
acagtcacaa gcacaggaag aggctggggg actagaaaga ggccctgccc tctagaaagc	1800
tcagatcttg gcttctgtta ctcatactcg ggtgggctcc ttagtcagat gcctaaaaca	1860
ttttgcctaa agctcgatgg gttctggagg acagtgtggc ttgtcacagg cctagagtct	1920
gagggagggg agtgggagtc tcagcaatct cttggtcttg gcttcatggc aaccactgct	1980
cacccttcaa catgcctggt ttaggcagca gcttgggctg ggaagagggt gtggcagagt	2040
ctcaaagctg agatgctgag agagatagct ccctgagctg ggccatctga cttctacctc	2100
ccatgtttgc tctcccaact cattagctcc tgggcagcat cctcctgagc cacatgtgca	2160
ggtactggaa aacctccatc ttggctccca gagctctagg aactcttcat cacaactaga	2220
tttgctctt ctaagtgtct atgagcttgc accatattta ataaattggg aatggggttg	2280
gggtattaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa	2320

<210> SEQ ID NO 2

<211> LENGTH: 255

<212> TYPE: PRT

<213> ORGANISM: Human

<400> SEQUENCE: 2

Met Val Gln Asp Cys Gln Arg Asn Leu Ala Arg Leu Leu Pro Val

-continued

1	5	10	15
Lys Val Met Arg Ser Leu Asp His Pro Asn Val Leu Lys Phe Ile Gly	20	25	30
Val Leu Tyr Lys Asp Lys Lys Leu Asn Leu Leu Thr Glu Tyr Ile Glu	35	40	45
Gly Gly Thr Leu Lys Asp Phe Leu Arg Ser Met Asp Pro Phe Pro Trp	50	55	60
Gln Gln Lys Val Arg Phe Ala Lys Gly Ile Ala Ser Gly Met Asp Lys	65	70	80
Thr Val Val Val Ala Asp Phe Gly Leu Ser Arg Leu Ile Val Glu Glu	85	90	95
Arg Lys Arg Ala Pro Met Glu Lys Ala Thr Thr Lys Lys Arg Thr Leu	100	105	110
Arg Lys Asn Asp Arg Lys Lys Arg Tyr Thr Val Val Gly Asn Pro Tyr	115	120	125
Trp Met Ala Pro Glu Met Leu Asn Gly Lys Ser Tyr Asp Glu Thr Val	130	135	140
Asp Ile Phe Ser Phe Gly Ile Val Leu Cys Glu Ile Ile Gly Gln Val	145	150	160
Tyr Ala Asp Pro Asp Cys Leu Pro Arg Thr Leu Asp Phe Gly Leu Asn	165	170	175
Val Lys Leu Phe Trp Glu Lys Phe Val Pro Thr Asp Cys Pro Pro Ala	180	185	190
Phe Phe Pro Leu Ala Ala Ile Cys Cys Arg Leu Glu Pro Glu Ser Arg	195	200	205
Pro Ala Phe Ser Lys Leu Glu Asp Ser Phe Glu Ala Leu Ser Leu Tyr	210	215	220
Leu Gly Glu Leu Gly Ile Pro Leu Pro Ala Glu Leu Glu Glu Leu Asp	225	230	240
His Thr Val Ser Met Gln Tyr Gly Leu Thr Arg Asp Ser Pro Pro	245	250	255

<210> SEQ ID NO 3
 <211> LENGTH: 59065
 <212> TYPE: DNA
 <213> ORGANISM: Human

<400> SEQUENCE: 3

tcaccccttg gcaggggcca tgctaaccct ctgtgtctca gtccaatttt aatgtatgtg	60
ctgctgaagc gagagtacca gaggtttttt tgatggcagt gacttgaact tatttaaaag	120
ataaggagga gccagtgagg gagaggggtg ctgtaaagat aactaaaagt gcacttcttc	180
taagaagtaa gatggaatgg gatccagaac aggggtgtca taccgagtag cccagccttt	240
gttccgtgga cactggggag tctaaccag agctgagata gcttgcaagt tggatgagcc	300
agctgagtac agcagatagg gaaaagaagc caaaaatctg aagtagggct ggggtgaagg	360
acaggggaag gctagagaga catttggaat gtgaaaccag gtggatatga gaggagagag	420
tagagggtct tgatttcggg tctttcatgc ttaacccaaa gcaggtaact aagtatgtgt	480
tgattgaatg tctttgggtt tctcaagact ggagaaagca gggcaagctc tggaggggtat	540
ggcaataaca agttatcttg aatatcctca tgggtgaaag tcctgaccc ttttgaattt	600
tggaataaga aatcattcag agccaagaga ttgaattgtt gagtaagtgg gtggtcagggt	660
tacagactta attttgggtt aaaaagtaaa aacaagaac aaggtgtggc tctaaaataa	720

-continued

tgagatgtgc tgggggtggg gcatggcagc tcataaactg accctgaaag ctcttacatg	780
taagagttcc aaaaatattt caaaacttg gaagattcat ttggatgttt gtgttcatta	840
aaatctctca ctaattcatt gtcttgtcca ctgtccgtaa cccaacctgg gattggtttg	900
agtgagtctc tcagactttc tgccttgag tttgtgagag agatggcata ctctgtgacc	960
actgtcacc ctaaaacaaa aaggccctc ttgacaagga gtctgaggat ttagaccca	1020
ggaagaatga gtgatgggca tatatatatc ctattactga ggcagagaa gagtggaatg	1080
ggtgggttga ggtggtgttt taaggcctct tgccagcttg ttttaactctt ctctggggaa	1140
cgagggggac aactgtgtac attggctgct ccagaatgat gttgagcaat cttgaagtgc	1200
caggagctgt gctttgtcta ttcatggccc ctgtgcctgt gaaacagggt tcggtgactg	1260
tcactgtgcc tgtggcagtc ttagttacc cagagagaac aaagctgcat acacagagcg	1320
cacaaggag tcttgaaca accctgtcct gctttctagg gctgagtcag gtaccacagc	1380
ttgatctcag ctgtcctctt tatttcaaga agttgacatc tgagccatac caggagtatt	1440
gtattttgtt tgaggcctct ctttttgag gaacatggac cgactctgtg cttttgtcta	1500
tgtgtgtctc tgagctcaca caacccttca ccctccttcc tcagccagtg ataggtaatg	1560
cttccctatc ttgcaaggct cagctcaagt gtcagcttcc tctacaaaga ctttctgtgt	1620
tccctcatt ggagtgaaca agagtgtaca tggtagaatg gaaagagcag aagctttaga	1680
atgagccaga cctgagtatg aatgctagat ccaccactta gctagtcaac cctgcccct	1740
gcctcaagtt ttaattttcc tatccattaa gtgaatataa taatacctgt gtcacaggat	1800
tattttgaga attaaatgag attaggtcta tgaaagcacc tagcagagtt cttggcatat	1860
aggaggcatt cattaaatat ttgttcttcc ctttttatcc ccattacttt tctttttctg	1920
aactaaata atacttggtt ctatctctga aataacatcc aagtgaanaa tcaacaacat	1980
gaaagagcag ttcttttcca gtggatttgc ttcttaagga gcagagatta tgtaactaa	2040
cagcctccaa catacaaga gctttgtatc tagaacaggg gtcccagcc cctggaccgc	2100
caactgttac ggtgtgttag cctgttagga accaggctgc acagcaggag gtgagcgcg	2160
ggccagttag cattgtctgc tgagctctgc ctctgtcag atcagtgtg gcattagatt	2220
ctcataggag tgtgaacct attgtgaact gcacatgcaa gggatctggg ttgcatgtc	2280
cttatgagaa tctcactaat ggctgatgat ctgagttgga acagtttgat accaaaacca	2340
tccccccgcc ccccaacccc cagcctaggg tccgtggaaa aattggcccc tggtgccaaa	2400
aagggtgagg actgctgac tagaggacca atttattcaa tgttggttga gtaaatgagc	2460
tcttggtatta ggtgatggaa aaatctgaaa aaacagggct tttagggaat aggaaaaggc	2520
agtaacatgt ttaaccaga gagaagtttc tggctgttg ctgggaatag tcataggaag	2580
ggctgacact gaaaagaagg agattgtgtt cgtttcttct tctcagagct ataagcaaag	2640
gctgaaagt ctgaaaaag gcaagttttg tttcagtaga aaaaaggata atcagaacca	2700
tttttagaaa atggaatgag actacttttg aggccatgag ttcctgttcc ctggagagat	2760
gagcagaggt tggacaagt cttaccagag atcttgtgga ggcagaaact gtgcacttag	2820
cagagcattg gcctaacct ttcaaatgag atgctgttaa ctcagcttta ttctacatgg	2880
taggaatcct gtccctttgc ctctgtctac tttgggcctc tcaacctctt ggttttgtgt	2940
gcagggtgaag atgtctggag gtgtccaggc tgtggggacc acattgtctc aagccagata	3000
tggtagagga ctgtcaacga aacctggcac ggctcttgc tccggtaggt gggcctatcc	3060
tcccatcttt accagtgtac tatgggcca gcaacttttc atgttctgat ggaacacaca	3120

-continued

gaaacaagct tctgagttga gaatttcaat cttagggtgg ggaaaggaat gtaccaagga	3180
agagctcatg accaaacctc aagtgtggcc cccctgaacc caggttaa at tggagagacc	3240
ataaatgggc cagctggagg cagggtgggg ggatgagagg agccctttcc agggttgtcc	3300
catatccctc actttatggg tgaggaaact gagggccagg aagagtgaact ttctgtggc	3360
tgcactacag attatgcagg tacttcaaga gttgtttgta ttcttatttt attttatttt	3420
attttatttt attttatttt attttatgag agggattctt gctgttgccc aggctggagt	3480
gcagtgggac aatctcggt cactgcaatc tctgcctgct gggttcaagt gatttttctg	3540
ccttagcttc ctgagtagct gagatgacag gcacctgcca ccctgcgcag ctaatttttg	3600
tattttagtg gagacggggg ttccaacatg ttggtcaggc tggctctgaa ctctgacct	3660
caaagtatgc acccacctcg acctccaaa gtgctggaat tacaggcgtg aaccactgtg	3720
cccagccaag agttgttttt agtgtggttg gcagagccag ctcttccttc accacaggat	3780
gcctccctag gttcctactt ttgttacta gcttttatta tagctatatt attattatta	3840
ttattattat tattattatt attattgaga cagagtctcg ctctgtcgcc caggctgggtg	3900
tacagtgggt cgatcccggt ctactgcaa cctctgcctc ccgagttcaa gcagtctctc	3960
tgcctcagcc ccccgagtag gtgggactac aggcgcctgc caccacaccg ggctaatttt	4020
tgtattttta gttagagagg ggtttcacct tgttgaccag gctggtctgg agctcctgac	4080
ctcaggttaag tgctagaatc acaggcgtga accactgcgc ccagccaaga gttgttttta	4140
gtgtgggttg cagagccagc tcttcctcac cacagggtgc ctccctaggt tcctactttt	4200
tgttactagc ttattatag ctacattatt attattattg ttattattat tgagacagag	4260
tctcgtctg tcgcccaggc tgggtgtacag tgatgtgac ttggctcact gcaacctctg	4320
cccccgagt tcaagcaatt ctctgcttc agcccccta gtagggtgga ctccaggcac	4380
ctgccaccac gccagctaa tttttgtatt tttagtagag gcgggggttc acctgtgttg	4440
ccaggctggt ctcaaactcc tgacctcagg tgatccgctt gcctcggcct cccaaaatgt	4500
tgggattaca ggcatgagcc accgcgcctt gcctatagct acattatttt ttaggcagc	4560
tcagtttctt aaaaattata cagacttcaa atcagatttg ttctgtctgt ctgaggctca	4620
gtttcttcat ctggaaaatg gatggtaata atcttgttga gattgaatga aataatatat	4680
gcagtgtatc cagtacatgg tagacacca gtgaatgggtt attccttctt cccatcggt	4740
tggaaattctc aagggtggga acttgtcttt atattcttca caacgtaaaa tagttgaaat	4800
ttgttggttg aaagaagagc agtccactcc agaggctgga tgggcatgcc tggcccccac	4860
ggtctgaagt ggtagggttg tgcctatata ctgagaatga gatagactag gcaggcacct	4920
tgtgctgtag attccagctc ctgcacatag ctcttgttgt aaacatccc tgtgcttata	4980
ccaagtaatt gagttgacct ttaaacactt gcctcttccc tgggaacctt ataggggatt	5040
ggcctggaga cgtctggcct ctggaagagt tggaaagcag ccattattat tatcctttcc	5100
tttcagctat aactcagagc tctcaagtct tttctgtgga tcttattgcc ttgggtcttg	5160
ccccctttac tcccaggga gttgattctg tcttttctgt tccatttagt atgacaggag	5220
cagagaatgt cagagctga agggacctta tagttaaac ctttggtggt tcctttcatt	5280
ttatagctgg gactaataag taacgtcaaa acccaatgag ttcacagatt gggctctgcc	5340
ttggcatgta acccatatgt tcatattctt gctgttttcc tatgtgtatg aatattttct	5400
atccaaaata agcaggacag ggtagagcaa gttaatcttt ggaatttctg gattctctta	5460

-continued

gagctaaaaa acttcagaac tagaagaac caccactat atggtataac ccattcatat	5520
cacagatgag gcctgaaacc aaaaagactt gctcaggcca tggatgacaa gagctggccc	5580
tagcactgaa ctcttgggtc atttgtaggt ctagtcatat gctagcttgt tagctctgtg	5640
cgtgcgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgagat agagacagaa agataacata	5700
tgtacacaaa tacataaaga ggaagtagac acgttagcat ggtagataag agtacaggca	5760
ggccaggcgt ggtggctcac gcctgtaate ccagcacttt gggaggccaa ggcagggtga	5820
tcacctgagg tcaggaaattc gagaccagcc tgaccaacat ggtgaacccc catctctact	5880
aaatacagaa aaaaattagc ttggcatggt ggcacatgcc tgtaatccca gctacttggg	5940
aagctgaagc aggagaatcg ctgaaatccg ggaagcagaa gttgcagtga gccgagattg	6000
tgccattaca gtctagcctg ggcaacaaga gggaaactcc atcgcaaaaa aacaaccacc	6060
accaagagta caggctatgg aatgagacta tggttttaaa tcctggcctt gcaatttatt	6120
aactagcctt aagtgaactc cctgagcttc aggcaccaat ctgtaaatg aggataagaa	6180
tattactcat gccacatggt tgtagggag gattaatgt gataacctat ataaagtggc	6240
tagcatagca tctgacatat agaaaactct taatagggcc ggacgtggtg gcttatgcct	6300
gtaatcctag cactctggga ggccgaggca gaaggatcgc ttgagcccat gagccagga	6360
gttgagacc agcctggcca acatggcaaa actccacctc taaaaaaat aaaaaatat	6420
tagccaggcg tgatggcaca cacctgtagt cccagctact tgggaagctg aggagcgatg	6480
attacctgag cccagggata tcaaggctgt agtgagctgt gatcatgcca ctgtactcca	6540
tcacgctggg ggacagagtg aaacccctgt ctcaaaacaa aacaaatgaa aaaaaaacc	6600
cttaataatc agtaactgac actttatatt atgttgtgag tgtgtgtcta tatacaccta	6660
tatgtataca tttctcttat tacacattca ttggtgatct gatgtggagc cccagggtatt	6720
aagggaact ttgaactacc ctgacacaat caagccaaat atcattcccg tggagggaagt	6780
agagtatcta ggttctgtct cctagtgtga gctttacctt gaggacagag actctaattc	6840
agctgtgctg aaggagcaca tctcctgact tctgagcttt cccctggtaa attcaaatg	6900
gatgtcagcg cgcctcaga tagagcctgg taatttgccc tggggagagt gactgtcttt	6960
tggatctaatt ttgacttttg cccagtttg aggaanaatct tcagggttag gaaggattgt	7020
atttgtctga cccagagat aacctgggtt ttgaggaaca tggggcatca acctgaatgg	7080
tcttgtaaga tctctcccac gccagcttgc cagtgtttct ctgatgaatt tagagtacct	7140
gagtagtgca ggcctgctgg gaggaggact ctccctctgt gctactcaga gaaattcatt	7200
cttcaaggcc ccttccagc cttgctctta cccagctggg ctacagttac aataaaggaa	7260
atgacttttc tctccctt cccccagtac ctttgttttc ctatgcacag ggtgggctg	7320
gatattgaat ggagaaattg ctggggtcca tcctaaactc ctccctcat ctctccctta	7380
cattacccca tctctctgtc tgcagccaca tccataatcc tgctctgtt agccttccga	7440
cagacctca ggtgccagc acaacaggaa gctacttaaa gctggaacct cagactgtgc	7500
aatggaggcc agtgacaaaa ctgaaagtag ctctgtcagt aattgtgctg gtgcgattag	7560
gcagctggcc agaactcttt ggatctcctg gacatatggc tgactagtcc tcccaagcct	7620
tcccaacagc cctctttttt tctctttttt tctttctttt tttctttt tttctttt	7680
tctttttttt ttttttttag gctagtgaag tgaaattgtg ggagtggaaa aggaacaaag	7740
aaatcggtaa ctggtagtga tcaattactt gtaaacacta ttgtacttgg accagcccag	7800
taggcctttt ttaaaactct gatttacctc tcttctctt ccttgagcag tgcattaat	7860

-continued

tctgtatctg gggcaatcct ttctgatgtt ctctggacct ggctctctct ccttaggaga	7920
ggccaggaga gtaccagag agcatgtcat ttgtagctga ggttaaagtg tggagctatc	7980
aatggtgacc tggcctcttg gcatgttagc aagccagagg accttgacaa cttttttgat	8040
gattgtccgt tcacctgat caaagggtgt tggcttagga ggagggaaga aaagctaccc	8100
ctattagtct tgatggcccc agcgtgggtc tctattgctt gacctgggtc ctgacagcat	8160
tatcagaagg aaaaaccacc gctcttaagg ctctgggaa ctttcaggac ttccctttctc	8220
aggattgcaa acataagact attgagctt tcacttttga aaagcggtta ctaataccta	8280
tactctggga aagggttaat gcagatagaa gactgtgggtc actgcatcag gcaacagacc	8340
atttccgcta aatttagtga ctccaggaag gccagtgaag aaataacaca cgtagcaacc	8400
agagactgtg ttgtaatatg ttggctgaca gcagggtact ttctgtgatg ctgaaagcca	8460
cattcatttt ctctccctc atcccatct aagcaagcct ggtagaatca taattacagt	8520
aataggtagc acttattgag tactctgtgc cagacacct cctgagcata cgacatgcat	8580
agcacattta atccttaca tgacttaata aaatgtagta ctagtcttac ctacttcgag	8640
aatagggaaa tggaggttac ttgtttaaag tcacagagct aataggtagc atagctgaga	8700
tttgaactca ggcattctta ctcttgctc gcaagagtct cttggcattc ttgaatgcaa	8760
gcatatttct taacctcact gaggctcagt ttctcttat ataatatggg gtaaagagcc	8820
ctcacctgc ctgccacaca ctggtagtgt cagataacat tgaagggtgt tagtttaaag	8880
gcttcattga ctctataatg tcaacaaaag tgctgttaac tttcttcttg gtctcaggct	8940
cctgatgtag agtcagtga gcaaccctgc catctgctgt tatgctgttg atgttgcgtc	9000
cacacttact aacctaaacc tttgattctg gctgtggcct tctccagaag gtgtttactc	9060
attgtccag tttatctttt aggaacagc cagcccgtag atcattaagg ctggctattg	9120
gacagggggc tggggcctgc ctgacagagg aagggaaggc agacatctgg ttcttcctct	9180
gccctacaa gagactccag cctgaccaca gagtggtagt cctaggatgt agcagcagca	9240
tatgagcttg aatgtgcctt aatctgtctc ttacttttga gaagagagaa ctaaggaccc	9300
acagatgttt cacagcttct ataggaggca gaggtagaaa aatggagaga gatgaggcca	9360
gagatagata actgatatta attaaacgtt gtattaagaa cctcacttag attatctgat	9420
tcaatcttca taataaccct gcaaccccca ctttttttg agaacagggt cttgctctgt	9480
tgccaggct acagtgcact ggtacaatca tagttcactg cagtgtcaac ctctgagct	9540
caagcaatcc tcccacctca gccttgcaag cagcttgac tacaggcgtg ccaccacacc	9600
ttgccatttt tttttatttt aagtagaaac aaggtcttat taatactatg ttgccaggc	9660
tggtcttgaa ctccagcgat cctcctgccc cagcctccca aagtgttggt gattacggaa	9720
gtaagccact gtgctggcc agtgcaaccc ccattttata ctaaacagg aaggccaga	9780
aaggtttga gtaactgtc cagggtcaca cagatgatat ttgaactcag gtctccctg	9840
ctcccaagag agtctgcttt ccactaggac tcccaggaga aaaaaaaaaa aaaaacagt	9900
agacttgag acagaaaaac tgatttgagt cttagttgag ctaggctaac tgtgtaactg	9960
tgggcaagtt ccttagcccc tgtgagcctc agtttcttat ctgtaaatg tcataaaaga	10020
aatccatctc atggagtagt tgtgatgatc aaggactctg aaaacattag aatggtttaa	10080
tgtgaaggat tagcagcagc acatggcaac attgtgcac ttatattaac tatccaaata	10140
tatcaagcgt catttgctat atataaaagt catcaaatga ggcactgtgg gggatacgga	10200

-continued

gttggcatag tagcctggcc tcttaattaa ttcattaatt agcttattta tttttgagat 10260
 aggtcttgct ctattgccc ggctggagtg cagtggcatg atgatatgctt actatagcct 10320
 caatctccca ggcttaaaaca atcctcctga gtagctggga ctacaggcac acactaccat 10380
 gccagctaa ttttttttta attttttgta gagacagggt cttgctctgt tgcccaggct 10440
 ggtctcaaac tcctgggctc gagatcctcc cactggggcc tcacaaagtg ttgggattac 10500
 aggtatgagc caggccacct ggctgggtct cttaactggt tccctaagac agctggaaat 10560
 agagaatgct atggagcatt cctaaccatg ggctccagcc tggctttcat tctgtttctc 10620
 cctgaaaca acattccttt agtaatatc cgaataacag cttcatcagt ctgtctaccg 10680
 accactcttc aggtctcctc ttatatgacc tcccaactg cactaagggt tgtattagag 10740
 aaaagtggat aaagtccga gtcaggctgc ttgagcttaa atgccagctt cacttaccag 10800
 ccactgacc atgagtcagc tgcttaacca ttctttgcca cagtttcctt gtctatgaaa 10860
 agggaaatgg ctcccacctc aaaaagtgtg taacattaaa ttcaatcagc tattcaaagt 10920
 cctgagcaga atgtctggcc atgactggga cttaacagat gttagcattt attattagta 10980
 tctgtcagtc ttgaaatggt ctcttccctt ggctttcatg acattccaca ctctcctggt 11040
 tttctcttac ctctctgcta atacctgtt gcttatcctt cttgtccag ctctgggatg 11100
 ttaccattcc ttcaggcgtg ctgtttctc cttaggcagt cttacacaca ctcatgactt 11160
 ccttcattg tctccacac actgatgacc ctaaaatcag tatctccagc cttaaccctt 11220
 ccactgagtt ctagaccat atgttgact atcaacctg cttgtccatt tgaatgtctt 11280
 ccaggcactt cagactctct tctctagact ttgctggact ttcactcttc cccctaaaac 11340
 tggctcctct tccactgaaa catgtatgct attgagaggc accaccatcc acccagtgcc 11400
 taagccagaa acctaggaat ccttgatacc tgttctctct catcctgcat atccaagcct 11460
 atcagtttta tctctaaatt atattttggt aggtttactt ctttcctttt ctcccaccac 11520
 caccctgctc caagctacca tcatctcacc tggatgtctg caatagctc atctcccaca 11580
 gccactctgc accccctaatt ctgttctcta tagagcagtt ggaaggagtg atttttgttg 11640
 ttgttttttg ttgttttag acagagtctc actctgttcc ccaaggctgg agtgagtggtg 11700
 cacaatttgc gtcactgca acttctgcct cccgggttta agcaattctc ctgcctcagc 11760
 ctcccaagta gctgggatta aggcaccggc ccccatacc agctaatttt tatattttta 11820
 gtagagatgg ggttttgcca tgttgccaa gctagtctcg aactcctgac ctcaagtgat 11880
 ccactgcct cggcctccca agtgctggg attacagggt tgagccactg cactggctg 11940
 gaaggagtga tcttaaaaaa aaaaaaaca aaaaaaact tgactgtgtc actctgtgtt 12000
 gtctctcta cctgtatac ttccacaact tcccagtggt ctgggataaa gacaaaatc 12060
 cttaacttgg ccaggcgctg tggctcacac ctatcatctc agcacttgg gagccgag 12120
 caggcagatc atgaagtcaa gagattgaga ccactcctgc caacatgggtg aaacccatc 12180
 tctactaaaa atacaaaat tagctggctg tggtgccgtg tgctgtagt cccagctact 12240
 tgggaggctg aggcaggaga atcacttgaa cctgggaggc agagggttga gtgagccag 12300
 atcacgccac tgcactccag cctggtgaca gactaagact ccatctcaaa aaaaaaaaa 12360
 aaaaaaaaaa ttccttaatt tggcctacag tagagccctc cgtaatgttg cctctctcca 12420
 catctccaca acctcctgct cctgcactt cagcctcacc tctctcttg acaggccctc 12480
 cttctgacaa gggctttgtt cattctgctc cctctgccta gaatgcccc ttactctgtt 12540
 cacttaactc ctgcttatcg tttagatctt tacctggatg gctcagagaa atatagaagt 12600

-continued

```

aattcctcac cctgaaaaat aggttaggtc cctgttttat gttttcatag acctttcctt 12660
tgaggctttt tttaaaaaag tagttttaat ctcacattta ttcatgtgat catctcctta 12720
atgatatctt aagacctcta atagaacaat ttggtcatgg actgtggggg ttttgccctt 12780
cattgtgtca gcaactgagca tattgttggc ataggaggga tattgtttga atgaattgct 12840
agagggtggc aagagatatg atgtaagtca ggcttttccc tgccttccc cttccccttc 12900
cccacatcct tcctatagca gccaccgtgg ctgcagttae tgtaaatggc aagacggaat 12960
cagttccgga cattgggttg ttttagaaaa ttgcctgcaa gtgtcagggt gataagttaa 13020
agctttgtct tttgcctca gaggagctat cccatagtga gtagaagcca gagaagctga 13080
ccccaggagt ccttctttcc agcagcaggt cttgagctgc acttctctgt agctacaatc 13140
caggcaggaa caagccctag gtacctccgg agaggagggc aagagaggaa gaatgagttc 13200
agctactcta gccaccaaac tgattatgaa ttgcctgaa atctgaaaaa tttcaattcc 13260
aatcgtaagt ttgttttgtt tcatTTTTgtt ttcttaaat gtatatTTga aagatggcat 13320
taactaaaga tatatatcca atatagagtg gaaaaaatgg aatacttgca tagtatcttt 13380
tacttatagg tgatttatga tggggagtgg ggtggatagg ttggcagttc cccaagaag 13440
ttggaatga agtttgcct ctgtgagttg aactaattag atccacaagt aatgaaagca 13500
gtattgtgtt gtatttaaga gcacactcta gaaccagatt gcttagtttc aaatcctggt 13560
tctgcttttt attatctgtg tactttgggc aagtacttg cctttgtgt gcttcatttt 13620
tctcatctag aaaaaggaga ggccaggcgt agtggctcat gcctataatc ccagcacttt 13680
gggaggccga ggggggcaga tcacctgagg tgagaagttc aagaccagcc tggccaacat 13740
ggtgaaaccc tgtctctaca aaatacaaaa aattagccag gcatgatggc ggggtgcctgt 13800
aatcccagct acccaggagc ctgaggcggg agaaacactt gaacctggaa ggcagagggt 13860
gtagttagcc aggattgcac cactgcactc cagcctgggt gacaagagct agactcagtc 13920
taaaaaaaaa aaaaaaaaaa aaactggaga tacaggctgg gtgcagggct tacacttata 13980
atatcagcac tttgggaggc ctaggcggga ggattgcttg aactcaggag tttcaagatc 14040
agtctgggta acagagcaag acctcatccc caaaaaaat caaaaattta gccaggcatg 14100
gtggctcatg cctgtgtgcc cagctactca ggaggctgag gcgagaggat tgcttgagcc 14160
caggaggttg aggtgcaggt gaacctgac tgcaccacta catgccagcc tggatgacag 14220
agcaagaccc tatctcaaaa aaaaaaaaaa aaagaacga gccaggcgcg tttgctcacg 14280
ccagtaatcc cagcactttg ggaggccaag gcagggtgat cacttgaggt caggagatcg 14340
agactagcct ggccaacatg gtgaaacccc atctcaactg aaatacaaaa aattagccag 14400
gcatgggtgc atgtctctgt agtccagct actcacttg aggctgaggc acgagaatcg 14460
cttgaaccca ggaggcggag gttgcagtgg gccaacatca tgctactgca ctccagcctg 14520
ggagacagag cgagactctg tctcaataaa taaataaaca taaaataaaa taaaataaaa 14580
taaaaataaaa taaaataaata tggaggccag caggcacggt ggctcacgca tgtaatccca 14640
gcactttggg aggcggaggg gggcgatca caaggtcagg agatcgagac catcctggct 14700
aacacagtga aaccgcgtct ctactaaaaa tacacaaaat tagccaggca tggtggcagg 14760
cacctgtagt ccctgtact caggaggctg aggcaggaga atggcgtgaa cccgggaggc 14820
ggagcttgca gtgagctgag atcgcgccac tgcagtcag cctgggagac agagcaagac 14880
tctgtctcaa aaaaaaaaaa aaatatggag gttgggcgcg gtggctcgcg cctgtaatcc 14940

```

-continued

cagcactttg	ggaggctcag	gcgggaggat	cacctgaggt	caggagttec	agaccagcct	15000
ggccaacatg	gtgaaacctt	gtctctacta	aaattacaaa	aattagccag	gcacgatggc	15060
aggcacctgt	aatcccagct	acttaggaga	ctaaggcagg	agaatagctt	gaacctggga	15120
gatggagggt	gcagtgtgct	gagatcgccg	cactgccctc	cagtagagtg	agattccgtc	15180
tcaaaaaaaa	aaaaaaagaa	gaatggaga	tacaaactta	ctacctacct	ccttacaaac	15240
tacctcaca	gtattactgt	gaataaaagt	gtgtgtagca	ctgggaacac	tattcacaga	15300
gcactcatga	atgtttgttc	ttgttatta	gttactagag	aggcaaatgt	ctgccagggc	15360
tgaataatat	gtgtgaattg	gtgattgtcg	cacatatcta	aagaagtagt	tatttttttc	15420
aattaaaact	tagtttaaaa	accaatataa	ggccgagcgc	agtggctcac	acctgtaatc	15480
ccagcacttt	gggaggccga	ggtgggcaga	tcatttgagg	tcaggagtgc	gagactagcc	15540
tggccaacat	ggtgaacccc	tgtctctgct	aaaaaaaaaa	aaaaagtaca	aaaattagcc	15600
aggcatgatg	gcaggtcctc	gtaatcccag	ctacttggga	ggccgaggca	ggagaattgc	15660
ttgaacccag	gagggtggag	ttgtagttag	ccgagtttgt	gccactgcac	ttcagcctgg	15720
gtgacagagg	gagacactgt	ctcaaaaaaa	aaaaaaaaaa	accaaacca	atataataaa	15780
taagtggcca	gcaatgaaac	agaaagtga	aagttagtga	agcaaaacta	gtactgtatt	15840
cagataaaga	tgtcgaatct	agatttggtc	accagaatag	ggtcctttgt	ggcaacctgg	15900
gctagtttgg	ctgactcacc	actgccagga	tgaattttct	ttcagtggct	actcatttcc	15960
ctttatttta	agtcactgct	cacagagcaa	ccttctgatg	cctaattcag	cttctctggga	16020
tacttaataa	caggaagggg	ctggaagtag	tacctgtata	ggggatatga	gtgttctgat	16080
tttaatagtc	aattcataag	tgtacagagg	gtttgataaa	tggttagggtc	agaacctca	16140
cagaatgtct	acacctcttt	ggacattagg	aaggtcaaaa	acctgaaagg	ccaaaagcta	16200
ggcctagatt	agggtcattc	accaagaaaa	catcagcctt	gaagagttct	ctgggtgggtc	16260
caccagtcaa	ccttcctttg	atcacacctc	cttctctggt	gcttctttaa	gcattgacct	16320
gtaatgggta	tggaaatttt	tgtcaccta	actccttcct	tttacagagg	aagaagttga	16380
agcccagaga	gatttaaatg	cttgccctaag	atcacacgca	gattttctgt	taaccagggt	16440
gatttttcag	gtgttccttg	ccagacgagg	gcttttttcc	ttgaattgcc	tagagatttc	16500
ttgagatata	cgaagcattt	ttcccagtgc	agcctggaga	aggatgtccc	tgtcaacaca	16560
gcattttgta	ctcaatgtta	gacattcaat	tttctaatta	gtatcatgga	gcaacagtgg	16620
atgattatct	ataagggggt	gcaattccat	gcttatgtgc	ttacagccca	tatagacaaa	16680
tatcagctgt	taaaatgaca	aggcagtaga	gatgtggccc	caggacaaag	gcatactctg	16740
ctgttagtga	acactagttg	gccagcaaat	ttcacatggg	catatacacg	gccaaactgta	16800
gacttttagc	atttataccc	attcagagag	ccaaactggc	aactaaagat	cagcattctc	16860
tttggcattt	cagcttttgc	ttctgttaaa	aatcactgct	tgcttaataa	cctctgatag	16920
ctcttcactg	cctgtaggca	actcttttag	ctagcagact	tggtctttag	tgtctgccc	16980
ctactctctt	ccaccattct	ggcctcctgt	ctaattgctg	cccatatgtg	ccatgcacta	17040
gagcttacag	acctgctcag	cgttatatga	gcataccata	ctctttatgc	ctcagtgcac	17100
ttgcacatgt	tgttccttca	ggccagaatg	cctgttactg	cctggcaatc	agcctattag	17160
agtctgccaa	taccatccca	tcttctgtgg	aggagccccc	cgccaaatcc	acctatacct	17220
ctccccacca	atcagagact	tcttctctct	ttgttattct	cttcgttatt	ctcttcatac	17280
ctcagttata	tccatttcag	tatttgttta	cacatctagc	atcactctta	gagtgtgaaa	17340

-continued

attgtcgggt atgttgagtt ctgtatctg atttttctag atttcctgcc cacattctta	19740
ctgtctggat atcaggaaa agtttatcaa atgcctgtg aaatccaaga taaggctca	19800
tgatgagtaa ccagtgaaa acatgaagtc aagtctaact agtcactact atttcactac	19860
tgctgactcc tgatgatcag ctccctttct aagtgttac tgtccactta ttccatcacc	19920
tgccatgaat ttatgtgaag gaatcaaac aaaaggatca taaggcttcc tttttccagt	19980
atgtttttcc tcctttttga aaactgggcc agttagctat ctccattttt atttcatgaa	20040
tacatcccca gcgcctggta tatagtagat atggaacatt acactttgga gatattgcac	20100
ccattctcca gtttctccaa agttactaac aatggttcca tcaactgtgcc aacataatct	20160
cttttttcaa tatattggga aataattctc ccagtctgaa aatctgaaca cttttcatgt	20220
gacttggtat cctcatatgt ctgggcttc caattctcca ttccatgttt caagttcatg	20280
aaactgtaaa caaaggatta gactaaatct cttaaagtct atccagatgc caaattcttt	20340
tctctttcca tgatacctaa gatagatgcc aaatattgtc ttttacctgg tgtttgtgaa	20400
catgacatca cattacagga gtagcagata ctaaactctc actctgtaaa acactgactg	20460
agttccatga gccagatact gaagtgaact tgttcacata tgttctcatt taatgtcat	20520
aacctgtga agctgggaat tgctgggaca ttttatttat ttattatttg agacggagtc	20580
tggtctctgc acctaggctg gtgtgcaatg gcatgatctt ggctcaccgc aacctccgcc	20640
tcccgggttc aagcgattct ctgcctcag cctccgcagt agctgggatt acggggcaca	20700
caccaccaca tccagctaat ttgtatttt tagcagagat ggagtttctc catgttggtc	20760
aggttggtca cgaacacttg acctcaagt atctgcctgc ctccgcctcc caaagtgtg	20820
ggattacagg catgagccac catgcctgcc cgggacctt gttttagaag gatgactgct	20880
gctataatgt agaaagtgat ttggaagagg ggaggagtgg ggcacgaaag atggttagta	20940
gatgggggtg gtaatgctta cttttcagta tttggaggct tcggagtcct caaaaattct	21000
cttcttgat tgagtcctc ccagccaata gagggcttca cacaacacgt ttcttggtt	21060
ttgaattgtt tgaccagagc tttcttccga caaaagggtg ggggtgattca ttcacttacc	21120
acaccttgcc tgaacattca ctggggctg ccggttatga aggtattgt tctccagcct	21180
gtcacagacg ctttgaagac ctgtgcctca gctggttcta aggagtcagt ttgttcagct	21240
ccgtgccagg tttccaact atgaaatgtg ctggagatta acacctctc tgccatttta	21300
tccctactat aattgccagt caaaggattc ctgcagttgc ctctggcagc cataactgat	21360
gaatgttctg ccagctctc tgaggacct gaagagcagt tttctatcca ggaccagttt	21420
ccaaggggtg gaggtgaaa tatatctcc agtgtgacat ttcatctccc agtgatgggt	21480
ggcttggtcc ctttgaagtt ggctctgagg aaccacacac ttgggtctga gcagccagca	21540
gcttatcaca tctggtgac aatcttcaa aggttcctcc tgaagtctga atttttggag	21600
gtcaaatgga ttccacctg gaggggcttc tgcctcaact caggacatgg ggagaaggct	21660
gttctcttc cagggggagg cagtttctat ggcattgaga tgcctctca cttattcccc	21720
acccaccac caagtcctt gtaagaggag tagggggaga ggagagcgc tgcagcctcc	21780
tgctcacatt cctagacacc gactcactga gcccgctgcc gctggaacag cagagctgtg	21840
tgaagtgtca agaggagta tgctcatagg ctccctggcc tcagtctctt tgtggcttgc	21900
atattcttcc attagtactg tttcatcac atggaatca gaggtacaa ttaaaagata	21960
atttgctagt ccagactta atttggggc ccctcttgc ctgattgaat tacaggggaa	22020
cataatagat ttttggtgag aaatagttgt ctgtgtggtt gggagaaaga ttgctcccag	22080

-continued

```

ctctccagct gggcagccct ttcagtatcc cgtatgttat tccccactt ccagcccacc 22140
tcacctcctc tgtggccctt gtgtgtcccc tcgcttagga tcctgacctc ctgctcaaga 22200
gtttaaacct aacttgagac ccaaggaaaa tagagagccc tctgcaacct cataggggtg 22260
aaaaatgttg atgctgggag ctatttagag acctaaccac gggccagaca gagagagtga 22320
cttgctaaag gccacatagc tagccacagc tagttgtaac aatagtctta atgatattaa 22380
tggctaacat ttatcaacct ttaatgtgtc ccagactttg tgccaagggc ttacatgcag 22440
tgcatgtctg cattcaaac ccagacgtct ggctctgggc ccaggctgag ctttggtata 22500
gcatggtaga acgttgtcta taatgtctag tctgggttca aatcctggct tcacttctca 22560
catttacagc tgagtgcact caggcaagtg atttaacctc cctgtacctc agttgcttta 22620
tctgtaaga gaaaaatcac agcactgtgg aatagtgggg gttaaaattc attcatacaa 22680
gtagtgtctg aagcaatgtt taatacaggg tgagcacctg ttcagtgtct ccttcttctg 22740
gtgcctctg gggctagagt gtggtgtctt cgtggtatag atagatagat atggctgagc 22800
tctgcacaaa caccaagagc tgttcttcac tattagaggt agtaaacaga gtggttgagc 22860
tctgtggttc tagaacagag gccggcaagc tatggcccat tgcctatttt aatacggcct 22920
gtgattgatt gatttttttt ttctttttga gacagagttt cactcttgtt gcccaggctg 22980
gaatgcaatg gcacgaactc agctcaccgc aacctctgcc tctctgggtc aagcgattct 23040
cctgtctcag cctctcgagt agctgggatt acaggcatgt gccaccacgc ctggctaatt 23100
tttgtatttt tagtagagac aggttttctc catgttggtc aggctagtct cgaacttcca 23160
acctcagggt atctgccccg ctcagccttc caaagtgtg ggattacagg cgtgagccac 23220
catgactggc ctgattgact gattttttta gttagatag ggtcttggtt tgttaccag 23280
gtcgggtctc aacttctggc ttcaagcagt cctccctcct tggcctctcg aatgctggga 23340
ttataggcat gagccactat gcctggccta tatgacctgt gatttttaat ggttagggga 23400
aaaaaagcaa aagaatgctt tgtgacatgt ggaaattaca tgaactcaa atatcagtgt 23460
cccagcctgg gcaacaaagt gagaccctgt ctctacaaaa aataaaaaaa aataagccag 23520
ggccggggcg agtggtctac acctataatc tcagcacttt gggaggccga ggcaagtgga 23580
tcacctgagg tcaggagttc aagaccagcc tgaccaatat ggtgaaaccc tgtctgtact 23640
aaaaacacaa aaattagcgc agcatggtg catgcgcctg tagtcccagc tacttgggag 23700
gctgagacaa gagaattgct tgaacctggg aggcggaggt tgcagtgagc caagatcgcg 23760
acactacact gcagcctggg caacagagcg agactccgac acacgcacgc acgcacacac 23820
acacacacac acacacacac acgctgggta tggtgccag cactgtgtgt cccaggatgc 23880
actggaggct taggtaggag gatcacttga gcttaggtgg ttgagactac aatgaacct 23940
gtttatacca ctgcacttta gccagggcaa cagtgtgaga ctgaatctca aaagaaaaaa 24000
aaaaaaaaa aaaaaatctt tccataagta aatatctgtt ggaacatagc catgtccctt 24060
agtttatgtt ttatatatgg ctgcttttgc cctataatga cacaattgag tggccacgac 24120
agtctgtatg gcctgcagag cctaagatat ttgctctctg gccctttaca gaaaaagtgc 24180
cttgacctgt gctctagagc catatgtacc aggtttgaaa ctacgcctca cagctgggtg 24240
tgatggcacg catctgtagt cccagctact ctggaggctg aggtgagagg atcacttgag 24300
tccagaaggt cgaggtcaag attgtagtga gccatgatgg catcaccgca ctccagcctg 24360
agtgacagag agagaccctg actcaaaaaa aaaaaaacaa aaaaaaaaa caccctcacc 24420

```

-continued

acttatcagc tatttgctt gagaatagtg acataacccc tcagaaccta tttcctaate 24480
 tgtaaataa ggctgatgac gtttctctt tttactggca atttaaacat gatggataat 24540
 aaatgctaag cacttaacac agggcctaga agatattaac tgctcaataa atggtagctt 24600
 cttaacagta ttcaaaccca tgtgctctta tcacatgcat tgtgtccct gtgtccagtt 24660
 ggtggaatgg gaaaaggctc ccttgtaacc ccatctacca tctttatcag actttcctgc 24720
 catggttcac agtaagagat agaagctgca cggtagcttc tggctcttta caatggtgag 24780
 cgggtgtgtc ctggttaagg agagctgatg tcaactgccc aaatccagta gtgagatctg 24840
 agtgttctgg tttcctccag cagccttgct ttttcttta caatcctgca ggcagggaga 24900
 caagggtctt ctacatgcta ggctctgggt tggctcatct cacaactggg ggctgttcag 24960
 gtgggctccc attccagata cctaggctta tcaatccctt ttggcaccac aggccttttt 25020
 ctccctcatg ccccatTTTT cagtttgaaa agcatggta tcacaggaca agtagaagaa 25080
 gctccactgt ccaactgagg caatggatgg tgtctgcat gtgaacactc agtgaatagt 25140
 gagtgaatga gagtaacctg ggctccatcc tatttgacga gagctttgga aaagattttt 25200
 ctcttaaaag agccagaatg aagcctggta gtgggagagc tccagctcta gactcacatg 25260
 agcctacatt taaattccag ccctgcccact gactcccttt ttgacctga gtgagttacc 25320
 taatctctct gtacctcact tttcttgtct gtagagtggg aataattcct gtctcagaga 25380
 aataaaagag tgcatatagt gtttgccaca tggagacaca tcagggtgag gtaataactc 25440
 tgggccttgt ttccttattt gcaacacagc cctgccctgg agtggaagtg gcacctccca 25500
 ttggtcagct cttgagctg tccccaggac aggcagaggg agggaaatgaa tgggagccct 25560
 agtgccagga cagaacagat ggcagctcag agctaggatg gctctctgga cctgtctctc 25620
 ctaccagagg tcccccgctc tgggtgggct ctccctggac ctggcatcct ctgctttttt 25680
 tttttttcca cctccaagca gaattactgt cctgtaggca gctcctctgc ttgaggacat 25740
 ctggggccag atatgttcac actctatcct gccttgccct tccctgagct caggatggac 25800
 gctcaattgg tcccagttat tgtctgcagc gcctgcccgc agcctcgatc cagcccagct 25860
 ccccccttg cctgcaaggt ctgtttccta acagctgctc caaccacaca cctcggttct 25920
 ggggagccc ctctctcttc tccctccctc cctcattcag ggggtgggact gaagaagaag 25980
 gctaacttga cagcagcgt tctttcttag ctatgcaccg gccctgctc aagaatgcca 26040
 gtgtgtgtgt agcctccaca gagaggtcgt tttctcggag tccagagggg ccgctgagc 26100
 tctgagaac tagggaggag ccatccagc catgagcccc tgtgggaatc tctggggggc 26160
 caagtggcct ggagtcctca ggtcccgca gctgctccgg agggagaggt gagctcaggg 26220
 cagcctgcct gcagccagag gtgcccggag ccccgggcct gtcattggtg ccatctacag 26280
 ccggcctgag gcagtcacag acggaatttg agctgagcct gtctatctgg tgtgggaaga 26340
 agatggggag ttacttgcga gtcccggtt acttcacctc cagagacctg tttcggtag 26400
 ttggtctccg agttcccttc tccatctctc ctggcccctg gtcctgagag gaggtgggtc 26460
 tccctaaatc tcttctcag ttactcctt accatcggtt ctgcccggca gaagccagcg 26520
 gaggttatcc caagagagaa tcggccttgt gaggtacccc cattatgtcc tggaggtggt 26580
 gaggggaggg atataccag aaggaaactc ttagggagct ccagctcccc ttctatccca 26640
 gacaaacctg aaggagcctc caaaagatgc cactgacctg cccattgtag atgttactgc 26700
 ttccgggggg aatagcccaa atagagtgt gtttccagct ctacatgtc ttacctgcgg 26760
 gccatgctgc ctgcccagga atttgtccca acaagcagga tgggcagggt ttgccaaact 26820

-continued

```

gtggaactg gcaagtcctg ggtgtggga gcctggtaca cagtaggcac cttataaacg 26880
tttgttctct taatggcagg cacatttgcc tctggccttg aagggtctct gagctcccag 26940
gtgaatgtag ttgctgggga aagacctggg cgagtgttc taagactgga gcaatgggct 27000
ttagagtgtt cctgagctgc tgggccagcc cccacacctc ctcagtcctt aggcctaagt 27060
acctccacga gcctctctct gtggggcttc tcagaggag atgtggaac tctacctcta 27120
acctggcttt ctttgcctat tgccccactc cacctcccat agaaactccc caggggggtt 27180
ctggccctct gggcccttc tgaatggag cattccaggc taggggtggg tttgttttca 27240
ttctttggga gcagcctgtt gttccaaaaa ggctgcctcc cctcaccag tggctcctgt 27300
cgacttttcc cttctggctt ctctaagcta ggtccagtgc ccagatcttg ctgccgggat 27360
actagtcagg tggccaggcc ctgggcagaa aagcagtgt ccatgtggtt ttgtggaatg 27420
accggacctt ggtagattgc tgggaagtgt ctggacaggg ggaaggggga agggaaactg 27480
tcctcaatgc tgactctacc aagcgccctg ctgacacctt tatcctttaa tctctcaaca 27540
gcctaaagag attatatatc cccattttac agatgaggca accagtttca acagagttaa 27600
catatggagc ctcactgggc agctttttct gtcttctga ctttctctca tccttcaggg 27660
ggctgcaggt ttgttttctt ctctagtgg agaggaaatt ctcaggtttg ttttctctc 27720
ctagcagaga gtaaaaaaag ggatagtgtt cctgacttgt tgaagggtg gctgagattg 27780
ttttctaaag agccaatgga aattgatctt gagtttagga gaaagctttt acatgtggaa 27840
ttaagatgcc aagtgttgaa gtagccacat ttcaggctct cattaatttc tcttaacct 27900
gggaaggcag cttaggagaa ggggtgttcc tttaggagcc aggaactata ccccttttac 27960
ccttgagag gcagggaagc caggaggac acaacttctc aggaagagga gaagctagag 28020
cagatagtga actctcaacc tgaaccttta agggccagac cactaatgcc acccaagtcc 28080
acctgccgtt tgtcttgctc gtccccaggc tttctggaga acctgatctt cttgccctta 28140
ccccaaagct ccgtttgccc agctagagtc tggggggtac tgactgactt tcgtagacat 28200
tcttcccttc cccaaataag aggccacatt cctgaagtca cttctgaaga gatagctgcc 28260
acacagggct ctttcccccc agggagggac caccagacc ctctgctctc ccaggatcc 28320
gttaccacat cactacctgg tcagaaagct gtttctgcca ttagcccttc cctcttttat 28380
tataggatat cctcaagggc tcctcttttg gcctcagttt catccttgcc agaaagttaga 28440
agctagactt cttgggctcc tgaacagggt ccttgctgga ttctgtgaaa caaattaagt 28500
tcttgacctt aggcctctgg gggagtacaa agtctatggg agttctgggg ctgtggttgc 28560
aaggaaagtg acgcaaccag attccatggg gacatgatca ggcgtgacat gtgagggagg 28620
aagaggggagc aagggaatga agaatacaac ttctgtgtcc catacaccct tgcctgacag 28680
gccatacata ctcagcagag aatgcactgt ctttctacc acactagcgt gaggagttag 28740
ctgcaattac cactgtgctt ccaagtaaga aaatacctca aattggaatt taaaaagag 28800
gtaaattagg gagtggcttt gtctggacat ctttaaagca tttttctttt tatagaattt 28860
cacttaatgt ccaatactga ttaaatgagc ttgggtttac acattatctc ttgaagaaaa 28920
caaatgaacc tttgtgttcc aaagcaatcc atgtttaag ggaanaaatt atgcataact 28980
ctgcccagct tcacagtaac ctttggcagg tgccttaggt cctctgggac tcttttctt 29040
atctgaaaaa tgaaggactt ggatcagggt aatgggtccc agctctgcaa cttatgtggc 29100
tcctcagagg cacacaagct cttttccatt atttgccaaa taatggaggc cctgtcttta 29160

```

-continued

actgcagtac aactacacaa aatacttgaa actacagtct tcttggtttt tggttggaac	29220
tgaatcagtg cactctagca acacttattt cttgctgttc gtaggcttca ttatgtgttt	29280
ggttaatttt ttaaaacaac aataacatat tccataataa ttacagctta attggcagac	29340
tgtttcagtc tataggatct gcaggaagga ggagtaataa agggattttt gactgagctc	29400
ttatggaaca gagtctctct aggccctgt catatctgcc cttctgggcc ctggggaaaa	29460
gttggcatcc ccagttgtgg tgctctccag gtgccctcag gctgtggtgg agggagcttc	29520
ccattctctc cttcagccca ctcaattcag aggctagggg ctgaaagaag cttctctaca	29580
actggctgtt cactgggagg ttaagggatg accatccagc caggccttcc tcaggacatg	29640
ggagggctta tgctttaaca tgtgtaaatc cactgcaata atgactggtt cttttacccc	29700
ataaggtga gaatttacct gtaaacattt ttgtctgaag aatttgatg taagtgggg	29760
ctgggcctct atcttatctc acttggtctc tctcagcaca gcacctgcc tgcttgttct	29820
tacacatcct agatgcacag taactatttc ctaattatta gaaatctatt agaatcaatt	29880
gatttcagct gggcttggtg gctccttccct gtaatcccag cactttggga ggctaaggct	29940
ggaggatcac ctgagtcacg gagtttaaga ccagcctggg caacataggg agaccctgtc	30000
tctacaaaaa ataaaaaatt agccaggcat ggtggtgtgc acctgtagtc ccagctactc	30060
aggaggctga ggcaggagga tctcttgagc ctgggaggtc agactacagt gagcaatgat	30120
tgtgccactg cactccagcc tgggtgacag agtaagactc tgtctcttaa aaaaaaaaaa	30180
aaaaaagttg atttctattt ggatagataa ataattcatt ttaggacctt tctttttcac	30240
ttacagaaat ctgtttcatt ctgggctgag aagcaggctc atattgctag gcataggaga	30300
aaaaggggtc tgtctgcatt tgcccttggt ggtctcaaat tggggagggg aagaaatgaa	30360
cacttactgg ctacctctcy tgagccaggc atcatgcaag acatctgtac ataatttaat	30420
tctcataacc ccataagata ttattagcaa tgtacaagtg aggaaactga ggctcagagt	30480
catgaagtaa ctggccttgg gtgacacaga tggtaaatgg cagagaagga atatggatcc	30540
aggtcttgaa agagaaaaat tcaactgatt atctttttta aaaaactcat atgttctctg	30600
ctgactcaaa aggtctctgt gtggatctgg gttgaccac tgaactgacc atcagggttc	30660
catgcacttt gtatctgccc aagccctcag aaccctcag taatgttttg gaagatgagt	30720
tttgagggtt gtccttaggc atagcctcag cgtatgtagg cctctagggt atctcccta	30780
acctgaggat ttcagctcaa ttcactctgg ctccctcagga cagtgggatg actggttcag	30840
acctcagctt taccacctcc cagctgggta ctcttctacc tacagccagg gcagattttg	30900
actttcactt gaaacttcca aaaattgaaa ggtagaaaaa cagccttggc tttgggaaga	30960
acgtatgatg tccatggcct ctaagcatct gaggtgggac atgttcgagt agcaccttac	31020
agttccaaag tgtgttctgg gttctttgtt taaaagaaca gagactgctg gggaaattgaa	31080
cactgtgaag tatatgaag aggagaattg tgctatttaa cattcagtac ttgggctaaa	31140
ggagaagcat cacgaagtgt taacactcaa aggtctctga gctgtcaggc ctccagcttc	31200
cttattttca cagggtgagaa tcttgaggct cagctgttga gatgtgctgt ctactccgg	31260
tgacatagta cagtggatgt ggctttgcag ccaagcacac atagcttcac attccagctc	31320
catcaattat gtattgggca gctttgcaga atgatttgac tttactctg cttttcagtc	31380
ttctgtaaaa cagggataat cctgctaccg tagggttgtc aggattagag ataataataa	31440
taaggtaacct catataggac ctggattatg gctggcattc aataaatagt agctgttaat	31500
tgatagctaa gctagaactc tgaagtctac catggcaact tcttaagtgg tctgagaacc	31560

-continued

aggacctcca aggagagtgt tacaggctga gaggaggata tacttaggtt gtctttaggg 36360
 aatcagaaaa ggagactctg gaataggctg gcagagagag gggctacctc ctatacctgc 36420
 tctggacaaa cgactttaag catagtaca gatttgccaa cctgtattg gaagaactga 36480
 tcttttttag tggggatgat tacttctggg gatttcttct cataactgag accaaaacag 36540
 ttttgtgcag tctcagaaat gacaggaggt accaatctga cacttccttt ggaagctcta 36600
 gggcagagag tgaaagagt gattttgacg ggggccttgc ttggaggta ttcacccacc 36660
 cctgtcctca ctccagcaac agtgataact cacttccttc ctccctttgt acacccttct 36720
 ccccacctgc tcacaggtag ctggggagtt caagtaccac ccagagtgtc ttgcctgtat 36780
 gagctgcaag gtgatcattg aggatgggga tgcatatgca ctggtgcagc atgccaccct 36840
 ctactggtaa gatatgtgtc ctttgtctat cctctcccat ataagagtgg ctggcgggga 36900
 gggacagtgg cagggtgagt tgggcagaag gagtgttagg gtagtcagag cattggattc 36960
 ttaccacagc agtgccttta accagctctt taacttgtaa gcagaatgat ttacacatgt 37020
 ctctaccctt tttccttacc aaccttgaaa atgtcttcac tctgccctgc aatcctccca 37080
 gtgggaggca ctcttcaagg acgatcccg aacattaaag tcaaagacc cttagagctc 37140
 accctgtcca accaccttg ttgataaaag aagtcagcct ggggcccatg gaatagaata 37200
 gtacaaggc aaggttctca ttgtagtca aaggtagagt gaagagaacc cagaccatct 37260
 caccacaacc caggccagt tttttccaaa tataccactt gctgcagatc tagctcagca 37320
 cccccagtcc cagccaccc tgagaacca ggctcctcat tctgagcagc cagctagaat 37380
 catgacaaag aggggtgtag tgagactatg ggtactgtt cttaaagcca catggtgcag 37440
 tgggtgctgg ggggcttctg tgtgggactc tagcatctta ttccccctg tgccctctcc 37500
 ccagtgggaa gtgccacaat gaggtgtgtc tggcaccat gtttgagaga ctctccacag 37560
 agtctgttca ggagcagctg cctactctg tcacgtcat ctccatgccg gccaccactg 37620
 aaggcaggcg gggcttctcc gtgtccgtg agagtgcctg ctccaaactac gccaccactg 37680
 tgcaagtga agagttaagta ttttgagaac ccttcagcag gggttcttga gcagagtctg 37740
 taaatgggcc tcagagggt tagacctcca aagtctcatg cagaactccc ttattctca 37800
 tctcatatct ttctctgga cccactatg ctgtaaccgt acctgggctt tggcacttac 37860
 tgttctctct gcccaggcta cttcttacc gatacttaag gcaagaatca ctccactttc 37920
 aggtgtcagg tttcaggta tgtttgtct ttgaaatcat ctggcttgat tatgtgtatt 37980
 agttgtttat cttctatccc ctccactaga atgtaaatc cagaagaaac ttgtgtctt 38040
 attcagtgtc gcatgccag ggcttggaag agtacctggc atatagtagg agttgattga 38100
 ttattatatt gtcagtcgag agaataatg gagaaaatgt ggtccatggc ccaaaagaag 38160
 ttaagaccct atcctagatt caggccagag accagatgga gaaagagtct gtgtctatct 38220
 aataccagta atgtcgtacc tctggccgct taccatgtaa atattgattg tgatctacc 38280
 atgtgttga cactaggcta gtgctgcac agcaggtgaa agatactaga gtttgggaag 38340
 tcaggaggag ctaaggctg tttctacaacc ttattagatg aagaggagag ggaattgtgt 38400
 tcagggcaga gggagaagca tttctccaaa agtaggagtc ttaatcatgt ctgatgtagg 38460
 ttgagtgtg ccagaaaagg ggtgtttaa tatagagggc ctggattatg aaaatccagc 38520
 agatccattg agagttaaag cagcaagggt ttgtgaccaa gtaacattt tagaaggatc 38580
 actggtatgg aggttgatt ggagagggga aagcctaaag gtatagagac tagttaggaa 38640

-continued

agataaaggt ggctgtctca ccaattatgt aaggattaaa tgtggaaaag gacataaagt 41100
tgtatagtgc tgccataggg acagtgttca gtaaacgtga cacattotta gtatcactaa 41160
gaatcaggtt cttggccagg caccgtggct catgcctgta atcccaacac tctgggagggc 41220
ctaggtcgga ggatggcttg aacacaggag tttagacca gcctgagcaa catagtgaga 41280
cactgtctct aaaaaaaaa aataataata ataattgttt ttaattagat gggcagggca 41340
ctgtggctca cacctgtaat ccacgacctt tgggaggcca aggccggagg attgcttgag 41400
gccaggagtt caggagcagc ctgggccaca ttctgtctc tacaagaat aaaaaagtta 41460
actgggcatg gtggcacatg cctgtaatcc cagctactca agaggctgag gaggaggatt 41520
gcctgagccc aggagttaa gactgcagtg agccttgatc acaccactgt actacagctt 41580
gggcaacaga gtgagacctt gtctccaaa aaaaaagttt gttttttttt atccactctc 41640
ctcaccaaac aaactgagta agttagagcc ctctcagctg gcatgtgttg gaaacagtgc 41700
cctctcatta aagtgtgcc ctactccca ttgcctcttg gccttggtca gtatgatgaa 41760
attagtggga ggcaggggcaa cagagggcag ggaagagcta gaaatccatg gcctggaaaa 41820
gggaagattt gggagtggcc aggtatctgt agagccacca tgcagaggag gggggcagct 41880
agccttgtgt gctctggttg gcatggtcag caggaggcag agcaaaagga caagggtaa 41940
taaacctgta ggtcgggaca agccaagagc catccagcgt cagtcctctc tgggtagccc 42000
aagtaaagca ggagcatacc ccagagagaa agttcgcagg gctgttcacc tgcagtgtg 42060
tggacttcaa ccttcttgtt ccttcttcag taagtgaata taacagtcac tgaccatgac 42120
tattatcgac cgcttttgaa aatgtaaaca tagtgacttt attgctgtaa aaatcatacg 42180
tgtttatcat cttanaattc aggaacatg gacaggtaca aagatgtgca aaatatcatc 42240
caaaatccca tttgtgtgcc aggcacggtg gctcacgcct gtaatcccag cacattggga 42300
ggccgagcgg ggcnaatcac ttgaggtcag gagtttgaga ccagcctggc caacatggtg 42360
aaaccctatc tctactaaaa atacaataat taggctgggc gcagtggctc acgcctataa 42420
tcccagcact ttgggaggcc gaggtggcgg aatcacagg tcaggagttt gagactagcc 42480
tggccaatat ggtgaaaccc catctctact aaaaatacaa aaattagggc cgggtgtggt 42540
ggctcacgcc tgtaatccca gcacttaggg aggccgagac agatggatcg cgagatcagg 42600
agttcgagac caacctagcc aacatggtga aaccccatct ctactaaaa aatacaaaaa 42660
ttattcggtt gtggtggcac acgcctgtaa tcccagctac ttgggaggct gaggcaggag 42720
aatctcttga acctgggagg cagaggttgc agtgagtga gatcccgccg ttgcactcca 42780
gcctgggcga cagagtgaga ctccatcaaa aaaaaaaaa aaaaaaaa aaattagccg 42840
ggcgtggttg cgtgcaccta tactcccagc tacttgggag gctgaggcag gagaatcgct 42900
tgaacctgga aggcggagggt cgcagtgagc cgagatcgtg ccattgcact tcagcctggg 42960
cgacagagcg agactctgtc tcaaaaaata taataataac aataactagc cgggcctggt 43020
ggcacatgcc tgtagtccca gttactcagg aggcggaggc atgagactca ggtgaactag 43080
ggagacagag gttgcagtga gccaaagatca caccactgca ctccagcctg gttgacagag 43140
cgagactctg tctcaaaaa aaaaaaatcc catttgcctc ttttttgat actagtataa 43200
ctatcactct aaaccagtta gtacttaaat caagcagata tgggagatgg tgaattacca 43260
tctacagtgt tgtcatatat gtcacatact gagcattatc agctagtaga atctagttaa 43320
ttgttctatg tgtgatgtat gcagagttcc cattttgaat gtgtttttac tatgcttaaa 43380

-continued

taaatgactg atgtcagcaa ccccaaatg atacatctga tgtaagagcc cctgttcccc	43440
aataataaca tctaaactat agacattgga atgaacaggt gccctaagt ttctccctc	43500
cagggtttct tggccgtctc ctgaggacta cacatcccta ctccgtctt tcctcatctt	43560
caggcgagct aacagtatct ccaagtcccc tggccccagc tccccaaagg agccctgct	43620
gttcagccgt gacatcagcc gtcagaaac ccttcgttgt tccagcagct attcacagca	43680
gatcttcccg ccctgtgacc taatccatgg ggaggtcctg ggaagggct tctttgggca	43740
ggctatcaag gtgagcgag gcaacaattg ctttgcctt ctgccccag tccctctgtc	43800
actgtcttcc ggggatttct catcacttgg ccccccaca caccatgcag gatgccagc	43860
ctccttccgt gctttgggtg ttggtgtgag aggtatcctt cccccccc caggccacct	43920
aaggtcaatg ttgctgttac agtgagcttg tggacctgga gatccaggtt gggttgagct	43980
gtgcctgtgg ccctcctgcc tccagtcagt ggggttttgt taggtgcctg cagacctcag	44040
taccgggcat gctacaagga gcacacaggg gaatggctcc tgccctccgt gtgaacagtc	44100
tcagggacta acctctctct ttctctctc ctctctctt tctgctgaga actgggaggg	44160
ggggtcaggt aagacgtgtg tctcagcttg ggggcagcag ggctggagag ctcaccccg	44220
atccaccag ctcctgtgtg catgtctttg gcactgacct tccctcccc agacttctgt	44280
tcactcagga gactcactc tatgcaaat gaccagagcc cctgcttggc ttggcagcat	44340
ccctcctgc cttctcccc acttccctt tctgggttct tgccctgctt ctgtgcatgc	44400
ccagctctcc aggaagagg gtttgcctcc gtgtgagtc catgttgctc cagctgcat	44460
cttcacaca tgaactctgt cattctgacc cggctcagtg tgccctccaa gggatgggat	44520
ggccagctgc atagatttcc tcaaacagtt ctccagaact tctctggtc tcagcaccat	44580
taacagtcac cctccctgta ggtgacacac aaagccacgg gcaaatgat ggtcatgaa	44640
gagttaattc gatgtgatga ggagaccag aaaactttc tgactgaggt aagaagatgg	44700
agggggccc ggaggttgtt gtcaccattg gaagagagaa gacctacaa ataatggctt	44760
caagagaaaa tacagtttgg aattactgtc ttaaagacta agcagaaaa agccctagag	44820
gaatatccca ctccctctaa attacagcgt aattatttgt tcaatgaaca ctactaaaa	44880
gcaacacaaa cagggtacaa gggatgcagt aacaaaagat acagggttca gaagagctct	44940
caggttatga ggatgatgga catgaaaaca ctccaattta gtacaactca atgttataat	45000
cctcacctga acgcccgtct aaggagacct ggaggggagc tccctgagca ctcacactcc	45060
ttgggcattt acagttttca ctacccctcc caagttactt catggagtaa cttaatgttg	45120
ggacacctgt ggtctgggta ttgccctcca agccacttgg ccaactccac ccagttctc	45180
ccaatgcagt tccaaggga aggcctatga agccatctcc atctatatg tgggtgtctt	45240
ccctcatcct gatcttagtg cctgtcata tcacaagata ggaggtagga gatacaggtg	45300
gtaacacttg tcaagctgat tccctggagg gaagaggtaa ggaagacagt gagaagtaa	45360
ccaccagctt tccctggctt ccccccccc caggtgaaag tgatgcgcag cctggaccac	45420
cccaatgtgc tcaagttcat tgggtgtctg tacaaggata agaagctgaa cctgctgaca	45480
gagtacattg aggggggac actgaaggac tttctgcga gtatggtgag cacaccacc	45540
catagtctcc aggagccttg gtgggtgtc agacacctat gctatcacta cctaggagc	45600
ttaaagggca gaggggcctt gctttgcctc caaaggacca tgctgggtgg gactgagcat	45660
acatagggag gcttcaactg gagaccacat tgacctatgg ggcctggacc acgagtggga	45720
cagggtcaca cagcctctga aaatcattcc ccattctgca ggatccgttc ccctggcagc	45780

-continued

agaaggtcag gtttgccaaa ggaatcgccct ccggaatggt gagtcccacc acaaacctg 45840
ccagcagggc gagagtaggg agaggtgtga gaattgtggg cttcactgga aggtagagac 45900
cccttcctat gcaacttgtg tgggctgggt cagcagctat tcattgagtt tgtctgtgtc 45960
actgaaactg accccagcca actgttctca gttcacagcc ctgttttcaa agaattacac 46020
atctctaaag gcaaacaggg cacggacaag gcaaacctga gaggcacaaact gtagcctgag 46080
atggcctggg cttgccatca caggtattca ggtgctgagg gcccttagac caactagagc 46140
acctcactgc ctaggaaatc aatgaagggg aaatgagttc tagcggagcc ctgaaggatc 46200
agaattggat aaagtctcta ttggcagaga ggcaccagga ttgaagtgc aggagcaaa 46260
acctgggagg aaagaggaga aaatcatcta tttcacctgg aaacaaatga ttccaagcat 46320
agaaataata acagctgaca agtactgagt gccctctata tgctaggcac tgggctgagg 46380
gattaacatg catgtgcatg tttattcctc atgacaacct tggtttccag ataagctgga 46440
ctggaaggag acagagctgg gatcctgggc taatcagtct ggtcgccaag cctgagactt 46500
tagccactgc ccttcacatg ggggtccatg aaaatagtag tagtctgga cagtttggg 46560
gtacatcaag gtcgctgtgt tttaaactat ggagctgga ctataggaga caaatgtaaa 46620
agagttttt ggttactggg ctttttgggt tttttgtttg tttgtttgtg tgtttgtttg 46680
tttgtttgtt ttttcctgtt tctggggctt gaatcaggaa ggaggttttt ttgtgtgtgt 46740
tgttttgaga aaggatattg ctctgttgcc cagactggag tgcagtggca cgtatcatggc 46800
tactacagc ttgcacctcc tgggtcaag caatcctcct gccttagcct cccaagtagc 46860
tggactacag gtgtgtacca ccacacctaa ttttttgaat ttttttttct tttttttttt 46920
ttttttttt ggtagagaca ggttctcact ttgttgcca ggcctgaatc tcaaacctct 46980
gggtcgaagc attcctcctg cctcgccctc ccaaaagtgt gggattacag ttgtgagcca 47040
ccatgcccg caggaaaaga tttttaagca agaaagctta agagctgtgg tttttccaaa 47100
atgagctggt gctggcacag tggctcatgc ctgtaatccc agcacttttt tgggaggccg 47160
agggtagtg atcacttag gtcaggagtt tgagaccagc ctggccaact ggtgaaaccc 47220
ctgtttctac taaagaaaaa aatgcaaaaa ttagctgggc gtggtggtgc acgcctgtag 47280
tcccagctac tcaggaggcc gaggcaggag aatagcttga acctgggagg cagaagtgtc 47340
agtgagccaa gatcacacca ctgcattcca gcctgggtga cagagtgaga cttcatctca 47400
aaaaaaaaa aaagagaga ctgatattgt tagtacattg ggggtgaatg cggagggtcc 47460
agggaatgga gccctgcata gggggctaata gaaacatttc agatttctga attaaggtag 47520
tggctgtggg gacaggagcc tgggaggcag ggtggagtca gaatggagag actgggtggc 47580
aatgagggaa caggaggagg aggaggagga gttacgagtg gcttgaggtg tcaactacca 47640
gacatttggg ggtgggggga tagccgtgat tgttgagcaa ctgggttggg aagagctagc 47700
attgatccct gctgttctgt gctagcagaa cctatcagca tcttctgggc aggaaactgg 47760
ctccatgaga ctggcttagg gagaggctgc tagtcacctc atctgcagag aaggggcagc 47820
tggagctgtg ggacagaaga ggcattccatg tagctggtgg ggggtgtctca gcttgtgaag 47880
aggagatggc tttgagcagg gctgacactg aaaaggctgg aagaaaaaaa cagacacaca 47940
agagctctag gatcaggtag cataggaaag ttgtggacag tctttgagga gcaactccctc 48000
aggcaggcag caggcaggt catgagctat agcgattcag gaagagctcc ctgggtgtgt 48060
gagcagctcc aggagcctaa gggatgaaag tagtattgca gggggctgga gagcaaggag 48120

-continued

tggctccttc tacatttgca aggggaaggag aaaggaagtt gctcctgaga gtggttaagag	48180
tcagtgggtg aggcctggag aggagacata acaaacaaat ttgttgacaa acattttggt	48240
aggaaggggg agagcttaaa gtttagacag tggggaaggt ggagtcttag aggaggtgaa	48300
tgtctgaaag acagagctag ctggagcaag aagtcacttc tctgttgca gcaaggaagga	48360
tccaaagtgg ctcaagccag agattgggag agtggggagg agggagcagc ctggatctaa	48420
gtaaaatggg tagaggtgga ggggtgctg caacggccag ggttttctga agttggggac	48480
attaggagag agctgtgagg gctttggcca gccactgtgc tagtgattgg tgaaccaaag	48540
gatgggcagg agatggcagc agggaagcag aggaagtcca ggcttcctgt tggatttggg	48600
acaagggaga ggccatagga ggccctggcc ctgttgcca ggttgggttc tgaagctggg	48660
tgggcatggc ctggtaggag agcatctatg gcgcccaatt ccagattcag ggtctagttg	48720
atttgctggc cctgtagcct cagctcatgc ttctgttcca ggccattttg cactctatgt	48780
gcacatcca ccgggatctg aactcgaca actgcctcat caagttggtg tgtccactg	48840
ctctgggctt ggccctcagg gtcctatcct tcctggcttc ctgtcacaa aggaggtga	48900
cttgccctct ctggctagag ggcagaggtg ttgcctagga gctcctatct tccccttct	48960
gcttcttcca atgcccttct ctgtcctctg ggagctccga gacacacaca gacataattt	49020
cacctctctt cattagcaac ctttgaata atttgattag aagggaacttc agaagtttgt	49080
tgactatatg tagaaaacc tgctatttta cctgcttttg ccccatagta gtcttgtaa	49140
acagttcatt gctgacccca ttttacagt gtggcacctg aagcctcagc ctgagggcac	49200
cgagctagta aatttacagg gaccagttt agaccagcat tcctccact gccctcagc	49260
tgtggtggtt acaatgttgt ttgtcttact gacttgctat ctggcttctt ggtgtctac	49320
cggctggccc tggctctgcc ctctagacc acaccacgca atcttcattt ctttccaca	49380
tgactgccct gtagctatcc aaagagcttg tctccccc aa gctcctccat ctactgcctc	49440
caccttgctt tttctgtct tatcctgggt ctagccactg cctgaaatca ttttaggaat	49500
aagacaggac agggaaaaac aaagcaacc ccctgtccca cctctgagtt ccactctcca	49560
agtcctgag cctcacctcc agggctccag tggctctgcc atgaaccac tgtgggctgg	49620
gagctgctg tgcacagata ccagaccctc agaaacacaa atgccaagt gtctgtttt	49680
tttgtttgt tttgtttgt ttttagatg gagtctcatt ctgtttcca ggctggagt	49740
cagtgggtca atcttggtt actgcagcct ctacctccg ggttctagt attgttctgc	49800
ttcagcctcc cagtagctag gactacaggc gtgtgccacc acgcccagct aattttttt	49860
ttttttttt tttttttt gtagagacag ggttttgcca tgttgccag gctggtctt	49920
aactcctgac ctacagtgat tcacccgct tggcctcca aagttctggg attacagtg	49980
gaagccaccg tgctggcct gagtggtct atttgataga gctttctgct ctgattctcc	50040
cttgctatac accttttct cccttctcag tggcttctt tgctatgct tcctccccc	50100
ggccaggttt gagaacatcc ccatgaagtc ctgacctgtc ttttatccta ccaggacaag	50160
actgtggtg tggcagactt tgggctgtca cggctcatg tggagagag gaaaagggcc	50220
cccatggaga agggccacc caagaaacgc accttgccga agaaccagcc caagaagcgc	50280
tacacggtg tgggaaaccc ctactggatg gccctgaga tgctgaacgg tgagtcctga	50340
agccctggag gggacacccg cagagggagg acagatgctg cccttgcatc agagccctg	50400
gaattccagg ggagcctgt gaagcgtagg accggatacc cagagctgag gatattttt	50460
ccttgccagg tggggcctca cgaattagct cctgagctca gggggctggg aactgatcag	50520

-continued

tgtcccatca tgggggataa ggtgagttct gactgtggca tttgtgcctc agggatcgct 50580
 aagagctcag gctattgtcc cagctttagc cttctctctc catggtgaga actgaagtgt 50640
 ggtgccctct ggtggataat gctcaaacca accagagatg ctggttgagg tctctgaaat 50700
 caggggtgtg aggcctcaga aatggtctga atacaatcca ttttgagatc tgaggcccag 50760
 agaagttcag tgaattgcct aggagcatat agctgcctaa tggcagaggc tagatgaacc 50820
 ctagtctggt tcttttccac tttaacgtgc agtttcatcc taggcagtgt tatgttataa 50880
 gggctctcca aggcagtcca cctacggctg aggaaggact attttcaggt ggtgtctgctg 50940
 caggacagcc tgtggggtgt ccctacagaa cctgttctag ccctagtctt tagctgtggc 51000
 ttagattgac ctagaccca gtgcagagca ggtaagggat gtaaaactaa cagtgtgctc 51060
 tcctgtgttc cccaaggaaa gagctatgat gagacgggtg atatcttctc ctttgggagc 51120
 gtctctgtg aggtgagctc tggcaccaag gccatgcccg aggcagcagg cctagcagct 51180
 ctgccttccc tcggaactgg ggcctctcct cctagggatg actagcttga ctaaaatcaa 51240
 catgggtgta gggttttatg gtttataacg catctgcaca tctttgccac gttcgtgttt 51300
 cattggtctt aagagaagga ctggcagggt ttttttgttt tagatggagc ctcacttcgt 51360
 tgcccaggct ggagtgcagt ggcacatct gggctcactg caacctctgc cttctgggtt 51420
 caagtgatcc tcctgcctca gccctccaag tagctgggac taccggcaca caccaccatg 51480
 cccggctaatt ttttgtatct ttagtagaga cagggtttca ccattgtggc caggctggtc 51540
 ttgaactccg gacctcaggt gatccgcctg cctcagcctc taaaagtgtt ggaattaata 51600
 ggctgtgagct acctcgcccg gccagggttt tttttttttt ttttttagtg aggaaactga 51660
 ggcttggaag agggcagtggt cttgcacatg gtgcataagg ggcagatgag actcagaatt 51720
 ccagaaggaa gggcaagaga ctgttcattgt ggctgtctag ctagctcttg ggccaaatgt 51780
 agcccttctc agtcccttc aagtagaagt agccactcta ggaagtgtca gccctgtgcc 51840
 aggtaccacg tggacagagt gaggaatctt ggaagattc ctaccttag gagtttagtc 51900
 aggtgacagc atatctcagc gactcaaca cacacacatt caaagccttc tgtaattcct 51960
 acaaagttgt gaggggtaga ggagaggaga gacaagggat ggttaggata atgaaggaa 52020
 gttttgtttt tgtttttgtt tttgagatgg agtttcactc tgtcaccag gctggagtgc 52080
 agaggtgcaa tcttggtcca ctgcagcctc cgcctcccag gttcaagcaa tcctcctgcc 52140
 tcagcctccc aagtagctgg gactacaggt gtgcgccacc acgcctggct aatttttgta 52200
 ttttcagtag agacagggtt tcgccatatt ggccaggctg gtctcaaatg cctgacctca 52260
 ggtgatacac ccgtctcagc ctcccaaagt gctgagatta caggcatgag ctaccgtgcc 52320
 tggccatgaa ggaagatttg ttttaaaaaa ttgttttctt taatattaat tgaacacctc 52380
 tgttcagagc actgggctgg tgccagaggg tttcagacat gaatcagatc cagcacctca 52440
 tagagcctta atctggcaca cacacacagc cacaaggaga cacagacaag gcagggtagg 52500
 atgagtggaa gctaggagca gatgctgatt tggaaacctt ggcttctgca gtgaagcccc 52560
 ttcttagtcc tcttcagtaa cccagctctc agtggatata ggtctggatt agtaagattt 52620
 ggagagatga ttggggattg gggagagctc tctaacctat ttaccacct cctctctgct 52680
 cattcttctc gtccacatcc ccagcatccc tttcccttgc caagtatctg tggcctctgt 52740
 agtcctttgt aaacagctgt cttcttacc caccagatcat tgggcagggt tatgcagatc 52800
 ctgactgcct tccccgaaca ctggactttg gcctcaactg gaagcttttc tgggagaagt 52860

-continued

ttgttccac agattgtccc cggccttct tcccgtggc cggcatctgc tgcagactgg 52920
 agcctgagag caggttgga tctgccttt ttctccagc tcacagggtc ctgggacgtt 52980
 tgctctgtc taaggccacc cctgagccct ctgcaagcac aggggtgaga gaagcctga 53040
 ggtcaagaat gtggctgtca acccctgagc catctgacaa cacatatgta caggttgga 53100
 aagagagagg taaagacata gcagcaagta atctggatag gacacagaaa cacagccatt 53160
 aaaagaagt taaaagaag gaaattcacc caaaccttt gaatacagta agtgatttca 53220
 tctttcgata ttcccctgtc catatctaca catatacttt tttttatagt aaatagtctt 53280
 gtattttgcc ctgcatttcc cttgtgttta ctatccagtc ttctgttta tcatttttgt 53340
 cgacaacatg aaattctatt gagagactgt ctgaacatat tgtaatgtag atgttcaggt 53400
 tttccagtt tctctttaca ataggtatct aactacagtg agcagtttta tgcatttagc 53460
 taatttctcc ttgaggaag tttttcaaa attaccttta ttcttctcag gtaataattt 53520
 cattattacc aaagtacc ctaggtcttt caagtgtgtg gtaaaaaac gagaatctgg 53580
 ctgggcgaga tggctcacac ctgtaatccc agcactttgg gaggtgagg ctggtggatc 53640
 acctgaggtc tggagttcga gaccagcctg gccaacatgg tgaaccccca tctctactaa 53700
 aaatacaaaa cttagccagg catggtggca ggtgcctgta accccagcta cttgggaggc 53760
 tgaggcagga gaattgctt aaccagggg cgaggttgc agtgagcga taccagcca 53820
 ttgactcca gccctggcaa caagagtga actctgtctc aaaaatgggg ttcttttctt 53880
 gccatcaaaa atcatgtttc ttttaaaac aagttcaaac attaccaaa tttatagcac 53940
 aggaatacag tcttctgtaa tctcccttaa ccaatatatc cctcaacatt ctctcacc 54000
 ccaactccac cctcccagga taaccagttg ggacataatc tttattttaa aatggtttcc 54060
 ggatagagaa agcgtctcgg cggcggcagc cccggcgggc gccgcagggg acaaggggcg 54120
 ggcggatcgg cggggagggg gcggggcgcg accaggccag gccggggggc tccgcatgct 54180
 gcagctgcct ctccggcgcc cccgcgcgcg cctcgcgcg ggagccggcg agctaacctg 54240
 agccagccgg cggcgctcac ggagggcgcg gcacaaggag gggccccacg cgcgcacgtg 54300
 gccccggagg ccgcctggcg ggacagcgcg accgcggggg gcgcggcggt ggcgccccg 54360
 gccccggccc ccaggccagg cagtgggggc caaggaccac gcattactt tcagagcccc 54420
 cccccggccc gcaggagagg gcccgggctg ggcggatgat gagggccag tgaggcgcca 54480
 agggaggtc accatcaagt atgaccccaa ggagctacgg aagcacctca acctagagga 54540
 gtggatcctg gagcagctca cgcgcctcta cgaactgccg gaagaggaga tctcagaact 54600
 agagattgac gtggatgagc tctggacat ggagagtga gatgcctggg cttccagggt 54660
 caaggagctg ctggttgact gttacaaac cacagaggcc ttcattcttg gcctgctgga 54720
 caagatccgg gccatgcaga agctgagcac accccagaag aagtgagggt ccccgaccca 54780
 ggcgaacggt ggctccata ggacaatcgc taccctccga cctcgtagca acagcaatc 54840
 cgggggaccc tgcggccagg cctggttcca tgagcagggc tctcgtgcc cctggcccag 54900
 gggctcttc cctgcccc tcagttttcc acttttggat tttttattg ttattaaact 54960
 gatgggactt tgtgtttta tattactct gcggcacggg ccttttaata aagcgaggta 55020
 gggtagcct ttggtgcagc tcaaaaaaa aaaaaaaat gatttccagc ggtccacatt 55080
 agagttgaaa ttttctggg ggagaatcta taccttgttc ctttataggc caaggaccgc 55140
 agtcttcag taacaccagt gtaaaagctt gaggagaaat tgtgaagcta cacagtattt 55200
 tttttcta atctctgtc attctaaata tctttaattt attaaaaat atatataac 55260

-continued

agtattgaat gcctactgtg tgctaggtag agttctaacc acttgggtta cagcagcgaa 55320
 caaaataaag gtgcttacc tcatagaaca tagattctag catggtatct actgtatcat 55380
 acagtagata caataagtaa actatattga atattagaat gtggcagatg ctatggaaaa 55440
 agagtcaaga caagtaaaga cgattgttca gggtagcagt tgcaatttta aatatggtcg 55500
 tcagagcagg cctcactgag gtgacatgac atttaagcat aaacatggag gaggaggagt 55560
 aagcctgagc tgtcttaggc ttccggggca gccaaagcat ttccgtggca ctaggagcct 55620
 ggtgtttccg attccacctt tgataactgc attttctcta agatatggga gggaaagttt 55680
 tctcctattg tttttaagta ttaactccag ctagtccagc cttgttatag tgttacctaa 55740
 tctttatagc aaatatatga ggtaccggta acattatgcc catttctcac agaggcacta 55800
 ctaggtaag gagtttgctt gacgttatac aaccaggaag tagctgagcc tagatccctt 55860
 ccacccaccc catggccctg ctcatgttcc acctgcctct aatttacctc ttttccttct 55920
 agaccagcat tctcgaaatt ggaggactcc tttagggccc tctccctgta cctgggggag 55980
 ctgggcatcc cgctgcctgc agagctggag gagttggacc acaactgtgag catgcagtac 56040
 ggctgaccc gggactcacc tccctagccc tggcccagcc cctgcaggg ggtgttcta 56100
 cagccagcat tgccccctg tgccccattc ctgctgtgag cagggccgctc cgggcttctt 56160
 gtggtattggc ggaatgttta gaagcagaac aagccattcc tattacctcc ccaggaggca 56220
 agtgggcgca gcaccaggga aatgtatctc cacaggttct ggggcctagt tactgtctgt 56280
 aaatccaata ctgctcgaa agctgtgaag aagaaaaaa cccctggcct ttggggccagg 56340
 aggaatctgt tactcgaatc caccaggaac ctccctggca gtggattgtg ggaggtctt 56400
 gcttacacta atcagcgtga cctggacctg ctgggcagga tcccagggtg aacctgcctg 56460
 tgaactctga agtcactagt ccagctgggt gcaggaggac ttcaagtgtg tggacgaaag 56520
 aaagactgat ggctcaaagg gtgtgaaaa gtcagtgatg ctccccctt ctactccaga 56580
 tcctgtcctt cctggagcaa ggttgaggga gtagggtttg aagagtcctt taatatgtg 56640
 tggaaacaggc caggagttag agaaagggt ggcttctgtt tacctgctca ctggctctag 56700
 ccagcccagg gaccacatca atgtgagagg aagcctccac ctcatgtttt caaacttaat 56760
 actggagact ggctgagaac ttacggacaa catcctttct gtctgaaaca aacagtcaca 56820
 agcacaggaa gaggtctggg gactagaaag aggccctgcc ctctagaaag ctcatgctt 56880
 ggcttctgtt actcatactc gggtagggct cttagtcaga tgcctaaaac attttgccta 56940
 aagctcgatg ggttctggag gacagtgtgg cttgtcacag gcctagagtc tgaggggagg 57000
 gagtgggagt ctacgaatc tcttggtctt ggcttcagtg caaccactgc tcacccttca 57060
 acatgcctgg tttaggcagc agcttgggct gggaaagggt ggtggcagag tctcaaagct 57120
 gagatgctga gagagatagc tccctgagct gggccatctg acttctacct cccatgtttg 57180
 ctctcccaac tcattagctc ctgggcagca tcctcctgag ccacatgtgc aggtactgga 57240
 aaacctccat cttggtctcc agagctctag gaactcttca tcacaactag atttgcctct 57300
 tctaagtgtc tatgagcttg caccatattt aataaattgg gaatgggttt ggggtattaa 57360
 tgcaatgtgt ggtggttgta ttggagcagg gggaaattgat aaaggagagt ggttgctgtt 57420
 aatattatct tatctattgg gtggtatgtg aatattgta catagacctg atgagttgtg 57480
 ggaccagatg tcatctctgg tcagagtta cttgctatat agactgtact tatgtgtgaa 57540
 gtttgcaagc ttgctttagg gctgagcctt ggactcccag cagcagcaca gttcagcatt 57600

-continued

```

gtgtggctgg ttgtttctg gctgtcccca gcaagtgtag gagtgggtgg cctgaactgg 57660
gccattgata agactaaata aattaagcag ttaacataac tggcaatatg gagagtgaan 57720
acatgattgg ctacaggaca taaatgtaga gggctctgcta gccaccttct ggcctagccc 57780
acacaaactc cccatagcag agagttttca tgcacccaag tctaaaacct tcaagcagac 57840
acccatctgc tctagagaat atgtacatcc cacctgaggc agcccccttc ttgcagcagg 57900
tgtgactgac tatgaccttt tcctggcctg gctctcacat gccagctgag tcattcctta 57960
ggagccctac cctttcatcc tctctatatg aatacttcca tagcctgggt atcctggctt 58020
gctttcctca gtgctgggtg ccacctttgc aatgggaaga aatgaatgca agtcacccca 58080
cccccttggt ttccttaaca gtgcttgaga ggagaagacc agtttcttct tgcttctgca 58140
tgtgggggat gtcgtagaag agtgaccatt ggaagagaca atgctatctg gtagtgagg 58200
ccttgggcac aatataaatc tgtaaaccca aagggtgttt ctcccaggca ctctcaaac 58260
ttgaagaatc caacttaagg acagaatatg gttcccgaaa aaaactgatg atctggagta 58320
cgcattgctg gcagaaccac agagcaatgg ctgggcatgg gcagagggtca tctgggtggt 58380
cctgaggctg ataacctgtg gctgaaatcc cttgctaaaa gtccaggaga cactcctgtt 58440
ggatatcttt cttctggagt catagtagtc accttgaggc gaacttcctc agcccagggc 58500
tgctgcaggc agcccagtga ccttctctcc tctgcagtta tccccctttt ggctgctgca 58560
gcacaccccc cgtcacccac caccacaacc ctgcccgcact ccagccttta acaagggtgt 58620
tctagatatt cattttaact acctccacct tggaaacaat tgctgaaggg gagaggattt 58680
gcaatgacca accaccttgt tgggagcctt gcacacctgt ctttctgtct tcaacctgaa 58740
agattcctga tgatgataat ctggacacag aagccgggca cggtggtctt agcctgtaat 58800
ctcagacctt tgggaggcct cagcagggtg atcacctgag atcaagagtt tgagaacagc 58860
ctgaccaaca tgggtgaacc ccgtctctac taaaaatata aaaattagcc aggtgtggtg 58920
gcacatacct gtaatcccag ctactctgga ggctgaggca ggagaatcgc ttgaaccac 58980
aaggcagagg ttgcagttag gcgagatcat gccattgcac tccagcctgt gcaacaagag 59040
ccaaactcca tctcaaaaaa aaaaaa 59065

```

<210> SEQ ID NO 4
<211> LENGTH: 265
<212> TYPE: PRT
<213> ORGANISM: Human

<400> SEQUENCE: 4

```

Leu Thr Glu Val Lys Val Met Arg Ser Leu Asp His Pro Asn Val Leu
 1             5             10             15

Lys Phe Ile Gly Val Leu Tyr Lys Asp Lys Lys Leu Asn Leu Leu Thr
 20             25             30

Glu Tyr Ile Glu Gly Gly Thr Leu Lys Asp Phe Leu Arg Ser Met Asp
 35             40             45

Pro Phe Pro Trp Gln Gln Lys Val Arg Phe Ala Lys Gly Ile Ala Ser
 50             55             60

Gly Met Ala Tyr Leu His Ser Met Cys Ile Ile His Arg Asp Leu Asn
 65             70             75             80

Ser His Asn Cys Leu Ile Lys Leu Asp Lys Thr Val Val Val Ala Asp
 85             90             95

Phe Gly Leu Ser Arg Leu Ile Val Glu Glu Arg Lys Arg Ala Pro Met
100            105            110

```

-continued

Glu	Lys	Ala	Thr	Thr	Lys	Lys	Arg	Thr	Leu	Arg	Lys	Asn	Asp	Arg	Lys
	115						120					125			
Lys	Arg	Tyr	Thr	Val	Val	Gly	Asn	Pro	Tyr	Trp	Met	Ala	Pro	Glu	Met
	130					135					140				
Leu	Asn	Gly	Lys	Ser	Tyr	Asp	Glu	Thr	Val	Asp	Ile	Phe	Ser	Phe	Gly
	145				150					155					160
Ile	Val	Leu	Cys	Glu	Ile	Ile	Gly	Gln	Val	Tyr	Ala	Asp	Pro	Asp	Cys
			165					170						175	
Leu	Pro	Arg	Thr	Leu	Asp	Phe	Gly	Leu	Asn	Val	Lys	Leu	Phe	Trp	Glu
			180					185					190		
Lys	Phe	Val	Pro	Thr	Asp	Cys	Pro	Pro	Ala	Phe	Phe	Pro	Leu	Ala	Ala
		195				200						205			
Ile	Cys	Cys	Arg	Leu	Glu	Pro	Glu	Ser	Arg	Pro	Ala	Phe	Ser	Lys	Leu
	210				215					220					
Glu	Asp	Ser	Phe	Glu	Ala	Leu	Ser	Leu	Tyr	Leu	Gly	Glu	Leu	Gly	Ile
	225			230					235						240
Pro	Leu	Pro	Ala	Glu	Leu	Glu	Glu	Leu	Asp	His	Thr	Val	Ser	Met	Gln
			245					250						255	
Tyr	Gly	Leu	Thr	Arg	Asp	Ser	Pro	Pro							
		260					265								

That which is claimed is:

1. An isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of:
 - (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2;
 - (b) a nucleic acid molecule consisting of the nucleic acid sequence of SEQ ID NO:1;
 - (c) a nucleic acid molecule consisting of the nucleic acid sequence of SEQ ID NO:3; and
 - (d) a nucleotide sequence that is completely complementary to a nucleotide sequence of (a)-(c).
2. A nucleic acid vector comprising a nucleic acid molecule of claim 1.
3. A host cell containing the vector of claim 2.
4. A process for producing a polypeptide comprising culturing the host cell of claim 3 under conditions sufficient for the production of said polypeptide, and recovering the peptide from the host cell culture.

5. An isolated polynucleotide consisting of a nucleotide sequence set forth in SEQ ID NO:1.

6. An isolated polynucleotide consisting of a nucleotide sequence set forth in SEQ ID NO:3.

7. A vector according to claim 2, wherein said vector is selected from the group consisting of a plasmid, virus, and bacteriophage.

8. A vector according to claim 2, wherein said isolated nucleic acid molecule is inserted into said vector in proper orientation and correct reading frame such that the protein of SEQ ID NO:2 may be expressed by a cell transformed with said vector.

9. A vector according to claim 8, wherein said isolated nucleic acid molecule is operatively linked to a promoter sequence.

* * * * *